<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">1524</journal-id><journal-id journal-id-type="pmc-domain">frontpharmacol</journal-id><journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id><journal-title-group><journal-title>Frontiers in Pharmacology</journal-title></journal-title-group><issn pub-type="epub">1663-9812</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10598667</article-id><article-id pub-id-type="pmcid-ver">PMC10598667.1</article-id><article-id pub-id-type="pmcaid">10598667</article-id><article-id pub-id-type="pmcaiid">10598667</article-id><article-id pub-id-type="pmid">37886127</article-id><article-id pub-id-type="doi">10.3389/fphar.2023.1239159</article-id><article-id pub-id-type="publisher-id">1239159</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject><subj-group><subject>Mini Review</subject></subj-group></subj-group></article-categories><title-group><article-title>&#956;-opioid receptor agonists and psychedelics: pharmacological opportunities and challenges</article-title><alt-title alt-title-type="left-running-head">Salinsky et al.</alt-title><alt-title alt-title-type="right-running-head"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.3389/fphar.2023.1239159" ext-link-type="uri">10.3389/fphar.2023.1239159</ext-link></alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Salinsky</surname><given-names initials="LM">Leah M.</given-names></name><xref rid="fn001" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2344347/overview"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Merritt</surname><given-names initials="CR">Christina R.</given-names></name><xref rid="fn001" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/608917/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zamora</surname><given-names initials="JC">Joshua C.</given-names></name><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2374960/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Giacomini</surname><given-names initials="JL">Juliana L.</given-names></name><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2385994/overview"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Anastasio</surname><given-names initials="NC">Noelle C.</given-names></name><xref rid="c001" ref-type="corresp">*</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/457072/overview"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Cunningham</surname><given-names initials="KA">Kathryn A.</given-names></name><xref rid="c001" ref-type="corresp">*</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/7709/overview"/></contrib></contrib-group><aff>
<institution>Center for Addiction Sciences and Therapeutics and Department of Pharmacology and Toxicology</institution>, <institution>John Sealy School of Medicine</institution>, <institution>University of Texas Medical Branch</institution>, <addr-line>Galveston</addr-line>, <addr-line>TX</addr-line>, <country>United States</country>
</aff><author-notes><fn fn-type="edited-by"><p>
<bold>Edited by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1598877/overview" ext-link-type="uri">Cody Wenthur</ext-link>, University of Wisconsin-Madison, United States</p></fn><fn fn-type="edited-by"><p>
<bold>Reviewed by:</bold>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1113735/overview" ext-link-type="uri">Thomas M. Keck</ext-link>, Rowan University, United States</p></fn><corresp id="c001">*Correspondence: Noelle C. Anastasio, <email>ncanasta@utmb.edu</email>; Kathryn A. Cunningham, <email>kcunning@utmb.edu</email></corresp><fn fn-type="equal" id="fn001"><label>
<sup>&#8224;</sup>
</label><p>These authors share first authorship</p></fn></author-notes><pub-date pub-type="epub"><day>11</day><month>10</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>14</volume><issue-id pub-id-type="pmc-issue-id">427358</issue-id><elocation-id>1239159</elocation-id><history><date date-type="received"><day>12</day><month>6</month><year>2023</year></date><date date-type="accepted"><day>28</day><month>9</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>11</day><month>10</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>26</day><month>10</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-01-26 12:25:10.740"><day>26</day><month>01</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2023 Salinsky, Merritt, Zamora, Giacomini, Anastasio and Cunningham.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Salinsky, Merritt, Zamora, Giacomini, Anastasio and Cunningham</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fphar-14-1239159.pdf"/><abstract><p>Opioid misuse and opioid-involved overdose deaths are a massive public health problem involving the intertwined misuse of prescription opioids for pain management with the emergence of extremely potent fentanyl derivatives, sold as standalone products or adulterants in counterfeit prescription opioids or heroin. The incidence of repeated opioid overdose events indicates a problematic use pattern consistent with the development of the medical condition of opioid use disorder (<bold>OUD</bold>). Prescription and illicit opioids reduce pain perception by activating &#181;-opioid receptors (<bold>MOR</bold>) localized to the central nervous system (<bold>CNS</bold>). Dysregulation of meso-corticolimbic circuitry that subserves reward and adaptive behaviors is fundamentally involved in the progressive behavioral changes that promote and are consequent to OUD. Although opioid-induced analgesia and the rewarding effects of abused opioids are primarily mediated through MOR activation, serotonin (<bold>5-HT</bold>) is an important contributor to the pharmacology of opioid abused drugs (including heroin and prescription opioids) and OUD. There is a recent resurgence of interest into psychedelic compounds that act primarily through the 5-HT<sub>2A</sub> receptor (<bold>5-HT</bold>
<sub>
<bold>2A</bold>
</sub>
<bold>R</bold>) as a new frontier in combatting such diseases (e.g., depression, anxiety, and substance use disorders). Emerging data suggest that the MOR and 5-HT<sub>2A</sub>R crosstalk at the cellular level and within key nodes of OUD circuitry, highlighting a major opportunity for novel pharmacological intervention for OUD. There is an important gap in the preclinical profiling of psychedelic 5-HT<sub>2A</sub>R agonists in OUD models. Further, as these molecules carry risks, additional analyses of the profiles of non-hallucinogenic 5-HT<sub>2A</sub>R agonists and/or 5-HT<sub>2A</sub>R positive allosteric modulators may provide a new pathway for 5-HT<sub>2A</sub>R therapeutics. In this review, we discuss the opportunities and challenges associated with utilizing 5-HT<sub>2A</sub>R agonists as therapeutics for OUD.</p></abstract><kwd-group><kwd>opioid use disorder</kwd><kwd>serotonin</kwd><kwd>5-HT<sub>2A</sub>R</kwd><kwd>MOR</kwd><kwd>psychedelics</kwd></kwd-group><funding-group><funding-statement>This work was supported in part by R01DA038446, T32DA07287, UG3DA052282, and UG3DA050317 from the National Institutes of Health, the Chauncey Leake Distinguished Professor Endowment and the Center for Addiction Sciences and Therapeutics at UTMB.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Experimental Pharmacology and Drug Discovery</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title>1 Introduction</title><p>Opioid-involved overdose deaths remain at crisis levels in the United States (<xref rid="B35" ref-type="bibr">Ciccarone and Shoptaw, 2022</xref>; <xref rid="B1" ref-type="bibr">Ahmad et al., 2023</xref>). Initially attributable to overprescription of opioid analgesics for pain control, the overdose crisis is now amplified by deaths involving synthetic opioids in the illicit drug supply (<xref rid="B122" ref-type="bibr">Humphreys et al., 2022</xref>; <xref rid="B123" ref-type="bibr">Humphreys and Shover, 2023</xref>). Pain management practices evolved to reduce opioid-involved overdoses (<xref rid="B30" ref-type="bibr">Bruera and Del Fabbro, 2018</xref>; <xref rid="B90" ref-type="bibr">Friedman et al., 2020</xref>), however, a substantial proportion of the population remains at risk for overdose and the evolution to opioid use disorder (<bold>OUD</bold>) (<xref rid="B289" ref-type="bibr">Vowles et al., 2015</xref>; <xref rid="B287" ref-type="bibr">Volkow and McLellan, 2016</xref>). A debilitating condition with significant health consequences (<xref rid="B106" ref-type="bibr">Hasin et al., 2013</xref>), &#8764;2.7 million people aged 12 or older in the United States were diagnosed with OUD in 2020 (<xref rid="B238" ref-type="bibr">SAMHSA, 2021</xref>). The diagnosis of substance use disorders (<bold>SUDs</bold>), including OUD, in the United States is currently based upon the <italic toggle="yes">Diagnostic and Statistical Manual of Mental Disorders-5</italic> (DSM-5) which defines symptoms (e.g., taking more drug than intended, inability to stop, intense craving, withdrawal/tolerance, unsuccessful efforts to control use, etc.) on a continuum from mild (2&#8211;3 symptoms) to moderate (4&#8211;5 symptoms) to severe (6&#8211;11 symptoms) (<xref rid="B106" ref-type="bibr">Hasin et al., 2013</xref>). The <italic toggle="yes">International Statistical Classification of Diseases and Related Health Problems-10</italic> (ICD-10) criteria align in general with DSM-5 (<xref rid="B106" ref-type="bibr">Hasin et al., 2013</xref>). OUD may develop at opioid doses employed in prescription pain management (<xref rid="B177" ref-type="bibr">McAuliffe, 2013</xref>; <xref rid="B184" ref-type="bibr">Minozzi et al., 2013</xref>; <xref rid="B39" ref-type="bibr">Campbell et al., 2015</xref>; <xref rid="B69" ref-type="bibr">Degenhardt et al., 2021</xref>), although the burden of prescription OUD in pain patients is difficult to estimate (<xref rid="B101" ref-type="bibr">Guillou-Landreat et al., 2021</xref>; <xref rid="B107" ref-type="bibr">Hasin et al., 2022</xref>; <xref rid="B261" ref-type="bibr">Sullivan and Ballantyne, 2022</xref>).</p><p>The multitude of opioid compounds include opioid poppy alkaloids (e.g., morphine), semi-synthetic (e.g., heroin) and fully synthetic opioids (e.g., fentanyl and fentanyl analogs) which bind to the &#181;-opioid receptor (<bold>MOR</bold>), a G protein-coupled receptor (<bold>GPCR</bold>). Agonist-induced activation of the MOR mitigates pain and evokes intense and pleasurable euphoria, which in turn contributes to the evolution of OUD (<xref rid="B147" ref-type="bibr">Le Merrer et al., 2009</xref>; <xref rid="B11" ref-type="bibr">Baldo, 2016</xref>; <xref rid="B115" ref-type="bibr">Higginbotham et al., 2022</xref>). The activation of MOR triggers G protein coupling to intracellular signal transduction mechanisms in cells of the peripheral and central nervous system (<bold>CNS</bold>); for instance, MOR-activated G&#945;<sub>i/o</sub> inhibits adenylyl cyclase release, calcium- and voltage-gated channels to hyperpolarize and suppress neuronal activity (<xref rid="B115" ref-type="bibr">Higginbotham et al., 2022</xref>). The MOR also signals from both membrane and intracellular localizations to bias distinct downstream effector pathways which may differentially drive on- and off-target effects (<xref rid="B257" ref-type="bibr">Stoeber et al., 2018</xref>; <xref rid="B215" ref-type="bibr">Pineyro and Nagi, 2021</xref>). Chronic opioid exposure results in a myriad of cellular adaptations and plasticity in neural systems that contribute to the development and maintenance of OUD and chronic pain syndromes (<xref rid="B52" ref-type="bibr">Christie et al., 1992</xref>; <xref rid="B295" ref-type="bibr">Williams et al., 2001</xref>; <xref rid="B51" ref-type="bibr">Christie, 2008</xref>; <xref rid="B201" ref-type="bibr">O'Brien, 2009</xref>; <xref rid="B226" ref-type="bibr">Puretic and Demarin, 2012</xref>; <xref rid="B216" ref-type="bibr">Pitchers et al., 2014</xref>).</p><p>The MOR is also the target for medications for OUD (<bold>MOUD</bold>) which are effective in treating OUD, managing craving and withdrawal, as well as reducing overdoses (<xref rid="B287" ref-type="bibr">Volkow and McLellan, 2016</xref>; <xref rid="B290" ref-type="bibr">Wakeman et al., 2020</xref>; <xref rid="B27" ref-type="bibr">Brandt et al., 2023</xref>). However, the MOUD medications buprenorphine and methadone are partial and full MOR agonists, respectively, and are subject to abuse, misuse and diversion (<xref rid="B142" ref-type="bibr">Koob and Volkow, 2016</xref>; <xref rid="B49" ref-type="bibr">Chilcoat et al., 2019</xref>; <xref rid="B259" ref-type="bibr">Strang et al., 2020</xref>), prompting the field to mine mechanistic targets outside of the opioid system for novel medications for OUD (<xref rid="B58" ref-type="bibr">Coussens et al., 2019</xref>; <xref rid="B169" ref-type="bibr">Marek et al., 2019</xref>; <xref rid="B231" ref-type="bibr">Rasmussen et al., 2019</xref>). An area of intense interest is the prospect that psychedelics may be harnessed for the treatment of OUD (<xref rid="B71" ref-type="bibr">DiVito and Leger, 2020</xref>; <xref rid="B143" ref-type="bibr">Koslowski et al., 2021</xref>; <xref rid="B14" ref-type="bibr">Barnett and Weleff, 2022</xref>; <xref rid="B279" ref-type="bibr">Urban et al., 2023</xref>) and pain conditions (<xref rid="B308" ref-type="bibr">Zia et al., 2023</xref>).</p><p>Psychedelics include a large group of natural and synthetic compounds (<xref rid="B197" ref-type="bibr">Nichols, 2016</xref>) that preferentially bind to the serotonin (5-hydroxytryptamine; <bold>5-HT</bold>) 5-HT<sub>2A</sub> receptor (<bold>5-HT</bold>
<sub>
<bold>2A</bold>
</sub>
<bold>R</bold>) to alter sensory perceptions and cognitive processes in humans (<xref rid="B227" ref-type="bibr">Quednow et al., 2012</xref>; <xref rid="B139" ref-type="bibr">Kometer et al., 2013</xref>; <xref rid="B118" ref-type="bibr">Holze et al., 2021a</xref>; <xref rid="B18" ref-type="bibr">Becker et al., 2023</xref>). Intriguingly, the &#8220;classical&#8221; psychedelic <italic toggle="yes">d</italic>-lysergic acid diethylamide (<bold>LSD</bold>) was reported to evoke effective analgesia, likely linked to altered pain perception (<xref rid="B133" ref-type="bibr">Kast and Collins, 1964</xref>; <xref rid="B230" ref-type="bibr">Ramaekers et al., 2021</xref>). Furthermore, analyses of anecdotal and self-reported data support the consideration of psychedelics for treatment of OUD (<xref rid="B241" ref-type="bibr">Savage and McCabe, 1973</xref>; <xref rid="B93" ref-type="bibr">Garcia-Romeu et al., 2019</xref>; <xref rid="B8" ref-type="bibr">Argento et al., 2022</xref>; <xref rid="B130" ref-type="bibr">Jones et al., 2022</xref>), and several clinical trials with psilocybin are ongoing for OUD (e.g., NCT0416066, NCT0542029, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06005662">NCT06005662</ext-link>) and pain conditions (e.g., <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06001749">NCT06001749</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05224336">NCT05224336</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05068791">NCT05068791</ext-link>). MOR function is fundamentally integrated with 5-HT neurotransmission (<xref rid="B268" ref-type="bibr">Tao et al., 1998</xref>; <xref rid="B266" ref-type="bibr">Tao and Auerbach, 2002b</xref>; <xref rid="B267" ref-type="bibr">Tao et al., 2003</xref>; <xref rid="B207" ref-type="bibr">Ozdemir, 2017</xref>) with a prominent role for the 5-HT<sub>2A</sub>R (<xref rid="B2" ref-type="bibr">Aira et al., 2012</xref>; <xref rid="B111" ref-type="bibr">Heijmans et al., 2021</xref>; <xref rid="B152" ref-type="bibr">Li et al., 2021</xref>; <xref rid="B247" ref-type="bibr">Sierra et al., 2022</xref>), from the 5-HT<sub>2</sub>R family (5-HT<sub>2A</sub>R, 5-HT<sub>2B</sub>R, 5-HT<sub>2C</sub>R) (<xref rid="B13" ref-type="bibr">Barnes et al., 2021</xref>). As opposed to the MOR, the coupling of the 5-HT<sub>2A</sub>R to G&#945;<sub>q/11</sub> heterotrimeric G proteins triggers phosphatidylinositol-4,5-bisphosphate hydrolysis and subsequent release of inositol triphosphate, diacylglycerol, and other effectors (<xref rid="B13" ref-type="bibr">Barnes et al., 2021</xref>). Both the 5-HT<sub>2A</sub>R (<xref rid="B13" ref-type="bibr">Barnes et al., 2021</xref>) and MOR (<xref rid="B215" ref-type="bibr">Pineyro and Nagi, 2021</xref>) interact directly with intracellular &#946;-arrestins to control signaling and membrane trafficking which is driven by a diversity of cellular signaling factors. The MOR and 5-HT<sub>2A</sub>R co-express in individual neurons that mediate aspects of nociception and OUD processes (<xref rid="B156" ref-type="bibr">Lopez-Gimenez et al., 2008</xref>; <xref rid="B2" ref-type="bibr">Aira et al., 2012</xref>). Co-activation of the 5-HT<sub>2A</sub>R in heterologous cells is permissive in evoking MOR cellular localization and function (<xref rid="B156" ref-type="bibr">Lopez-Gimenez et al., 2008</xref>), actions which may contribute to 5-HT-mediated outcomes upon opioid exposure <italic toggle="yes">in vivo</italic> (<xref rid="B268" ref-type="bibr">Tao et al., 1998</xref>; <xref rid="B105" ref-type="bibr">Harris and Aston-Jones, 2001</xref>; <xref rid="B250" ref-type="bibr">Singh et al., 2003</xref>).</p><p>Much remains to be learned about cellular and circuit interactions between MOR and 5-HT<sub>2A</sub>R, and the renewed interest in psychedelics for their potential therapeutic efficacy in neuropsychiatric disorders (<xref rid="B178" ref-type="bibr">McClure-Begley and Roth, 2022</xref>; <xref rid="B251" ref-type="bibr">Slocum et al., 2022</xref>) premises the goal to explore the engagement of 5-HT<sub>2A</sub>R processes in OUD. In the current quest to develop non-opioid medications for OUD, psychedelics may provide value as medication candidates. <italic toggle="yes">The goal of the present review is to explore interactions between opioids and psychedelics as well as the opportunities and challenges for pain and OUD therapeutics</italic>.</p></sec><sec id="s2"><title>2 Psychedelic pharmacology</title><p>Psychedelics derived from plants and fungi have served significant spiritual and medical purposes since ancient times (<xref rid="B100" ref-type="bibr">Griffiths and Grob, 2010</xref>; <xref rid="B73" ref-type="bibr">Doblin et al., 2019</xref>; <xref rid="B26" ref-type="bibr">Bouso and Sanchez-Aviles, 2020</xref>). Three main structural classes of serotonergic hallucinogens include ergolines (e.g., LSD), tryptamines (e.g., psilocybin, converted by the body to the active molecule psilocin) and phenethylamines [e.g., 2,5-dimethoxy-4-methylamphetamine (<bold>DOM</bold>), 2,5-dimethoxy-4-iodophenyl]-2-aminopropane (<bold>DOI</bold>)]. These compounds share close structural similarity to the endogenous tryptamine 5-HT (<xref rid="B91" ref-type="bibr">Gaddum and Hameed, 1954</xref>) which spurred the discovery that 5-HT<sub>2A</sub>R agonist efficacy is a key mechanism of action for this class of compounds to evoke overlapping and powerful subjective effects in humans (<xref rid="B198" ref-type="bibr">Nichols and Walter, 2021</xref>), although psychedelic pharmacology is complex and nuanced (<xref rid="B121" ref-type="bibr">Howell and Cunningham, 2015</xref>; <xref rid="B45" ref-type="bibr">Castellanos et al., 2020</xref>; <xref rid="B178" ref-type="bibr">McClure-Begley and Roth, 2022</xref>; <xref rid="B301" ref-type="bibr">Wulff et al., 2023</xref>). While the presumed abuse liability and limited medical value historically restricted clinical studies of psychedelics (<xref rid="B114" ref-type="bibr">Henningfield et al., 2022</xref>; <xref rid="B113" ref-type="bibr">Hendricks et al., 2023</xref>), 5-HT<sub>2A</sub>R neurotransmission was established to mediate hallucinations in schizophrenia and Parkinson&#8217;s disease psychosis (<xref rid="B243" ref-type="bibr">Schmidt et al., 1995</xref>; <xref rid="B12" ref-type="bibr">Ballanger et al., 2010</xref>; <xref rid="B102" ref-type="bibr">Hacksell et al., 2014</xref>; <xref rid="B50" ref-type="bibr">Cho et al., 2017</xref>). With nanomolar potency as a 5-HT<sub>2A</sub>R inverse agonist/antagonist and selectivity for the 5-HT<sub>2A</sub>R over other GPCRs (<xref rid="B282" ref-type="bibr">Vanover et al., 2006</xref>), pimavanserin blocked hallucinations and delusions in refractory schizophrenia (<xref rid="B192" ref-type="bibr">Nasrallah et al., 2019</xref>) and Parkinson&#8217;s disease patients (<xref rid="B180" ref-type="bibr">Meltzer et al., 2010</xref>), and is now approved for treatment for the latter indication (<xref rid="B102" ref-type="bibr">Hacksell et al., 2014</xref>; <xref rid="B67" ref-type="bibr">Davis et al., 2021</xref>). Although the efficacy of pimavanserin to suppress psychedelic-induced hallucinations is not yet reported, the 5-HT<sub>2</sub>R antagonist ketanserin (<xref rid="B28" ref-type="bibr">Brogden and Sorkin, 1990</xref>) reversed the subjective effects (e.g., visual/auditory alterations) of LSD (<xref rid="B221" ref-type="bibr">Preller et al., 2017</xref>; <xref rid="B222" ref-type="bibr">Preller et al., 2019</xref>; <xref rid="B218" ref-type="bibr">Pokorny et al., 2020</xref>; <xref rid="B119" ref-type="bibr">Holze et al., 2021b</xref>; <xref rid="B18" ref-type="bibr">Becker et al., 2023</xref>) and psilocybin in humans (<xref rid="B227" ref-type="bibr">Quednow et al., 2012</xref>; <xref rid="B139" ref-type="bibr">Kometer et al., 2013</xref>). It is also important to recognize that the functional network mechanisms underlying psychedelic-vs. disease-evoked hallucinations are distinguishable (<xref rid="B234" ref-type="bibr">Rolland et al., 2014</xref>; <xref rid="B149" ref-type="bibr">Leptourgos et al., 2020</xref>; <xref rid="B248" ref-type="bibr">Silverstein and Lai, 2021</xref>).</p><p>Preclinical model systems are essential in linking 5-HT<sub>2A</sub>R functionality with hallucinogenesis, particularly the rodent head twitch response (<bold>HTR</bold>). The HTR is a rapid, rotational head movement evoked by LSD and other hallucinogens which is eliminated in constitutive 5-HT<sub>2A</sub>R knockout mice (<xref rid="B97" ref-type="bibr">Gonzalez-Maeso et al., 2007</xref>; <xref rid="B104" ref-type="bibr">Halberstadt and Geyer, 2010</xref>). The 5-HT<sub>2A</sub>R antagonist M100907 (MDL100907; volinanserin) exhibits &#8764;100-fold selectivity at the 5-HT<sub>2A</sub>R versus other monoamine GPCRs (<xref rid="B208" ref-type="bibr">Palfreyman et al., 1993</xref>; <xref rid="B134" ref-type="bibr">Kehne et al., 1996</xref>; <xref rid="B44" ref-type="bibr">Casey et al., 2022</xref>) and blocks psychedelic-evoked HTRs (<xref rid="B40" ref-type="bibr">Canal et al., 2013</xref>; <xref rid="B85" ref-type="bibr">Fink et al., 2015</xref>; <xref rid="B103" ref-type="bibr">Halberstadt et al., 2020</xref>). Importantly, the potency of LSD to evoke the HTR correlates positively with its potency to evoke psychoactivity in humans (<xref rid="B56" ref-type="bibr">Corne and Pickering, 1967</xref>), providing a rodent &#8220;proxy&#8221; for hallucinogenic actions. Direct cortical 5-HT<sub>2A</sub>R activation induces the HTR in rats (<xref rid="B296" ref-type="bibr">Willins and Meltzer, 1997</xref>) while the subjective response to psilocybin positively correlated with neocortical 5-HT<sub>2A</sub>R occupancy (<xref rid="B162" ref-type="bibr">Madsen et al., 2019</xref>), supporting a critical role of cortical 5-HT<sub>2A</sub>R in psychedelic mechanisms of action.</p><p>The case for the role of the 5-HT<sub>2A</sub>R in the mechanisms of action of psychedelics is strong, but we would be remiss to overlook the fact that distinct <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> profiles are recognized across psychedelic molecules which variably bind to multiple 5-HT receptors, dopamine D<sub>1</sub> receptor (<bold>D</bold>
<sub>
<bold>1</bold>
</sub>
<bold>R</bold>) and D<sub>2</sub>R, as well as other brain-localized targets (<xref rid="B121" ref-type="bibr">Howell and Cunningham, 2015</xref>; <xref rid="B45" ref-type="bibr">Castellanos et al., 2020</xref>; <xref rid="B178" ref-type="bibr">McClure-Begley and Roth, 2022</xref>; <xref rid="B301" ref-type="bibr">Wulff et al., 2023</xref>). For instance, LSD potently binds to human 5-HT<sub>2A</sub>R but also 5-HT<sub>1A</sub>R, 5-HT<sub>2C</sub>R, D<sub>2</sub>R and with some affinity for <italic toggle="yes">&#945;</italic> adrenergic, D<sub>1</sub>R and D<sub>3</sub>R (<xref rid="B232" ref-type="bibr">Rickli et al., 2015</xref>; <xref rid="B233" ref-type="bibr">Rickli et al., 2016</xref>). LSD exhibits distinct stimulus effects mediated by the 5-HT<sub>2A</sub>R (<xref rid="B64" ref-type="bibr">Cunningham et al., 1985</xref>; <xref rid="B199" ref-type="bibr">Nielsen et al., 1985</xref>; <xref rid="B63" ref-type="bibr">Cunningham and Appel, 1987</xref>; <xref rid="B62" ref-type="bibr">Cunningham and Appel, 1988</xref>; <xref rid="B9" ref-type="bibr">Baker, 2018</xref>), while lisuride, non-hallucinogenic congener of LSD, only partially substituted for LSD or DOI in drug discrimination analyses and is proposed to engage dopaminergic D<sub>2</sub>R and 5-HT<sub>1A</sub>R signaling (<xref rid="B37" ref-type="bibr">Callahan and Appel, 1990</xref>; <xref rid="B170" ref-type="bibr">Marona-Lewicka et al., 2002</xref>). Further, the recent discovery that LSD and psilocybin bind to the tropomyosin receptor kinase B receptor for brain-derived neurotrophic factor suggests new complexity to the actions of these intriguing compounds (<xref rid="B187" ref-type="bibr">Moliner et al., 2023</xref>).</p><p>Some serotonergic hallucinogens exhibit high affinity for both the 5-HT<sub>2A</sub>R and 5-HT<sub>2C</sub>R which colocalize in many of the same brain regions and are reported to interact at the cellular level <italic toggle="yes">in vitro</italic> (<xref rid="B189" ref-type="bibr">Moutkine et al., 2017</xref>; <xref rid="B82" ref-type="bibr">Felsing et al., 2018</xref>), in rat medial prefrontal cortex (<bold>mPFC</bold>) <italic toggle="yes">ex vivo</italic> (<xref rid="B224" ref-type="bibr">Price et al., 2019</xref>), and <italic toggle="yes">in vivo</italic> preclinical models (<xref rid="B217" ref-type="bibr">Pockros et al., 2012</xref>; <xref rid="B32" ref-type="bibr">Burton et al., 2013</xref>; <xref rid="B60" ref-type="bibr">Cunningham et al., 2013</xref>; <xref rid="B4" ref-type="bibr">Anastasio et al., 2015</xref>; <xref rid="B15" ref-type="bibr">Bazovkina et al., 2015</xref>; <xref rid="B189" ref-type="bibr">Moutkine et al., 2017</xref>) to control neural bases for several behaviors (<xref rid="B61" ref-type="bibr">Cunningham and Anastasio, 2014</xref>; <xref rid="B121" ref-type="bibr">Howell and Cunningham, 2015</xref>). A modulatory role for the 5-HT<sub>2C</sub>R over psychedelic actions is suggested to contribute to some behavioral outcomes in animals (<xref rid="B144" ref-type="bibr">Krebs-Thomson et al., 1998</xref>; <xref rid="B252" ref-type="bibr">Smith et al., 2003</xref>; <xref rid="B145" ref-type="bibr">Krebs-Thomson et al., 2006</xref>), while a functional interaction between the 5-HT<sub>2A</sub>R and 5-HT<sub>2C</sub>R is proposed to mediate <italic toggle="yes">in vivo</italic> effects of psilocybin in mice (<xref rid="B75" ref-type="bibr">Erkizia-Santamaria et al., 2022</xref>). Of note, endogenous 5-HT binds to the transmembrane domains that comprise the 5-HT<sub>2A</sub>R orthosteric site which shares &#8764;80% homology with the 5-HT<sub>2B</sub>R and 5-HT<sub>2C</sub>R (<xref rid="B13" ref-type="bibr">Barnes et al., 2021</xref>). Agonist actions at the 5-HT<sub>2B</sub>R cause cardiac valvulopathy and pulmonary hypertension, as seen with the anti-obesity medication fenfluramine (<xref rid="B235" ref-type="bibr">Rothman and Baumann, 2009</xref>; <xref rid="B13" ref-type="bibr">Barnes et al., 2021</xref>). LSD and psilocin, the active metabolite of psilocybin, exhibit similar affinity at the 5-HT<sub>2A</sub>R and 5-HT<sub>2B</sub>R <italic toggle="yes">in vitro</italic> (<xref rid="B220" ref-type="bibr">Porter et al., 1999</xref>), but neither are projected to pose risk for valvulopathy, particularly on acute dosing (<xref rid="B262" ref-type="bibr">Tagen et al., 2023</xref>). However, given the critical liability of off-target 5-HT<sub>2B</sub>R agonist actions (<xref rid="B120" ref-type="bibr">Horvath et al., 2004</xref>; <xref rid="B124" ref-type="bibr">Hutcheson et al., 2011</xref>), current efforts to identify 5-HT<sub>2A</sub>R-selective agonists as novel chemical entities require 5-HT<sub>2B</sub>R affinity and efficacy screening early in molecule discovery (<xref rid="B41" ref-type="bibr">Cao et al., 2022</xref>; <xref rid="B48" ref-type="bibr">Chen et al., 2023</xref>; <xref rid="B66" ref-type="bibr">Cunningham et al., 2023</xref>).</p></sec><sec id="s3"><title>3 Abuse liability of MOR agonists vs. psychedelics</title><p>The effectiveness of MOR agonists for pain management is complicated by its powerful efficacy to evoke euphoric and pleasurable effects which are at the core of their abuse liability. The FDA guidelines define abuse liability as the probability that a psychoactive drug will sustain patterns of non-medical self-administration, drug-seeking and craving, a triad likely to result in undesirable health consequences (<xref rid="B43" ref-type="bibr">Carter and Griffiths, 2009</xref>; <xref rid="B148" ref-type="bibr">Leiderman, 2009</xref>; <xref rid="B55" ref-type="bibr">Comer et al., 2012</xref>; <xref rid="B34" ref-type="bibr">Calderon et al., 2015</xref>). The capacity of a drug to maintain self-administration under experimental conditions in animals aligns well with the likelihood of abuse by humans (<xref rid="B210" ref-type="bibr">Panlilio et al., 2005</xref>; <xref rid="B260" ref-type="bibr">Sughondhabirom et al., 2005</xref>; <xref rid="B34" ref-type="bibr">Calderon et al., 2015</xref>; <xref rid="B36" ref-type="bibr">Calderon et al., 2023</xref>). This model system is based upon the operant construct that a psychoactive drug serves as a positive rewarding stimulus which increases the prospect of a behavioral response (e.g., lever press) to gain drug access (<xref rid="B188" ref-type="bibr">Morse and Skinner, 1958</xref>). This assay has high predictive validity in assessing the abuse liability of novel drugs and in aligning molecular and neurobiological adaptations associated with repeated drug self-intake in rodents (<xref rid="B202" ref-type="bibr">O'Connor et al., 2011</xref>; <xref rid="B19" ref-type="bibr">Belin-Rauscent and Belin, 2012</xref>; <xref rid="B61" ref-type="bibr">Cunningham and Anastasio, 2014</xref>; <xref rid="B121" ref-type="bibr">Howell and Cunningham, 2015</xref>; <xref rid="B194" ref-type="bibr">Neelakantan et al., 2017</xref>; <xref rid="B256" ref-type="bibr">Spanagel, 2017</xref>; <xref rid="B76" ref-type="bibr">Ezeomah et al., 2020</xref>; <xref rid="B182" ref-type="bibr">Merritt et al., 2022</xref>) and humans (<xref rid="B131" ref-type="bibr">Jones and Comer, 2013</xref>; <xref rid="B258" ref-type="bibr">Stoops, 2022</xref>). Self-administration models are widely deployed to identify the primary role for MOR mechanisms in the rewarding properties of opioid agonists (e.g., morphine, heroin, fentanyl) which are prevented by MOR antagonists naloxone or naltrexone (<xref rid="B141" ref-type="bibr">Koob et al., 1984</xref>; <xref rid="B16" ref-type="bibr">Beardsley et al., 2004</xref>; <xref rid="B150" ref-type="bibr">Leri and Burns, 2005</xref>; <xref rid="B285" ref-type="bibr">Vendruscolo et al., 2018</xref>). In contrast to MOR agonists, psychedelics [e.g., DOI, DOM, <italic toggle="yes">N</italic>,<italic toggle="yes">N</italic>-dimethyltryptamine (<bold>DMT</bold>), mescaline, psilocybin] exhibit limited reinforcing effects. At best, psychedelics support transient or sporadic drug-taking in self-administration assays (<xref rid="B78" ref-type="bibr">Fantegrossi et al., 2004a</xref>; <xref rid="B79" ref-type="bibr">Fantegrossi et al., 2004b</xref>; <xref rid="B164" ref-type="bibr">Maguire et al., 2013</xref>; <xref rid="B99" ref-type="bibr">Goodwin, 2016</xref>; <xref rid="B128" ref-type="bibr">Johnson et al., 2018</xref>), although intermittent-access self-administration may be useful to further interrogate psychedelic abuse liability (<xref rid="B99" ref-type="bibr">Goodwin, 2016</xref>). Of note, near complete tolerance to psychedelics (e.g., LSD) occurs under several dosing paradigms in humans (<xref rid="B20" ref-type="bibr">Belleville et al., 1956</xref>; <xref rid="B229" ref-type="bibr">Rosenberg et al., 1963</xref>) and animals (<xref rid="B275" ref-type="bibr">Trulson and Jacobs, 1977</xref>; <xref rid="B242" ref-type="bibr">Schlemmer et al., 1986</xref>; <xref rid="B31" ref-type="bibr">Buchborn et al., 2015</xref>), perhaps accounting for the limited repetitive abuse liability of psychedelics (<xref rid="B20" ref-type="bibr">Belleville et al., 1956</xref>).</p><p>Only a handful of studies explored the efficacy of psychedelics to alter self-administration of opioid analgesics. The psychedelic DOM attenuated heroin self-administration, resulting in a downward shift of the heroin dose-response curve in one study (<xref rid="B164" ref-type="bibr">Maguire et al., 2013</xref>); however, in a more recent study deployed in a sucrose versus drug choice procedure, DOM did not impact fentanyl intake, but did decrease completed choice trials and response rates (<xref rid="B163" ref-type="bibr">Maguire, 2023</xref>). Employing a behavioral economics variant of the self-administration paradigm which estimates unique descriptors of opioid demand as a function of its &#8220;price,&#8221; DOI decreased the motivation to consume fentanyl and total fentanyl consumption in a 5-HT<sub>2A</sub>R-dependent manner (i.e., blocked by M100907) (<xref rid="B171" ref-type="bibr">Martin et al., 2021</xref>). While initial research may support the potential usage of psychedelics to reduce the abuse liability and intake of opioids, future studies are necessary to disentangle the key mechanistic facets of psychedelics that impact opioid self-administration. That said, 5-HT<sub>2A</sub>R agonist psychedelics are thought to maintain a large margin of safety and a low level of toxicity (<xref rid="B197" ref-type="bibr">Nichols, 2016</xref>; <xref rid="B237" ref-type="bibr">Sakloth et al., 2019</xref>), particularly in contrast to opioid agonists (<xref rid="B288" ref-type="bibr">Von Korff et al., 2011</xref>; <xref rid="B126" ref-type="bibr">Jeffery et al., 2020</xref>; <xref rid="B223" ref-type="bibr">Preuss et al., 2023</xref>).</p><p>A complementary model to assess abuse liability in keeping with FDA guidelines (<xref rid="B34" ref-type="bibr">Calderon et al., 2015</xref>; <xref rid="B80" ref-type="bibr">FDA, 2017</xref>; <xref rid="B36" ref-type="bibr">Calderon et al., 2023</xref>) is the drug discrimination paradigm which is robust, sensitive and exhibits predictive validity (<xref rid="B6" ref-type="bibr">Appel et al., 1982</xref>; <xref rid="B179" ref-type="bibr">McMahon, 2015</xref>; <xref rid="B24" ref-type="bibr">Bolin et al., 2018</xref>). This assay involves training subjects through differential reinforcement to recognize the stimulus effects of a psychoactive drug versus no (or another) drug. Useful in establishing whether novel CNS-active compounds are predicted to have abuse liability (<xref rid="B255" ref-type="bibr">Soto et al., 2019</xref>; <xref rid="B294" ref-type="bibr">Wild et al., 2019</xref>; <xref rid="B299" ref-type="bibr">Wold et al., 2020</xref>; <xref rid="B258" ref-type="bibr">Stoops, 2022</xref>), this assay is an indirect measure of reinforcing efficacy with remarkable pharmacological specificity and utility in assessing <italic toggle="yes">in vivo</italic> pharmacology in humans and animals (<xref rid="B131" ref-type="bibr">Jones and Comer, 2013</xref>; <xref rid="B179" ref-type="bibr">McMahon, 2015</xref>; <xref rid="B24" ref-type="bibr">Bolin et al., 2018</xref>; <xref rid="B258" ref-type="bibr">Stoops, 2022</xref>). Drug discrimination analyses established deep knowledge of the neural mechanisms underlying the interoceptive effects of MOR agonists (<xref rid="B16" ref-type="bibr">Beardsley et al., 2004</xref>; <xref rid="B159" ref-type="bibr">Meert and Vermeirsch, 2005</xref>; <xref rid="B244" ref-type="bibr">Schwienteck et al., 2019</xref>; <xref rid="B291" ref-type="bibr">Walker et al., 2021</xref>), which are blocked by naloxone or naltrexone (<xref rid="B16" ref-type="bibr">Beardsley et al., 2004</xref>; <xref rid="B89" ref-type="bibr">Flynn and France, 2021</xref>), albeit larger doses are required to block the long-acting MOR agonist carfentanil (<xref rid="B89" ref-type="bibr">Flynn and France, 2021</xref>). Drug discrimination assays also detailed a complex interaction between MOR agonists with kappa and delta opioid receptor agonists and mixed agonists (<xref rid="B214" ref-type="bibr">Picker, 1997</xref>; <xref rid="B302" ref-type="bibr">Yadlapalli et al., 2018</xref>).</p><p>In contrast to the limited psychedelic intake seen in self-administration models, animals readily learn to discriminate the interoceptive effects of hallucinogens (e.g., LSD, DOM, DOI, and others) from no drug (e.g., saline) and cross-substitution occurs across this class of drugs (<xref rid="B6" ref-type="bibr">Appel et al., 1982</xref>; <xref rid="B5" ref-type="bibr">Appel and Cunningham, 1986</xref>; <xref rid="B87" ref-type="bibr">Fiorella et al., 1995b</xref>; <xref rid="B86" ref-type="bibr">a</xref>;<xref rid="B9" ref-type="bibr">Baker, 2018</xref>; <xref rid="B24" ref-type="bibr">Bolin et al., 2018</xref>; <xref rid="B108" ref-type="bibr">Heal et al., 2018</xref>). The effective doses of hallucinogens in drug discrimination analyses correlate significantly with their potency to evoke hallucinations in humans, HTRs in rodents as well as affinity as 5-HT<sub>2A</sub>R agonists (<xref rid="B96" ref-type="bibr">Glennon et al., 1983</xref>; <xref rid="B236" ref-type="bibr">Sadzot et al., 1989</xref>; <xref rid="B196" ref-type="bibr">Nelson et al., 1999</xref>; <xref rid="B103" ref-type="bibr">Halberstadt et al., 2020</xref>). Notably, for a series of 5-HT<sub>2</sub>R antagonists tested, the dose that blocked 50% of the stimulus effects of LSD correlated significantly with the affinity for the 5-HT<sub>2A</sub>R, but not the 5-HT<sub>2C</sub>R (<xref rid="B199" ref-type="bibr">Nielsen et al., 1985</xref>; <xref rid="B87" ref-type="bibr">Fiorella et al., 1995b</xref>). This 5-HT<sub>2A</sub>R-dominant mechanism occurs within the 30-min pretreatment timeframe with 5-HT<sub>2A</sub>R antagonists, while a late-stage (90&#160;min) of the stimulus effects of LSD involve dopamine D<sub>2</sub>R properties (<xref rid="B170" ref-type="bibr">Marona-Lewicka et al., 2002</xref>). There is conjecture that these time-dependent effects in drug discrimination may align with the transition from the psychedelic effects to aversive aspects of the experience (<xref rid="B170" ref-type="bibr">Marona-Lewicka et al., 2002</xref>; <xref rid="B304" ref-type="bibr">Zamberlan et al., 2018</xref>). Interestingly, a recent analysis speculated that opioid receptors may be involved in the reported subjective effects of psychedelics (<xref rid="B304" ref-type="bibr">Zamberlan et al., 2018</xref>).</p></sec><sec id="s4"><title>4 The 5-HT<sub>2A</sub>R as a target for opioid use disorder</title><p>Opioid signaling, particularly through the MOR, is mechanistically implicated in the rewarding effects of abused opioids (<xref rid="B141" ref-type="bibr">Koob et al., 1984</xref>; <xref rid="B195" ref-type="bibr">Negus et al., 1993</xref>) as well as pain relief in rodents (<xref rid="B137" ref-type="bibr">King et al., 2011</xref>; <xref rid="B204" ref-type="bibr">Okun et al., 2011</xref>; <xref rid="B193" ref-type="bibr">Navratilova et al., 2012</xref>) and humans (<xref rid="B17" ref-type="bibr">Becerra and Borsook, 2008</xref>), effects mediated by meso-corticolimbic circuitry (<xref rid="B259" ref-type="bibr">Strang et al., 2020</xref>). These actions in circuitry are ultimately dependent upon the selectivity of opioid compounds for MOR, potency, half-life, pharmacokinetics and specific pharmacological profiles (<xref rid="B280" ref-type="bibr">Vearrier and Grundmann, 2021</xref>). With continuing abuse in vulnerable individuals, initially impulsive opioid use evolves to compulsive use which reflects direct and indirect actions and adaptations within neurocircuitry (<xref rid="B161" ref-type="bibr">Madden et al., 1997</xref>; <xref rid="B10" ref-type="bibr">Bakhshipour-Rudsari and Karimpour-Vazifehkhorani, 2021</xref>; <xref rid="B272" ref-type="bibr">Tolomeo et al., 2021</xref>; <xref rid="B212" ref-type="bibr">Peck et al., 2022</xref>). The evolution from initial opioid use to diagnosis of OUD involves altered biological homeostasis, rendering behavior increasingly resistant to change, even in the face of the negative consequences (<xref rid="B142" ref-type="bibr">Koob and Volkow, 2016</xref>; <xref rid="B259" ref-type="bibr">Strang et al., 2020</xref>). An overactive incentive-motivational system centered in ventral tegmental area (<bold>VTA</bold>) dopamine (<bold>DA</bold>) neurons and its neural projections to the nucleus accumbens (<bold>NAc</bold>) serves as the &#8220;accelerator&#8221; (reward, persistent drug-induced behaviors) (<xref rid="F1" ref-type="fig">Figure 1</xref>). Subregions of the prefrontal cortex (<bold>PFC</bold>) play both direct and subtle regulatory roles as a &#8220;behavioral brake&#8221; over drug use (inhibitory control, executive function) and is vulnerable to disruption by chronic opioid exposure leading to heightened preoccupation and anticipation of drug acquisition (<xref rid="B278" ref-type="bibr">Ujcikova et al., 2021</xref>; <xref rid="B46" ref-type="bibr">Ceceli et al., 2023</xref>). A well-characterized role for the 5-HT<sub>2A</sub>R in meso-corticolimbic neurocircuitry serves to illustrate the power and complexity of this system (<xref rid="F1" ref-type="fig">Figure 1</xref>).</p><fig position="float" id="F1" orientation="portrait"><label>FIGURE 1</label><caption><p>Cellular distribution of 5-HT<sub>2A</sub>R and MOR within meso-corticolimbic circuitry derived primarily from rodent studies. Serotonergic axons from DRN (<bold>red arrows</bold>) innervate the circuit. The VTA consists of locally projecting GABA interneurons (<bold>blue</bold>) and dopaminergic neurons (<bold>orange</bold>) that project to the NAc and PFC. In the PFC, GABAergic interneurons (<bold>blue</bold>) project locally while pyramidal glutamatergic neurons in the PFC (<bold>green</bold>) project to NAc and VTA. The NAc is comprised of GABA medium spiny neurons (<bold>blue</bold>) that project to VTA and other structures not shown. Figure created with <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://BioRender.com" ext-link-type="uri">BioRender.com</ext-link>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fphar-14-1239159-g001.jpg"/></fig><p>A large population (50%&#8211;66%) of PFC pyramidal neurons express the 5-HT<sub>2A</sub>R (<xref rid="B22" ref-type="bibr">Blue et al., 1988</xref>; <xref rid="B183" ref-type="bibr">Miner et al., 2003</xref>; <xref rid="B239" ref-type="bibr">Santana et al., 2004</xref>) within layer V pyramidal neurons (<xref rid="B219" ref-type="bibr">Pompeiano et al., 1994</xref>; <xref rid="B157" ref-type="bibr">Lopez-Gimenez et al., 2001</xref>; <xref rid="B3" ref-type="bibr">Amargos-Bosch et al., 2004</xref>; <xref rid="B224" ref-type="bibr">Price et al., 2019</xref>) which affords stimulatory glutamate drive to the VTA DA neurons (<xref rid="B284" ref-type="bibr">Vazquez-Borsetti et al., 2009</xref>; <xref rid="B283" ref-type="bibr">Vazquez-Borsetti et al., 2011</xref>) and NAc (<xref rid="B185" ref-type="bibr">Mocci et al., 2014</xref>), indirectly enhancing mesolimbic DA neurotransmission. Intriguingly, PFC axons preferentially contact VTA DA neurons that project back to the mPFC (<xref rid="B42" ref-type="bibr">Carr and Sesack, 2000</xref>). Systemic administration or direct infusion of the 5-HT<sub>2A</sub>R agonist and hallucinogen DOI into the medial PFC (<bold>mPFC</bold>) not only evokes the HTR (<xref rid="B296" ref-type="bibr">Willins and Meltzer, 1997</xref>), but also increases the rate of firing of VTA DA neurons (<xref rid="B25" ref-type="bibr">Bortolozzi et al., 2005</xref>) with both outcomes blocked by the selective 5-HT<sub>2A</sub>R antagonist M100907 (<xref rid="B296" ref-type="bibr">Willins and Meltzer, 1997</xref>; <xref rid="B25" ref-type="bibr">Bortolozzi et al., 2005</xref>). Intra-mPFC infusion of M100907 blocked DOI-evoked mesocortical DA release in the VTA and DA release in the mPFC of the same rats, supporting the clarification that 5-HT<sub>2A</sub>R activation of corticotegmental glutamate projections synapse on mesocortical DA neurons (<xref rid="B213" ref-type="bibr">Pehek et al., 2006</xref>). Also, systemic DOI increased glutamate release in the VTA, which was blocked by intracortical administration of M100907 (<xref rid="B213" ref-type="bibr">Pehek et al., 2006</xref>). Thus, the 5-HT<sub>2A</sub>R in PFC projections increases stimulatory drive on the VTA, explaining the observed 5-HT<sub>2A</sub>R-stimulated DA release in the PFC (<xref rid="B25" ref-type="bibr">Bortolozzi et al., 2005</xref>; <xref rid="B213" ref-type="bibr">Pehek et al., 2006</xref>). Of note, this multi-synaptic template is likely to have additional elements, since approximately 50% of the 5-HT<sub>2A</sub>R-expressing pyramidal neurons that synapse in the VTA also synapse in the dorsal raphe nucleus (<bold>DRN</bold>), the major contributor to serotonergic innervation of PFC (<xref rid="B284" ref-type="bibr">Vazquez-Borsetti et al., 2009</xref>) with broad opportunities for modified 5-HT<sub>2A</sub>R control of meso-corticolimbic pathways involved in opioid actions. Further, activation of the 5-HT<sub>2A</sub>R is essential for induction of cortical neuroplasticity, giving rise to the hypothesis that 5-HT<sub>2A</sub>R agonists hold promise to &#8220;liberate&#8221; cortical activity as a therapeutic approach (<xref rid="B158" ref-type="bibr">Ly et al., 2018</xref>). Future studies should explore the nature of &#8220;corrective&#8221; neuroplasticity (as may occur with psychedelics) vs. &#8220;deranged&#8221; neuroplasticity (noted as decreased function of normal reward and cognitive function in OUD) to understand vulnerability to continued drug use and relapse vulnerability (<xref rid="B140" ref-type="bibr">Koob and Le Moal, 2005</xref>).</p><p>Opioid and 5-HT<sub>2A</sub>R biology intersect at multiple circuit and cellular levels (<xref rid="B13" ref-type="bibr">Barnes et al., 2021</xref>; <xref rid="B111" ref-type="bibr">Heijmans et al., 2021</xref>; <xref rid="B240" ref-type="bibr">Sasaki et al., 2021</xref>). Systemic administration of the MOR agonists morphine and fentanyl acutely raises extracellular 5-HT levels in the DRN and areas of the forebrain that receive innervation from 5-HT DRN efferents (i.e., PFC, striatum, amygdala, etc.) (<xref rid="B265" ref-type="bibr">Tao and Auerbach, 1995</xref>; <xref rid="B264" ref-type="bibr">2002a</xref>; <xref rid="B267" ref-type="bibr">Tao et al., 2003</xref>) (<xref rid="F1" ref-type="fig">Figure 1</xref>). Interestingly, this effect wanes upon repeated exposure to opioid agonists indicating a reduced responsivity of 5-HT signaling with chronic opioid use (<xref rid="B268" ref-type="bibr">Tao et al., 1998</xref>). Extracellular 5-HT in the raphe is also significantly diminished during opioid withdrawal which likely contributes to abstinence evoked phenomena (<xref rid="B268" ref-type="bibr">Tao et al., 1998</xref>). Further, functional crosstalk between the MOR and 5-HT<sub>2A</sub>R was suggested to regulate opioid-mediated abuse liability (<xref rid="B168" ref-type="bibr">Marek, 2003</xref>; <xref rid="B156" ref-type="bibr">Lopez-Gimenez et al., 2008</xref>; <xref rid="B186" ref-type="bibr">Mohammadi et al., 2016</xref>; <xref rid="B209" ref-type="bibr">Pang et al., 2016</xref>; <xref rid="B194" ref-type="bibr">Neelakantan et al., 2017</xref>; <xref rid="B247" ref-type="bibr">Sierra et al., 2022</xref>). Morphine and other opioids suppress LSD-evoked HTRs, most likely through 5-HT<sub>2A</sub>R agonist actions (<xref rid="B57" ref-type="bibr">Corne et al., 1963</xref>; <xref rid="B286" ref-type="bibr">Vetulani et al., 1980</xref>). The selective 5-HT<sub>2A</sub>R antagonist M100907 augments the antinociceptive effects of the MOR agonist oxycodone in a sex-specific manner in mice supporting a role for 5-HT<sub>2A</sub>R mechanisms in MOR evoked analgesia (<xref rid="B247" ref-type="bibr">Sierra et al., 2022</xref>). The psychedelics DOM and quipazine (<xref rid="B68" ref-type="bibr">de la Fuente Revenga et al., 2021</xref>) decreased the discriminative stimulus effects of morphine in monkeys in a 5-HT<sub>2A</sub>R-dependent manner (<xref rid="B153" ref-type="bibr">Li et al., 2011</xref>). Nonetheless, the exact mechanistic nature of this interaction between 5-HT<sub>2A</sub>R and MOR systems is difficult to disentangle based upon current knowledge, but we propose the convergent effects of the 5-HT<sub>2A</sub>R and opioid systems may occur at the level of the mPFC (<xref rid="F1" ref-type="fig">Figure 1</xref>) (<xref rid="B296" ref-type="bibr">Willins and Meltzer, 1997</xref>).</p><p>Signaling through MOR VTA and NAc are well studied (<xref rid="B273" ref-type="bibr">Trigo et al., 2010</xref>; <xref rid="B84" ref-type="bibr">Fields and Margolis, 2015</xref>), and the MOR also localizes in high density to the PFC (<xref rid="B269" ref-type="bibr">Tempel and Zukin, 1987</xref>; <xref rid="B166" ref-type="bibr">Mansour et al., 1988</xref>; <xref rid="B165" ref-type="bibr">Mansour et al., 1995</xref>) (<xref rid="F1" ref-type="fig">Figure 1</xref>) which is highlighted as a &#8220;hot spot&#8221; for dysregulated motivational function and opioid-mediated behaviors (<xref rid="B11" ref-type="bibr">Baldo, 2016</xref>). The MOR localizes in &#947;-aminobutyric acid (<bold>GABA</bold>) interneurons in the neocortex and is proposed to disinhibit glutamate-driven outflow to its terminal fields (<xref rid="B263" ref-type="bibr">Taki et al., 2000</xref>; <xref rid="B83" ref-type="bibr">Ferezou et al., 2007</xref>). A subset of cortical glutamate neurons is also reported to express MOR (<xref rid="B21" ref-type="bibr">Birdsong et al., 2019</xref>; <xref rid="B306" ref-type="bibr">Zhang et al., 2020</xref>; <xref rid="B74" ref-type="bibr">Du et al., 2022</xref>). Opportunistically, the 5-HT<sub>2A</sub>R localizes within these key regions (<xref rid="F1" ref-type="fig">Figure 1</xref>) (<xref rid="B155" ref-type="bibr">Liu et al., 2014</xref>; <xref rid="B121" ref-type="bibr">Howell and Cunningham, 2015</xref>; <xref rid="B29" ref-type="bibr">Browne et al., 2019</xref>; <xref rid="B65" ref-type="bibr">Cunningham et al., 2020</xref>; <xref rid="B190" ref-type="bibr">Nagai et al., 2020</xref>). Intriguingly, repeated morphine treatment of rats elevates 5-HT<sub>2A</sub>R protein levels within the PFC as assessed <italic toggle="yes">ex vivo</italic> (<xref rid="B209" ref-type="bibr">Pang et al., 2016</xref>), while altered 5-HT<sub>2A</sub>R-mediated G&#945;<sub>q/11</sub> activation was observed in the dorsolateral PFC dissected from <italic toggle="yes">postmortem</italic> brains of OUD patients (<xref rid="B203" ref-type="bibr">Odagaki et al., 2021</xref>), suggesting that the 5-HT<sub>2A</sub>R in PFC plays a role in the modulation of processes involved in OUD.</p><p>Cellular colocalization of 5-HT<sub>2A</sub>R and MOR transcripts was observed in layer V of rat neocortex (<xref rid="B156" ref-type="bibr">Lopez-Gimenez et al., 2008</xref>), although the resident cell type remains to be described. MOR agonists suppress 5-HT<sub>2A</sub>R agonist-mediated excitation of PFC pyramidal neurons (<xref rid="B167" ref-type="bibr">Marek and Aghajanian, 1998</xref>). Along these lines, in the presence of 5-HT<sub>2A</sub>R expression, upregulation of MOR levels was observed, and co-addition of 5-HT plus morphine resulted in rapid desensitization, internalization and downregulation of MOR in cellular models; these effects were not observed in the absence of 5-HT<sub>2A</sub>R transfection (<xref rid="B156" ref-type="bibr">Lopez-Gimenez et al., 2008</xref>). As morphine-induced MOR desensitization was demonstrated to maintain potent analgesic efficacy without leading to antinociceptive tolerance (<xref rid="B135" ref-type="bibr">Kim et al., 2008</xref>), co-activation of 5-HT<sub>2A</sub>R and MOR may provide an opportunity for opioid-sparing therapy for conditions of chronic opioid pain management or to reduce the likelihood of OUD development. Taken together, these behavioral and cellular observations putatively support a cooperative MOR and 5-HT<sub>2A</sub>R regulation of outflow of the PFC (<xref rid="B167" ref-type="bibr">Marek and Aghajanian, 1998</xref>) to control output of OUD neurocircuitry, and premise future studies to further clarify this hypothesis.</p></sec><sec id="s5"><title>5 Novel perspectives in 5-HT<sub>2A</sub>R molecule discovery</title><p>Largely based on the historical bias that all psychedelics evoke hallucinations and have abuse potential (and remain in Schedule I), there is an important gap in the preclinical profiling of 5-HT<sub>2A</sub>R agonists in OUD models. New chemical biology initiatives are underway to identify novel 5-HT<sub>2A</sub>R agonist-targeted molecules with distinctive profiles, perhaps lacking hallucinogenic effects, as seen with structural congeners the hallucinogen LSD and non-hallucinogen lisuride (<xref rid="B292" ref-type="bibr">White and Appel, 1982</xref>; <xref rid="B293" ref-type="bibr">White, 1986</xref>; <xref rid="B98" ref-type="bibr">Gonzalez-Maeso et al., 2003</xref>). In particular, there is intense investment in characterizing the promise of hallucinogenic and non-hallucinogenic 5-HT<sub>2A</sub>R agonists for medications development for OUD and other SUDs (<xref rid="B71" ref-type="bibr">DiVito and Leger, 2020</xref>; <xref rid="B143" ref-type="bibr">Koslowski et al., 2021</xref>; <xref rid="B14" ref-type="bibr">Barnett and Weleff, 2022</xref>; <xref rid="B129" ref-type="bibr">Jones and Nock, 2022</xref>; <xref rid="B279" ref-type="bibr">Urban et al., 2023</xref>). One such effort focused on ibogaine, an indole alkaloid derived from the evergreen shrub <italic toggle="yes">Tabernanthe iboga</italic> (<xref rid="B127" ref-type="bibr">Jenks, 2002</xref>). Ibogaine is a molecule with affinity for opioid receptors which is reported to decrease opioid withdrawal symptoms (<xref rid="B211" ref-type="bibr">Parke et al., 2002</xref>; <xref rid="B174" ref-type="bibr">Mash, 2023</xref>) and alleviate drug cravings (<xref rid="B172" ref-type="bibr">Mash et al., 2016</xref>; <xref rid="B173" ref-type="bibr">Mash et al., 2018</xref>; <xref rid="B200" ref-type="bibr">Noller et al., 2018</xref>; <xref rid="B174" ref-type="bibr">Mash, 2023</xref>). The hallucinogen ibogaine has a complex mechanism of action (<xref rid="B175" ref-type="bibr">Mash et al., 1995a</xref>; <xref rid="B176" ref-type="bibr">Mash et al., 1995b</xref>) and an unacceptable safety profile (<xref rid="B138" ref-type="bibr">Koenig et al., 2014</xref>; <xref rid="B271" ref-type="bibr">Thurner et al., 2014</xref>), but recently served as a promising starting point for new chemical entities (<xref rid="B38" ref-type="bibr">Cameron et al., 2021</xref>). The synthesis of ibogaine analogs resulted in identification of tabernanthalog (<bold>TBG</bold>) which exhibits a better preclinical safety profile than ibogaine (<xref rid="B38" ref-type="bibr">Cameron et al., 2021</xref>). The TBG binding profile is, however, complex as multiple receptor systems are involved in its pharmacology, including the 5-HT<sub>2A</sub>R, 5-HT<sub>2C</sub>R as well as other monoamine receptors, the 5-HT transporter and monoamine oxidase (<xref rid="B38" ref-type="bibr">Cameron et al., 2021</xref>). This unique molecule did not evoke HTRs in rodents, suggesting the possibility that TBG serves an example of a &#8220;non-hallucinogenic&#8221; derivative which is effective in reducing alcohol and heroin intake in rodents, but not sucrose ingestion, effects blocked by ketanserin (<xref rid="B38" ref-type="bibr">Cameron et al., 2021</xref>; <xref rid="B112" ref-type="bibr">Heinsbroek et al., 2023</xref>).</p><p>An historically interesting compound is BOL-148 (2-bromo-LSD) (<xref rid="B274" ref-type="bibr">Troxler and Hofmann, 1957</xref>; <xref rid="B151" ref-type="bibr">Lewis et al., 2023</xref>) which was initially identified in the 1950s as lacking hallucinogenic effects (<xref rid="B276" ref-type="bibr">Turner et al., 1959</xref>; <xref rid="B132" ref-type="bibr">Karst et al., 2010</xref>). BOL-148, long recognized for its inability to evoke HTRs (<xref rid="B56" ref-type="bibr">Corne and Pickering, 1967</xref>), blocked the psychological effects of LSD in a small human study (<xref rid="B94" ref-type="bibr">Ginzel and Mayer-Gross, 1956</xref>). More recent studies validated that BOL-148 lacks efficacy to evoke HTRs but does exhibit an antidepressant-like profile in mice, and 5-HT<sub>2A</sub>R-dependent neuronal plasticity (<xref rid="B151" ref-type="bibr">Lewis et al., 2023</xref>). An additional molecule, Ariadne (4-methyl-2,5-dimethoxy-alpha-ethylphenethylamine) did not evoke classical psychedelic effects in humans (<xref rid="B246" ref-type="bibr">Shulgin and Shulgin, 1991</xref>) nor the HTR in mice (<xref rid="B66" ref-type="bibr">Cunningham et al., 2023</xref>), but drug discrimination analyses demonstrated substitution for the empathogen 3,4-methylenedioxymethamphetamine (<xref rid="B95" ref-type="bibr">Glennon, 1993</xref>) and LSD (<xref rid="B297" ref-type="bibr">Winter, 1980</xref>). Thus, Ariadne exhibits an interesting behavioral profile as a unique non-hallucinogenic molecule possibly distinguished from classical hallucinogens at the level of restricted 5-HT<sub>2A</sub>R signaling efficacy (<xref rid="B66" ref-type="bibr">Cunningham et al., 2023</xref>).</p><p>These advances are key steps toward our future understanding of 5-HT<sub>2A</sub>R signaling specificity as well as the requirements for maximizing psychedelics for therapeutic efficacy and rationally designing such analogs (<xref rid="B158" ref-type="bibr">Ly et al., 2018</xref>; <xref rid="B206" ref-type="bibr">Olson et al., 2018</xref>; <xref rid="B38" ref-type="bibr">Cameron et al., 2021</xref>; <xref rid="B72" ref-type="bibr">Dong et al., 2021</xref>; <xref rid="B41" ref-type="bibr">Cao et al., 2022</xref>; <xref rid="B66" ref-type="bibr">Cunningham et al., 2023</xref>). Additionally, molecular studies of ligand-activated GPCRs and GPCR-transducer complexes are expanding our understanding of how 5-HT<sub>2A</sub>R activation leads to biased and unbiased signal transduction (<xref rid="B117" ref-type="bibr">Hilger et al., 2018</xref>; <xref rid="B136" ref-type="bibr">Kim et al., 2020</xref>). As the science of 5-HT<sub>2A</sub>R molecular signaling advances to define hallucinogenic versus non-hallucinogenic 5-HT<sub>2A</sub>R agonists, future studies will allow interrogation of how 5-HT<sub>2A</sub>R agonists with distinct profiles of biased signaling efficacy may impact opioid-evoked behaviors and their relative propensity to correct opioid-mediated neuronal dysfunction.</p><p>Selective 5-HT<sub>2A</sub>R activation may be useful in combating impaired serotonergic control that contributes to vulnerability to pain conditions and OUD. As noted, selective agonist targeting of the 5-HT<sub>2A</sub>R and/or 5-HT<sub>2C</sub>R is challenged by the high sequence homology with the 5-HT<sub>2B</sub>R at the 5-HT orthosteric binding pocket at which repeated activation can cause valvulopathy and pulmonary hypertension (<xref rid="B88" ref-type="bibr">Fitzgerald et al., 2000</xref>). While activation of the 5-HT<sub>2C</sub>R may be a benefit for pain management and/or treatment of OUD (<xref rid="B191" ref-type="bibr">Nakai et al., 2010</xref>; <xref rid="B194" ref-type="bibr">Neelakantan et al., 2017</xref>; <xref rid="B160" ref-type="bibr">Ma et al., 2019</xref>; <xref rid="B231" ref-type="bibr">Rasmussen et al., 2019</xref>; <xref rid="B116" ref-type="bibr">Higgins et al., 2020</xref>), there are on-target side effects such as hypophagia and anhedonia (<xref rid="B146" ref-type="bibr">Lam et al., 2008</xref>; <xref rid="B303" ref-type="bibr">Yamamoto et al., 2017</xref>) as is the case for 5-HT<sub>2A</sub>R agonists (hallucinations) that may limit their clinical practicality (<xref rid="B245" ref-type="bibr">Shalit et al., 2019</xref>; <xref rid="B205" ref-type="bibr">Olson, 2021</xref>). In addition to direct agonist actions at GPCRs, allosteric modulation is an alternate strategy to design ligands that do not directly engage the orthosteric binding pocket, but rather modulate the function of the GPCR. A positive allosteric modulator (<bold>PAM</bold>) can increase receptor functional responses and/or the intrinsic affinity for the orthosteric ligand through binding to sites on GPCRs that are topographically distinct from the orthosteric site targeted by endogenous (i.e., 5-HT) and synthetic agonists (<xref rid="B154" ref-type="bibr">Lindsley et al., 2016</xref>; <xref rid="B298" ref-type="bibr">Wold et al., 2019a</xref>). Several medicinal chemistry campaigns reported 5-HT<sub>2C</sub>R PAMs with pharmacological profiles different from agonists (<xref rid="B92" ref-type="bibr">Garcia-Carceles et al., 2017</xref>; <xref rid="B300" ref-type="bibr">Wold et al., 2019b</xref>; <xref rid="B249" ref-type="bibr">Singh et al., 2019</xref>; <xref rid="B294" ref-type="bibr">Wild et al., 2019</xref>; <xref rid="B299" ref-type="bibr">Wold et al., 2020</xref>; <xref rid="B48" ref-type="bibr">Chen et al., 2023</xref>). In this light, oleamide is an intriguing example of an endogenous lipid in mammals (<xref rid="B7" ref-type="bibr">Arafat et al., 1989</xref>; <xref rid="B59" ref-type="bibr">Cravatt et al., 1995</xref>) that controls behavior (<xref rid="B110" ref-type="bibr">Hedlund et al., 2003</xref>; <xref rid="B254" ref-type="bibr">Soria-Gomez et al., 2010</xref>; <xref rid="B225" ref-type="bibr">Prospero-Garcia et al., 2016</xref>; <xref rid="B181" ref-type="bibr">Mendez-Diaz et al., 2019</xref>) and activates 5-HT<sub>2A</sub>R signaling (<xref rid="B41" ref-type="bibr">Cao et al., 2022</xref>), but non-selectively (<xref rid="B270" ref-type="bibr">Thomas et al., 1997</xref>; <xref rid="B23" ref-type="bibr">Boger et al., 1998</xref>; <xref rid="B47" ref-type="bibr">Cheer et al., 1999</xref>; <xref rid="B109" ref-type="bibr">Hedlund et al., 1999</xref>; <xref rid="B81" ref-type="bibr">Fedorova et al., 2001</xref>). A recent synthetic campaign resulted in a series of oleamide-based analogues characterized as selective 5-HT<sub>2C</sub>R PAMs or dual 5-HT<sub>2C</sub>R/5-HT<sub>2A</sub>R PAMs (<xref rid="B48" ref-type="bibr">Chen et al., 2023</xref>), as seen with another the natural product derivative PNU-69176E (<xref rid="B125" ref-type="bibr">Im et al., 2003</xref>; <xref rid="B70" ref-type="bibr">Ding et al., 2012</xref>). In the process, CTW0404 and CTW0419 were identified as potential 5-HT<sub>2A</sub>R PAMs which exhibit distinct pharmacological profiles relative to 5-HT<sub>2A</sub>R agonists (WO2023023287A1) (<xref rid="B307" ref-type="bibr">Zhou et al., 2023</xref>). These new discoveries allow for future studies to explore the possibility that 5-HT<sub>2A</sub>R PAMs may be an alternative strategy to engage a subset of 5-HT<sub>2A</sub>R-mediated biological actions distinct from psychedelic 5-HT<sub>2A</sub>R agonists.</p></sec><sec sec-type="conclusion" id="s6"><title>6 Conclusion</title><p>Medications that are FDA-approved for OUD are available, however even when utilized, OUD patients maintain a high propensity for relapse and overdose death (<xref rid="B27" ref-type="bibr">Brandt et al., 2023</xref>) and suffer adverse side effects on current MOUD (<xref rid="B77" ref-type="bibr">FDA, 2018</xref>). Here, we reviewed evidence for 5-HT<sub>2A</sub>R agonists as novel therapeutics for OUD and propose potential next steps in the elucidation of the complex interactions occurring between 5-HT<sub>2A</sub>R and MOR systems. The behavioral evidence implicates the potential of functional MOR and 5-HT<sub>2A</sub>R interactions in regions controlling opioid-evoked behavioral outcomes and MOR and 5-HT<sub>2A</sub>R are known to colocalize within nodes of OUD circuitry. However, the degree to which cellular and signaling dynamics mediate crosstalk between the MOR and 5-HT<sub>2A</sub>R in the mPFC and how these may be modulated by opioids or exploited by psychedelics remains unresolved. Notably, we focus here on MOR to the exclusion of kappa, delta and nociceptin receptors which are involved in pain (<xref rid="B53" ref-type="bibr">Chu Sin Chung and Kieffer, 2013</xref>; <xref rid="B305" ref-type="bibr">Zaveri, 2016</xref>; <xref rid="B253" ref-type="bibr">Snyder et al., 2018</xref>; <xref rid="B228" ref-type="bibr">Quirion et al., 2020</xref>) and OUD (<xref rid="B33" ref-type="bibr">Butelman et al., 2012</xref>; <xref rid="B53" ref-type="bibr">Chu Sin Chung and Kieffer, 2013</xref>; <xref rid="B281" ref-type="bibr">Valentino and Volkow, 2018</xref>; <xref rid="B277" ref-type="bibr">Ubaldi et al., 2021</xref>) and could play a role in the psychomimetic effects of psychedelics (<xref rid="B54" ref-type="bibr">Clark and Abi-Dargham, 2019</xref>). Further, while classical psychedelics that act as 5-HT<sub>2A</sub>R agonists are showing promise for treatment of facets of OUD, these molecules carry risks (abuse, side effects) and may not be a viable option for many patients. Thus, further analyses of the profiles of non-hallucinogenic 5-HT<sub>2A</sub>R agonists and/or 5-HT<sub>2A</sub>R PAMs provides a new frontier to further characterize the therapeutic potential of the 5-HT<sub>2A</sub>R. Finally, as discussed above psychedelics exhibit a promiscuous pharmacology (e.g., 5-HT<sub>2C</sub>R affinity and efficacy) and how these &#8220;off-target&#8221; effects contribute to therapeutic efficacy is an important question for the field at large as is a greater knowledge of the interactions between psychedelics and the opioid system.</p></sec></body><back><sec id="s7"><title>Author contributions</title><p>All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.</p></sec><sec sec-type="COI-statement" id="s9"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s10"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec id="s11"><title>Abbreviations</title><p>5-HT, serotonin; 5-HT2AR, 5-HT2A receptor; BOL-148, 2-bromo-LSD; CNS, central nervous system; D1R, dopamine 1 receptor; D2R, dopamine 2 receptor; DA, dopamine; DMT, N,N-dimethyltryptamine; DOI, 1-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane; DOM, 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane; DRN, dorsal raphe nucleus; GABA, &#947;-aminobutyric acid; GPCR, G protein-coupled receptor; HTR, head twitch response; LSD, d-lysergic acid diethylamide; MOR, &#181;-opioid receptor; MOUD, medication for opioid use disorder; mPFC, medial prefrontal cortex; NAc, nucleus accumbens; OUD, opioid use disorder; PFC, prefrontal cortex; TBG, tabernanthalog; VTA, ventral tegmental area.</p></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Ahmad</surname><given-names>F. B.</given-names></name><name name-style="western"><surname>Cisewski</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Rossen</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Sutton</surname><given-names>P.</given-names></name></person-group> (<year>2023</year>). <article-title>Provisional drug overdose death counts</article-title>. <comment>Available: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm" ext-link-type="uri">https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm</ext-link> (Accessed April 2023</comment>.</mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aira</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Buesa</surname><given-names>I.</given-names></name><name name-style="western"><surname>Del Cano</surname><given-names>G. G.</given-names></name><name name-style="western"><surname>Salgueiro</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mendiable</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mingo</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Selective impairment of spinal mu-opioid receptor mechanism by plasticity of serotonergic facilitation mediated by 5-HT2A and 5-HT2B receptors</article-title>. <source>Pain</source><volume>153</volume>, <fpage>1418</fpage>&#8211;<lpage>1425</lpage>. <pub-id pub-id-type="doi">10.1016/j.pain.2012.03.017</pub-id><pub-id pub-id-type="pmid">22520172</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amargos-Bosch</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bortolozzi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Puig</surname><given-names>M. V.</given-names></name><name name-style="western"><surname>Serrats</surname><given-names>J.</given-names></name><name name-style="western"><surname>Adell</surname><given-names>A.</given-names></name><name name-style="western"><surname>Celada</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Co-expression and <italic toggle="yes">in vivo</italic> interaction of serotonin1A and serotonin2A receptors in pyramidal neurons of prefrontal cortex</article-title>. <source>Cereb. Cortex.</source><volume>14</volume>, <fpage>281</fpage>&#8211;<lpage>299</lpage>. <pub-id pub-id-type="doi">10.1093/cercor/bhg128</pub-id><pub-id pub-id-type="pmid">14754868</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anastasio</surname><given-names>N. C.</given-names></name><name name-style="western"><surname>Stutz</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Fink</surname><given-names>L. H.</given-names></name><name name-style="western"><surname>Swinford-Jackson</surname><given-names>S. E.</given-names></name><name name-style="western"><surname>Sears</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Dileone</surname><given-names>R. J.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Serotonin (5-HT) 5-HT<sub>2A</sub> receptor (5-HT<sub>2A</sub>R):5-HT<sub>2C</sub>R imbalance in medial prefrontal cortex associates with motor impulsivity</article-title>. <source>ACS Chem. Neurosci.</source><volume>6</volume>, <fpage>1248</fpage>&#8211;<lpage>1258</lpage>. <pub-id pub-id-type="doi">10.1021/acschemneuro.5b00094</pub-id><pub-id pub-id-type="pmid">26120876</pub-id><pub-id pub-id-type="pmcid">PMC4811199</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Appel</surname><given-names>J. B.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>K. A.</given-names></name></person-group> (<year>1986</year>). <article-title>The use of drug discrimination procedures to characterize hallucinogenic drug actions</article-title>. <source>Psychopharmacol. Bull.</source><volume>22</volume>, <fpage>959</fpage>&#8211;<lpage>967</lpage>.<pub-id pub-id-type="pmid">3797596</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Appel</surname><given-names>J. B.</given-names></name><name name-style="western"><surname>White</surname><given-names>F. J.</given-names></name><name name-style="western"><surname>Holohean</surname><given-names>A. M.</given-names></name></person-group> (<year>1982</year>). <article-title>Analyzing mechanism(s) of hallucinogenic drug action with drug discrimination procedures</article-title>. <source>Neurosci. Biobehav Rev.</source><volume>6</volume>, <fpage>529</fpage>&#8211;<lpage>536</lpage>. <pub-id pub-id-type="doi">10.1016/0149-7634(82)90036-7</pub-id><pub-id pub-id-type="pmid">7177512</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arafat</surname><given-names>E. S.</given-names></name><name name-style="western"><surname>Trimble</surname><given-names>J. W.</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>R. N.</given-names></name><name name-style="western"><surname>Dass</surname><given-names>C.</given-names></name><name name-style="western"><surname>Desiderio</surname><given-names>D. M.</given-names></name></person-group> (<year>1989</year>). <article-title>Identification of fatty acid amides in human plasma</article-title>. <source>Life Sci.</source><volume>45</volume>, <fpage>1679</fpage>&#8211;<lpage>1687</lpage>. <pub-id pub-id-type="doi">10.1016/0024-3205(89)90278-6</pub-id><pub-id pub-id-type="pmid">2586225</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Argento</surname><given-names>E.</given-names></name><name name-style="western"><surname>Socias</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mackay</surname><given-names>L.</given-names></name><name name-style="western"><surname>Christie</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting</article-title>. <source>Int. J. Drug Policy</source><volume>100</volume>, <fpage>103518</fpage>. <pub-id pub-id-type="doi">10.1016/j.drugpo.2021.103518</pub-id><pub-id pub-id-type="pmid">34758431</pub-id><pub-id pub-id-type="pmcid">PMC8890776</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baker</surname><given-names>L. E.</given-names></name></person-group> (<year>2018</year>). <article-title>Hallucinogens in drug discrimination</article-title>. <source>Curr. Top. Behav. Neurosci.</source><volume>36</volume>, <fpage>201</fpage>&#8211;<lpage>219</lpage>. <pub-id pub-id-type="doi">10.1007/7854_2017_476</pub-id><pub-id pub-id-type="pmid">28484970</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bakhshipour-Rudsari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Karimpour-Vazifehkhorani</surname><given-names>A.</given-names></name></person-group> (<year>2021</year>). <article-title>The role of impulsivity and sensitivity to reward in dropout of addiction treatment in heroin addicts</article-title>. <source>Addict. Health</source><volume>13</volume>, <fpage>45</fpage>&#8211;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.22122/ahj.v13i1.290</pub-id><pub-id pub-id-type="pmid">33995959</pub-id><pub-id pub-id-type="pmcid">PMC8080170</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baldo</surname><given-names>B. A.</given-names></name></person-group> (<year>2016</year>). <article-title>Prefrontal cortical opioids and dysregulated motivation: A network hypothesis</article-title>. <source>Trends Neurosci.</source><volume>39</volume>, <fpage>366</fpage>&#8211;<lpage>377</lpage>. <pub-id pub-id-type="doi">10.1016/j.tins.2016.03.004</pub-id><pub-id pub-id-type="pmid">27233653</pub-id><pub-id pub-id-type="pmcid">PMC5818385</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ballanger</surname><given-names>B.</given-names></name><name name-style="western"><surname>Strafella</surname><given-names>A. P.</given-names></name><name name-style="western"><surname>Van Eimeren</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zurowski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rusjan</surname><given-names>P. M.</given-names></name><name name-style="western"><surname>Houle</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Serotonin 2A receptors and visual hallucinations in Parkinson disease</article-title>. <source>Arch. Neurol.</source><volume>67</volume>, <fpage>416</fpage>&#8211;<lpage>421</lpage>. <pub-id pub-id-type="doi">10.1001/archneurol.2010.35</pub-id><pub-id pub-id-type="pmid">20385906</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barnes</surname><given-names>N. M.</given-names></name><name name-style="western"><surname>Ahern</surname><given-names>G. P.</given-names></name><name name-style="western"><surname>Becamel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bockaert</surname><given-names>J.</given-names></name><name name-style="western"><surname>Camilleri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chaumont-Dubel</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function</article-title>. <source>Pharmacol. Rev.</source><volume>73</volume>, <fpage>310</fpage>&#8211;<lpage>520</lpage>. <pub-id pub-id-type="doi">10.1124/pr.118.015552</pub-id><pub-id pub-id-type="pmid">33370241</pub-id><pub-id pub-id-type="pmcid">PMC7770494</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barnett</surname><given-names>B. S.</given-names></name><name name-style="western"><surname>Weleff</surname><given-names>J.</given-names></name></person-group> (<year>2022</year>). <article-title>Psychedelics in the treatment of substance use disorders</article-title>. <source>Psychiatr. Ann.</source><volume>52</volume>, <fpage>365</fpage>&#8211;<lpage>370</lpage>. <pub-id pub-id-type="doi">10.3928/00485713-20220804-01</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bazovkina</surname><given-names>D. V.</given-names></name><name name-style="western"><surname>Kondaurova</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Naumenko</surname><given-names>V. S.</given-names></name><name name-style="western"><surname>Ponimaskin</surname><given-names>E.</given-names></name></person-group> (<year>2015</year>). <article-title>Genotype-dependent difference in 5-HT2C receptor-induced hypolocomotion: Comparison with 5-HT2A receptor functional activity</article-title>. <source>Neural Plast.</source><volume>2015</volume>, <fpage>846589</fpage>. <pub-id pub-id-type="doi">10.1155/2015/846589</pub-id><pub-id pub-id-type="pmid">26380122</pub-id><pub-id pub-id-type="pmcid">PMC4563107</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beardsley</surname><given-names>P. M.</given-names></name><name name-style="western"><surname>Aceto</surname><given-names>M. D.</given-names></name><name name-style="western"><surname>Cook</surname><given-names>C. D.</given-names></name><name name-style="western"><surname>Bowman</surname><given-names>E. R.</given-names></name><name name-style="western"><surname>Newman</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>L. S.</given-names></name></person-group> (<year>2004</year>). <article-title>Discriminative stimulus, reinforcing, physical dependence, and antinociceptive effects of oxycodone in mice, rats, and rhesus monkeys</article-title>. <source>Exp. Clin. Psychopharmacol.</source><volume>12</volume>, <fpage>163</fpage>&#8211;<lpage>172</lpage>. <pub-id pub-id-type="doi">10.1037/1064-1297.12.3.163</pub-id><pub-id pub-id-type="pmid">15301633</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Becerra</surname><given-names>L.</given-names></name><name name-style="western"><surname>Borsook</surname><given-names>D.</given-names></name></person-group> (<year>2008</year>). <article-title>Signal valence in the nucleus accumbens to pain onset and offset</article-title>. <source>Eur. J. Pain</source><volume>12</volume>, <fpage>866</fpage>&#8211;<lpage>869</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejpain.2007.12.007</pub-id><pub-id pub-id-type="pmid">18226937</pub-id><pub-id pub-id-type="pmcid">PMC2581873</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Becker</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Klaiber</surname><given-names>A.</given-names></name><name name-style="western"><surname>Holze</surname><given-names>F.</given-names></name><name name-style="western"><surname>Istampoulouoglou</surname><given-names>I.</given-names></name><name name-style="western"><surname>Duthaler</surname><given-names>U.</given-names></name><name name-style="western"><surname>Varghese</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Ketanserin reverses the acute response to LSD in a randomized, double-blind, placebo-controlled, crossover study in healthy participants</article-title>. <source>Int. J. Neuropsychopharmacol.</source><volume>26</volume>, <fpage>97</fpage>&#8211;<lpage>106</lpage>. <pub-id pub-id-type="doi">10.1093/ijnp/pyac075</pub-id><pub-id pub-id-type="pmid">36342343</pub-id><pub-id pub-id-type="pmcid">PMC9926053</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Belin-Rauscent</surname><given-names>A.</given-names></name><name name-style="western"><surname>Belin</surname><given-names>D.</given-names></name></person-group> (<year>2012</year>). &#8220;<article-title>Animal models of drug addiction</article-title>,&#8221; in <source>Addictions</source>. Editor <person-group person-group-type="editor"><name name-style="western"><surname>Belin</surname><given-names>D</given-names></name></person-group>. <comment>IntechOpen</comment>.</mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belleville</surname><given-names>R. E.</given-names></name><name name-style="western"><surname>Fraser</surname><given-names>H. F.</given-names></name><name name-style="western"><surname>Isbell</surname><given-names>H.</given-names></name><name name-style="western"><surname>Logan</surname><given-names>C. R.</given-names></name><name name-style="western"><surname>Wikler</surname><given-names>A.</given-names></name></person-group> (<year>1956</year>). <article-title>Studies on lysergic acid diethylamide (LSD-25). I. Effects in former morphine addicts and development of tolerance during chronic intoxication</article-title>. <source>AMA Arch. Neurol. Psychiatry</source><volume>76</volume>, <fpage>468</fpage>&#8211;<lpage>478</lpage>.<pub-id pub-id-type="pmid">13371962</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Birdsong</surname><given-names>W. T.</given-names></name><name name-style="western"><surname>Jongbloets</surname><given-names>B. C.</given-names></name><name name-style="western"><surname>Engeln</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Scherrer</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>T.</given-names></name></person-group> (<year>2019</year>). <article-title>Synapse-specific opioid modulation of thalamo-cortico-striatal circuits</article-title>. <source>Elife</source><volume>8</volume>, <fpage>e45146</fpage>. <pub-id pub-id-type="doi">10.7554/eLife.45146</pub-id><pub-id pub-id-type="pmid">31099753</pub-id><pub-id pub-id-type="pmcid">PMC6541437</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blue</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Yagaloff</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Mamounas</surname><given-names>L. A.</given-names></name><name name-style="western"><surname>Hartig</surname><given-names>P. R.</given-names></name><name name-style="western"><surname>Molliver</surname><given-names>M. E.</given-names></name></person-group> (<year>1988</year>). <article-title>Correspondence between 5-HT2 receptors and serotonergic axons in rat neocortex</article-title>. <source>Brain Res.</source><volume>453</volume>, <fpage>315</fpage>&#8211;<lpage>328</lpage>. <pub-id pub-id-type="doi">10.1016/0006-8993(88)90172-2</pub-id><pub-id pub-id-type="pmid">3401769</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boger</surname><given-names>D. L.</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Q.</given-names></name></person-group> (<year>1998</year>). <article-title>Structural requirements for 5-HT2A and 5-HT1A serotonin receptor potentiation by the biologically active lipid oleamide</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>95</volume>, <fpage>4102</fpage>&#8211;<lpage>4107</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.95.8.4102</pub-id><pub-id pub-id-type="pmid">9539697</pub-id><pub-id pub-id-type="pmcid">PMC22449</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bolin</surname><given-names>B. L.</given-names></name><name name-style="western"><surname>Alcorn</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>A. R.</given-names></name><name name-style="western"><surname>Lile</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Stoops</surname><given-names>W. W.</given-names></name><name name-style="western"><surname>Rush</surname><given-names>C. R.</given-names></name></person-group> (<year>2018</year>). <article-title>Human drug discrimination: elucidating the neuropharmacology of commonly abused illicit drugs</article-title>. <source>Curr. Top. Behav. Neurosci.</source><volume>39</volume>, <fpage>261</fpage>&#8211;<lpage>295</lpage>. <pub-id pub-id-type="doi">10.1007/7854_2016_10</pub-id><pub-id pub-id-type="pmid">27272070</pub-id><pub-id pub-id-type="pmcid">PMC5461212</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bortolozzi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Az-Mataix</surname><given-names>L.</given-names></name><name name-style="western"><surname>Scorza</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Celada</surname><given-names>P.</given-names></name><name name-style="western"><surname>Artigas</surname><given-names>F.</given-names></name></person-group> (<year>2005</year>). <article-title>The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity</article-title>. <source>J. Neurochem.</source><volume>95</volume>, <fpage>1597</fpage>&#8211;<lpage>1607</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.2005.03485.x</pub-id><pub-id pub-id-type="pmid">16277612</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bouso</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Sanchez-Aviles</surname><given-names>C.</given-names></name></person-group> (<year>2020</year>). <article-title>Traditional healing practices involving psychoactive plants and the global mental health agenda: Opportunities, pitfalls, and challenges in the "Right to Science" framework</article-title>. <source>Health Hum. Rights</source><volume>22</volume>, <fpage>145</fpage>&#8211;<lpage>150</lpage>.<pub-id pub-id-type="pmid">32669796</pub-id><pub-id pub-id-type="pmcid">PMC7348435</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brandt</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Castillo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Odom</surname><given-names>G. J.</given-names></name><name name-style="western"><surname>Balise</surname><given-names>R. R.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Risk of experiencing an overdose event for patients undergoing treatment with medication for opioid use disorder</article-title>. <source>Am. J. Psychiatry</source><volume>180</volume>, <fpage>386</fpage>&#8211;<lpage>394</lpage>. <pub-id pub-id-type="doi">10.1176/appi.ajp.20220312</pub-id><pub-id pub-id-type="pmid">36891640</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brogden</surname><given-names>R. N.</given-names></name><name name-style="western"><surname>Sorkin</surname><given-names>E. M.</given-names></name></person-group> (<year>1990</year>). <article-title>Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease</article-title>. <source>Drugs</source><volume>40</volume>, <fpage>903</fpage>&#8211;<lpage>949</lpage>. <pub-id pub-id-type="doi">10.2165/00003495-199040060-00010</pub-id><pub-id pub-id-type="pmid">2079001</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Browne</surname><given-names>C. J.</given-names></name><name name-style="western"><surname>Abela</surname><given-names>A. R.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lambe</surname><given-names>E. K.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Dorsal raphe serotonin neurons inhibit operant responding for reward via inputs to the ventral tegmental area but not the nucleus accumbens: evidence from studies combining optogenetic stimulation and serotonin reuptake inhibition</article-title>. <source>Neuropsychopharmacology</source><volume>44</volume>, <fpage>793</fpage>&#8211;<lpage>804</lpage>. <pub-id pub-id-type="doi">10.1038/s41386-018-0271-x</pub-id><pub-id pub-id-type="pmid">30420603</pub-id><pub-id pub-id-type="pmcid">PMC6372654</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bruera</surname><given-names>E.</given-names></name><name name-style="western"><surname>Del Fabbro</surname><given-names>E.</given-names></name></person-group> (<year>2018</year>). <article-title>Pain management in the era of the opioid crisis</article-title>. <source>Am. Soc. Clin. Oncol. Educ. Book</source><volume>38</volume>, <fpage>807</fpage>&#8211;<lpage>812</lpage>. <pub-id pub-id-type="doi">10.1200/EDBK_208563</pub-id><pub-id pub-id-type="pmid">30231341</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buchborn</surname><given-names>T.</given-names></name><name name-style="western"><surname>Schroder</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dieterich</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Grecksch</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hollt</surname><given-names>V.</given-names></name></person-group> (<year>2015</year>). <article-title>Tolerance to LSD and DOB induced shaking behaviour: differential adaptations of frontocortical 5-HT(2A) and glutamate receptor binding sites</article-title>. <source>Behav. Brain Res.</source><volume>281</volume>, <fpage>62</fpage>&#8211;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2014.12.014</pub-id><pub-id pub-id-type="pmid">25513973</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burton</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>Rizos</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Diwan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nobrega</surname><given-names>J. N.</given-names></name><name name-style="western"><surname>Fletcher</surname><given-names>P. J.</given-names></name></person-group> (<year>2013</year>). <article-title>Antagonizing 5-HT&#8322;A receptors with M100907 and stimulating 5-HT&#8322;C receptors with Ro60-0175 blocks cocaine-induced locomotion and zif268 mRNA expression in Sprague-Dawley rats</article-title>. <source>Behav. Brain Res.</source><volume>240</volume>, <fpage>171</fpage>&#8211;<lpage>181</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2012.11.030</pub-id><pub-id pub-id-type="pmid">23201361</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Butelman</surname><given-names>E. R.</given-names></name><name name-style="western"><surname>Yuferov</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kreek</surname><given-names>M. J.</given-names></name></person-group> (<year>2012</year>). <article-title>&#954;-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction</article-title>. <source>Trends Neurosci.</source><volume>35</volume>, <fpage>587</fpage>&#8211;<lpage>596</lpage>. <pub-id pub-id-type="doi">10.1016/j.tins.2012.05.005</pub-id><pub-id pub-id-type="pmid">22709632</pub-id><pub-id pub-id-type="pmcid">PMC3685470</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Calderon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Giarola</surname><given-names>A.</given-names></name><name name-style="western"><surname>Heal</surname><given-names>D.</given-names></name></person-group> (<year>2015</year>). &#8220;<article-title>Regulatory framework and guidance to the evaluation of the abuse liability of drugs in the United States and Europe</article-title>,&#8221; in <source>Nonclinical assessment of abuse potential for new pharmaceuticals</source>. Editors <person-group person-group-type="editor"><name name-style="western"><surname>Markgraf</surname><given-names>C. G.</given-names></name><name name-style="western"><surname>Hudzik</surname><given-names>T. J.</given-names></name><name name-style="western"><surname>Compton</surname><given-names>D. R.</given-names></name></person-group> (<publisher-loc>Boston</publisher-loc>: <publisher-name>Academic Press</publisher-name>), <fpage>245</fpage>&#8211;<lpage>268</lpage>.</mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ciccarone</surname><given-names>D.</given-names></name><name name-style="western"><surname>Shoptaw</surname><given-names>S.</given-names></name></person-group> (<year>2022</year>). <article-title>Understanding stimulant use and use disorders in a new era</article-title>. <source>Med. Clin. North Am.</source><volume>106</volume>, <fpage>81</fpage>&#8211;<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1016/j.mcna.2021.08.010</pub-id><pub-id pub-id-type="pmid">34823736</pub-id><pub-id pub-id-type="pmcid">PMC8670631</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Calderon</surname><given-names>S. N.</given-names></name><name name-style="western"><surname>Bonson</surname><given-names>K. R.</given-names></name><name name-style="western"><surname>Reissig</surname><given-names>C. J.</given-names></name><name name-style="western"><surname>Lloyd</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Galati</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chiapperino</surname><given-names>D.</given-names></name></person-group> (<year>2023</year>). <article-title>Considerations in assessing the abuse potential of psychedelics during drug development</article-title>. <source>Neuropharmacology</source><volume>224</volume>, <fpage>109352</fpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2022.109352</pub-id><pub-id pub-id-type="pmid">36455646</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Callahan</surname><given-names>P. M.</given-names></name><name name-style="western"><surname>Appel</surname><given-names>J. B.</given-names></name></person-group> (<year>1990</year>). <article-title>Differentiation between the stimulus effects of (+)-lysergic acid diethylamide and lisuride using a three-choice, drug discrimination procedure</article-title>. <source>Psychopharmacology</source><volume>100</volume>, <fpage>13</fpage>&#8211;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1007/BF02245782</pub-id><pub-id pub-id-type="pmid">2296621</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cameron</surname><given-names>L. P.</given-names></name><name name-style="western"><surname>Tombari</surname><given-names>R. J.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pell</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Hurley</surname><given-names>Z. Q.</given-names></name><name name-style="western"><surname>Ehinger</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>A non-hallucinogenic psychedelic analogue with therapeutic potential</article-title>. <source>Nature</source><volume>589</volume>, <fpage>474</fpage>&#8211;<lpage>479</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-3008-z</pub-id><pub-id pub-id-type="pmid">33299186</pub-id><pub-id pub-id-type="pmcid">PMC7874389</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campbell</surname><given-names>G.</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Larance</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bruno</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mattick</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Pharmaceutical opioid use and dependence among people living with chronic pain: Associations observed within the pain and opioids in treatment (POINT) cohort</article-title>. <source>Pain Med.</source><volume>16</volume>, <fpage>1745</fpage>&#8211;<lpage>1758</lpage>. <pub-id pub-id-type="doi">10.1111/pme.12773</pub-id><pub-id pub-id-type="pmid">26011277</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Canal</surname><given-names>C. E.</given-names></name><name name-style="western"><surname>Booth</surname><given-names>R. G.</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>D.</given-names></name></person-group> (<year>2013</year>). <article-title>Support for 5-HT2C receptor functional selectivity <italic toggle="yes">in vivo</italic> utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2,5-dimethoxy-4-iodoamphetamine elicited head-twitch response model</article-title>. <source>Neuropharmacology</source><volume>70</volume>, <fpage>112</fpage>&#8211;<lpage>121</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2013.01.007</pub-id><pub-id pub-id-type="pmid">23353901</pub-id><pub-id pub-id-type="pmcid">PMC3754837</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>He</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Structure-based discovery of nonhallucinogenic psychedelic analogs</article-title>. <source>Science</source><volume>375</volume>, <fpage>403</fpage>&#8211;<lpage>411</lpage>. <pub-id pub-id-type="doi">10.1126/science.abl8615</pub-id><pub-id pub-id-type="pmid">35084960</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carr</surname><given-names>D. B.</given-names></name><name name-style="western"><surname>Sesack</surname><given-names>S. R.</given-names></name></person-group> (<year>2000</year>). <article-title>Dopamine terminals synapse on callosal projection neurons in the rat prefrontal cortex</article-title>. <source>J. Comp. Neurol.</source><volume>425</volume>, <fpage>275</fpage>&#8211;<lpage>283</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1096-9861(20000918)425:2&amp;#x0003c;275::aid-cne9&amp;#x0003e;3.0.co;2-z</pub-id><pub-id pub-id-type="pmid">10954845</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carter</surname><given-names>L. P.</given-names></name><name name-style="western"><surname>Griffiths</surname><given-names>R. R.</given-names></name></person-group> (<year>2009</year>). <article-title>Principles of laboratory assessment of drug abuse liability and implications for clinical development</article-title>. <source>Drug Alcohol Depend.</source><volume>105</volume> (<issue>1</issue>), <fpage>S14</fpage>&#8211;<lpage>S25</lpage>. <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2009.04.003</pub-id><pub-id pub-id-type="pmid">19443137</pub-id><pub-id pub-id-type="pmcid">PMC2763984</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Casey</surname><given-names>A. B.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>M.</given-names></name><name name-style="western"><surname>Booth</surname><given-names>R. G.</given-names></name><name name-style="western"><surname>Canal</surname><given-names>C. E.</given-names></name></person-group> (<year>2022</year>). <article-title>Selective" serotonin 5-HT2A receptor antagonists</article-title>. <source>Biochem. Pharmacol.</source><volume>200</volume>, <fpage>115028</fpage>. <pub-id pub-id-type="doi">10.1016/j.bcp.2022.115028</pub-id><pub-id pub-id-type="pmid">35381208</pub-id><pub-id pub-id-type="pmcid">PMC9252399</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Castellanos</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Woolley</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bruno</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Zeidan</surname><given-names>F.</given-names></name><name name-style="western"><surname>Halberstadt</surname><given-names>A.</given-names></name><name name-style="western"><surname>Furnish</surname><given-names>T.</given-names></name></person-group> (<year>2020</year>). <article-title>Chronic pain and psychedelics: a review and proposed mechanism of action</article-title>. <source>Reg. Anesth. Pain Med.</source><volume>45</volume>, <fpage>486</fpage>&#8211;<lpage>494</lpage>. <pub-id pub-id-type="doi">10.1136/rapm-2020-101273</pub-id><pub-id pub-id-type="pmid">32371500</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ceceli</surname><given-names>A. O.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kronberg</surname><given-names>G.</given-names></name><name name-style="western"><surname>Malaker</surname><given-names>P.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>P.</given-names></name><name name-style="western"><surname>King</surname><given-names>S. G.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Common and distinct fronto-striatal volumetric changes in heroin and cocaine use disorders</article-title>. <source>Brain</source><volume>146</volume>, <fpage>1662</fpage>&#8211;<lpage>1671</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awac366</pub-id><pub-id pub-id-type="pmid">36200376</pub-id><pub-id pub-id-type="pmcid">PMC10319776</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheer</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Cadogan</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Marsden</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Fone</surname><given-names>K. C.</given-names></name><name name-style="western"><surname>Kendall</surname><given-names>D. A.</given-names></name></person-group> (<year>1999</year>). <article-title>Modification of 5-HT2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors</article-title>. <source>Neuropharmacology</source><volume>38</volume>, <fpage>533</fpage>&#8211;<lpage>541</lpage>. <pub-id pub-id-type="doi">10.1016/s0028-3908(98)00208-1</pub-id><pub-id pub-id-type="pmid">10221757</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>E. J.</given-names></name><name name-style="western"><surname>Merritt</surname><given-names>C. R.</given-names></name><name name-style="western"><surname>Zamora</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Bolinger</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Pazdrak</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Discovery of novel oleamide analogues as brain-penetrant positive allosteric serotonin 5-HT2C receptor and dual 5-HT2C/5-HT2A receptor modulators</article-title>. <source>J. Med. Chem.</source><volume>66</volume>, <fpage>9992</fpage>&#8211;<lpage>10009</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.3c00908</pub-id><pub-id pub-id-type="pmid">37462530</pub-id><pub-id pub-id-type="pmcid">PMC10853020</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chilcoat</surname><given-names>H. D.</given-names></name><name name-style="western"><surname>Amick</surname><given-names>H. R.</given-names></name><name name-style="western"><surname>Sherwood</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Dunn</surname><given-names>K. E.</given-names></name></person-group> (<year>2019</year>). <article-title>Buprenorphine in the United States: Motives for abuse, misuse, and diversion</article-title>. <source>J. Subst. Abuse Treat.</source><volume>104</volume>, <fpage>148</fpage>&#8211;<lpage>157</lpage>. <pub-id pub-id-type="doi">10.1016/j.jsat.2019.07.005</pub-id><pub-id pub-id-type="pmid">31370979</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Strafella</surname><given-names>A. P.</given-names></name><name name-style="western"><surname>Duff-Canning</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zurowski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vijverman</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Bruno</surname><given-names>V.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>The relationship between serotonin-2A receptor and cognitive functions in nondemented Parkinson's disease patients with visual hallucinations</article-title>. <source>Mov. Disord. Clin. Pract.</source><volume>4</volume>, <fpage>698</fpage>&#8211;<lpage>709</lpage>. <pub-id pub-id-type="doi">10.1002/mdc3.12466</pub-id><pub-id pub-id-type="pmid">30363421</pub-id><pub-id pub-id-type="pmcid">PMC6174444</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Christie</surname><given-names>M. J.</given-names></name></person-group> (<year>2008</year>). <article-title>Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction</article-title>. <source>Br. J. Pharmacol.</source><volume>154</volume>, <fpage>384</fpage>&#8211;<lpage>396</lpage>. <pub-id pub-id-type="doi">10.1038/bjp.2008.100</pub-id><pub-id pub-id-type="pmid">18414400</pub-id><pub-id pub-id-type="pmcid">PMC2442443</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Christie</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>J. T.</given-names></name><name name-style="western"><surname>North</surname><given-names>R. A.</given-names></name></person-group> (<year>1992</year>). <article-title>Cellular mechanisms of opioid tolerance: studies in single brain neurons</article-title>. <source>Mol. Pharmacol.</source><volume>32</volume>, <fpage>633</fpage>&#8211;<lpage>638</lpage>.<pub-id pub-id-type="pmid">2824980</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chu Sin Chung</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kieffer</surname><given-names>B. L.</given-names></name></person-group> (<year>2013</year>). <article-title>Delta opioid receptors in brain function and diseases</article-title>. <source>Pharmacol. Ther.</source><volume>140</volume>, <fpage>112</fpage>&#8211;<lpage>120</lpage>. <pub-id pub-id-type="doi">10.1016/j.pharmthera.2013.06.003</pub-id><pub-id pub-id-type="pmid">23764370</pub-id><pub-id pub-id-type="pmcid">PMC3775961</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clark</surname><given-names>S. D.</given-names></name><name name-style="western"><surname>Abi-Dargham</surname><given-names>A.</given-names></name></person-group> (<year>2019</year>). <article-title>The role of dynorphin and the kappa opioid receptor in the symptomatology of schizophrenia: A review of the evidence</article-title>. <source>Biol. Psychiatry</source><volume>86</volume>, <fpage>502</fpage>&#8211;<lpage>511</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2019.05.012</pub-id><pub-id pub-id-type="pmid">31376930</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Comer</surname><given-names>S. D.</given-names></name><name name-style="western"><surname>Zacny</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Dworkin</surname><given-names>R. H.</given-names></name><name name-style="western"><surname>Turk</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Bigelow</surname><given-names>G. E.</given-names></name><name name-style="western"><surname>Foltin</surname><given-names>R. W.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations</article-title>. <source>Pain</source><volume>153</volume>, <fpage>2315</fpage>&#8211;<lpage>2324</lpage>. <pub-id pub-id-type="doi">10.1016/j.pain.2012.07.035</pub-id><pub-id pub-id-type="pmid">22998781</pub-id><pub-id pub-id-type="pmcid">PMC3494795</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corne</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Pickering</surname><given-names>R. W.</given-names></name></person-group> (<year>1967</year>). <article-title>A possible correlation between drug-induced hallucinations in man and a behavioural response in mice</article-title>. <source>Psychopharmacologia</source><volume>11</volume>, <fpage>65</fpage>&#8211;<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1007/BF00401509</pub-id><pub-id pub-id-type="pmid">5302272</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corne</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Pickering</surname><given-names>R. W.</given-names></name><name name-style="western"><surname>Warner</surname><given-names>B. T.</given-names></name></person-group> (<year>1963</year>). <article-title>A method for assessing the effects of drugs on the central actions of 5-hydroxytryptamine</article-title>. <source>Br. J. Pharmacol. Chemother.</source><volume>20</volume>, <fpage>106</fpage>&#8211;<lpage>120</lpage>. <pub-id pub-id-type="doi">10.1111/j.1476-5381.1963.tb01302.x</pub-id><pub-id pub-id-type="pmid">14023050</pub-id><pub-id pub-id-type="pmcid">PMC1703746</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coussens</surname><given-names>N. P.</given-names></name><name name-style="western"><surname>Sittampalam</surname><given-names>G. S.</given-names></name><name name-style="western"><surname>Jonson</surname><given-names>S. G.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>M. D.</given-names></name><name name-style="western"><surname>Gorby</surname><given-names>H. E.</given-names></name><name name-style="western"><surname>Tamiz</surname><given-names>A. P.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>The opioid crisis and the future of addiction and pain therapeutics</article-title>. <source>J. Pharmacol. Exp. Ther.</source><volume>371</volume>, <fpage>396</fpage>&#8211;<lpage>408</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.119.259408</pub-id><pub-id pub-id-type="pmid">31481516</pub-id><pub-id pub-id-type="pmcid">PMC6863454</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cravatt</surname><given-names>B. F.</given-names></name><name name-style="western"><surname>Prospero-Garcia</surname><given-names>O.</given-names></name><name name-style="western"><surname>Siuzdak</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gilula</surname><given-names>N. B.</given-names></name><name name-style="western"><surname>Henriksen</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Boger</surname><given-names>D. L.</given-names></name><etal/></person-group> (<year>1995</year>). <article-title>Chemical characterization of a family of brain lipids that induce sleep</article-title>. <source>Science</source><volume>268</volume>, <fpage>1506</fpage>&#8211;<lpage>1509</lpage>. <pub-id pub-id-type="doi">10.1126/science.7770779</pub-id><pub-id pub-id-type="pmid">7770779</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cunningham</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Anastasio</surname><given-names>N. C.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>R. G.</given-names></name><name name-style="western"><surname>Stutz</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Bubar</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Swinford</surname><given-names>S. E.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Synergism between a serotonin 5-HT<sub>2A</sub> receptor (5-HT<sub>2A</sub>R) antagonist and 5-HT<sub>2C</sub>R agonist suggests new pharmacotherapeutics for cocaine addiction</article-title>. <source>ACS Chem. Neurosci.</source><volume>4</volume>, <fpage>110</fpage>&#8211;<lpage>121</lpage>. <pub-id pub-id-type="doi">10.1021/cn300072u</pub-id><pub-id pub-id-type="pmid">23336050</pub-id><pub-id pub-id-type="pmcid">PMC3547488</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cunningham</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Anastasio</surname><given-names>N. C.</given-names></name></person-group> (<year>2014</year>). <article-title>Serotonin at the nexus of impulsivity and cue reactivity in cocaine addiction</article-title>. <source>Neuropharmacology</source><volume>76 Pt B</volume>, <fpage>460</fpage>&#8211;<lpage>478</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2013.06.030</pub-id><pub-id pub-id-type="pmid">23850573</pub-id><pub-id pub-id-type="pmcid">PMC4090081</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Cunningham</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Appel</surname><given-names>J. B.</given-names></name></person-group> (<year>1988</year>). &#8220;<article-title>Hallucinogenic and non-hallucinogenic 5-HT agonists: Differences in subjective effects parallel differences in receptor dynamics</article-title>,&#8221; in <source>5-HT agonists as psychoactive drugs</source>. Editors <person-group person-group-type="editor"><name name-style="western"><surname>Rech</surname><given-names>R. H.</given-names></name><name name-style="western"><surname>Gudelsky</surname><given-names>G. A.</given-names></name></person-group> (<publisher-loc>Ann Arbor, MI</publisher-loc>: <publisher-name>NPP Press</publisher-name>), <fpage>217</fpage>&#8211;<lpage>238</lpage>.</mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cunningham</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Appel</surname><given-names>J. B.</given-names></name></person-group> (<year>1987</year>). <article-title>Neuropharmacological reassessment of the discriminative stimulus properties of d-lysergic acid diethylamide (LSD)</article-title>. <source>Psychopharmacol. Berl.</source><volume>91</volume>, <fpage>67</fpage>&#8211;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1007/BF00690929</pub-id><pub-id pub-id-type="pmid">3103161</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cunningham</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Callahan</surname><given-names>P. M.</given-names></name><name name-style="western"><surname>Appel</surname><given-names>J. B.</given-names></name></person-group> (<year>1985</year>). <article-title>Differentiation between the stimulus effects of l-5-hydroxytryptophan and LSD</article-title>. <source>Eur. J. Pharmacol.</source><volume>108</volume>, <fpage>179</fpage>&#8211;<lpage>186</lpage>. <pub-id pub-id-type="doi">10.1016/0014-2999(85)90723-x</pub-id><pub-id pub-id-type="pmid">3156756</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Cunningham</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Howell</surname><given-names>L. L.</given-names></name><name name-style="western"><surname>Anastasio</surname><given-names>N. C.</given-names></name></person-group> (<year>2020</year>). &#8220;<article-title>Serotonin neurobiology in cocaine use disorder</article-title>,&#8221; in <source>Handbook of the behavioral neurobiology of serotonin</source>. Editors <person-group person-group-type="editor"><name name-style="western"><surname>Muller</surname><given-names>C. P.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>K. A</given-names></name></person-group>. <edition>2nd Edition</edition> (<publisher-loc>(United Kingdom</publisher-loc>: <publisher-name>Academic Press</publisher-name>), <fpage>745</fpage>&#8211;<lpage>802</lpage>.</mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cunningham</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Bock</surname><given-names>H. A.</given-names></name><name name-style="western"><surname>Serrano</surname><given-names>I. C.</given-names></name><name name-style="western"><surname>Bechand</surname><given-names>B.</given-names></name><name name-style="western"><surname>Vidyadhara</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Bonniwell</surname><given-names>E. M.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Pharmacological mechanism of the non-hallucinogenic 5-HT(2A) agonist ariadne and analogs</article-title>. <source>ACS Chem. Neurosci.</source><volume>14</volume>, <fpage>119</fpage>&#8211;<lpage>135</lpage>. <pub-id pub-id-type="doi">10.1021/acschemneuro.2c00597</pub-id><pub-id pub-id-type="pmid">36521179</pub-id><pub-id pub-id-type="pmcid">PMC10147382</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zamora</surname><given-names>D.</given-names></name><name name-style="western"><surname>Horowitz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Leucht</surname><given-names>S.</given-names></name></person-group> (<year>2021</year>). <article-title>Evaluating pimavanserin as a treatment for psychiatric disorders: A pharmacological property in search of an indication</article-title>. <source>Expert Opin. Pharmacother.</source><volume>22</volume>, <fpage>1651</fpage>&#8211;<lpage>1660</lpage>. <pub-id pub-id-type="doi">10.1080/14656566.2021.1942455</pub-id><pub-id pub-id-type="pmid">34404290</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De La Fuente Revenga</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>U. H.</given-names></name><name name-style="western"><surname>Nassehi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Jaster</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Hemanth</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sierra</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Psychedelic-like properties of quipazine and its structural analogues in mice</article-title>. <source>ACS Chem. Neurosci.</source><volume>12</volume>, <fpage>831</fpage>&#8211;<lpage>844</lpage>. <pub-id pub-id-type="doi">10.1021/acschemneuro.0c00291</pub-id><pub-id pub-id-type="pmid">33400504</pub-id><pub-id pub-id-type="pmcid">PMC7933111</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Degenhardt</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hungerford</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bruno</surname><given-names>R.</given-names></name><name name-style="western"><surname>Larance</surname><given-names>B.</given-names></name><name name-style="western"><surname>Clare</surname><given-names>P. J.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Pharmaceutical opioid use patterns and indicators of extramedical use and harm in adults with chronic noncancer pain, 2012-2018</article-title>. <source>JAMA Netw. Open</source><volume>4</volume>, <fpage>e213059</fpage>. <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2021.3059</pub-id><pub-id pub-id-type="pmid">33835176</pub-id><pub-id pub-id-type="pmcid">PMC8035647</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bremer</surname><given-names>N. M.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>T. D.</given-names></name><name name-style="western"><surname>Seitz</surname><given-names>P. K.</given-names></name><name name-style="western"><surname>Anastasio</surname><given-names>N. C.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>K. A.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Exploration of synthetic approaches and pharmacological evaluation of PNU-69176E and its stereoisomer as 5-HT<sub>2C</sub> receptor allosteric modulators</article-title>. <source>ACS Chem. Neurosci.</source><volume>3</volume>, <fpage>538</fpage>&#8211;<lpage>545</lpage>. <pub-id pub-id-type="doi">10.1021/cn300020x</pub-id><pub-id pub-id-type="pmid">22860223</pub-id><pub-id pub-id-type="pmcid">PMC3400380</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Divito</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Leger</surname><given-names>R. F.</given-names></name></person-group> (<year>2020</year>). <article-title>Psychedelics as an emerging novel intervention in the treatment of substance use disorder: a review</article-title>. <source>Mol. Biol. Rep.</source><volume>47</volume>, <fpage>9791</fpage>&#8211;<lpage>9799</lpage>. <pub-id pub-id-type="doi">10.1007/s11033-020-06009-x</pub-id><pub-id pub-id-type="pmid">33231817</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ly</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dunlap</surname><given-names>L. E.</given-names></name><name name-style="western"><surname>Vargas</surname><given-names>M. V.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>I. W.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Psychedelic-inspired drug discovery using an engineered biosensor</article-title>. <source>Cell</source><volume>184</volume>, <fpage>2779</fpage>&#8211;<lpage>2792.e18</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2021.03.043</pub-id><pub-id pub-id-type="pmid">33915107</pub-id><pub-id pub-id-type="pmcid">PMC8122087</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doblin</surname><given-names>R. E.</given-names></name><name name-style="western"><surname>Christiansen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jerome</surname><given-names>L.</given-names></name><name name-style="western"><surname>Burge</surname><given-names>B.</given-names></name></person-group> (<year>2019</year>). <article-title>The past and future of psychedelic science: An introduction to this issue</article-title>. <source>J. Psychoact. Drugs</source><volume>51</volume>, <fpage>93</fpage>&#8211;<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1080/02791072.2019.1606472</pub-id><pub-id pub-id-type="pmid">31132970</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>The contributions of mu-opioid receptors on glutamatergic and GABAergic neurons to analgesia induced by various stress intensities</article-title>. <source>eNeuro</source><volume>9</volume>, <fpage>0487</fpage>. <pub-id pub-id-type="doi">10.1523/ENEURO.0487-21.2022</pub-id><pub-id pub-id-type="pmcid">PMC9172284</pub-id><pub-id pub-id-type="pmid">35613854</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Erkizia-Santamaria</surname><given-names>I.</given-names></name><name name-style="western"><surname>Alles-Pascual</surname><given-names>R.</given-names></name><name name-style="western"><surname>Horrillo</surname><given-names>I.</given-names></name><name name-style="western"><surname>Meana</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Ortega</surname><given-names>J. E.</given-names></name></person-group> (<year>2022</year>). <article-title>Serotonin 5-HT2A, 5-HT2C and 5-HT1A receptor involvement in the acute effects of psilocybin in mice. <italic toggle="yes">In vitro</italic> pharmacological profile and modulation of thermoregulation and head-twich response</article-title>. <source>Biomed. Pharmacother.</source><volume>154</volume>, <fpage>113612</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2022.113612</pub-id><pub-id pub-id-type="pmid">36049313</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ezeomah</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Stutz</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>R. G.</given-names></name><name name-style="western"><surname>Bukreyeva</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dineley</surname><given-names>K. T.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Fentanyl self-administration impacts brain immune responses in male Sprague-Dawley rats</article-title>. <source>Brain Behav. Immun.</source><volume>87</volume>, <fpage>725</fpage>&#8211;<lpage>738</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2020.03.003</pub-id><pub-id pub-id-type="pmid">32165150</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="webpage"><collab>Fda</collab> (<year>2018</year>). <article-title>Public meeting on patient-focused drug development for opioid use disorder (Voice of the Patient)</article-title>. <comment>Available: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/industry/prescription-drug-user-fee-amendments/public-meeting-patient-focused-drug-development-opioid-use-disorder" ext-link-type="uri">https://www.fda.gov/industry/prescription-drug-user-fee-amendments/public-meeting-patient-focused-drug-development-opioid-use-disorder</ext-link> (Accessed 5/7/23</comment>.</mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fantegrossi</surname><given-names>W. E.</given-names></name><name name-style="western"><surname>Woods</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Winger</surname><given-names>G.</given-names></name></person-group> (<year>2004a</year>). <article-title>Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys</article-title>. <source>Behav. Pharmacol.</source><volume>15</volume>, <fpage>149</fpage>&#8211;<lpage>157</lpage>. <pub-id pub-id-type="doi">10.1097/00008877-200403000-00007</pub-id><pub-id pub-id-type="pmid">15096915</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fantegrossi</surname><given-names>W. E.</given-names></name><name name-style="western"><surname>Woolverton</surname><given-names>W. L.</given-names></name><name name-style="western"><surname>Kilbourn</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sherman</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hatzidimitriou</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2004b</year>). <article-title>Behavioral and neurochemical consequences of long-term intravenous self-administration of MDMA and its enantiomers by rhesus monkeys</article-title>. <source>Neuropsychopharmacology</source><volume>29</volume>, <fpage>1270</fpage>&#8211;<lpage>1281</lpage>. <pub-id pub-id-type="doi">10.1038/sj.npp.1300442</pub-id><pub-id pub-id-type="pmid">15039771</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Fda</surname></name></person-group> (<year>2017</year>). <source>Assessment of abuse potential of drugs: guidance for industry</source>. <publisher-name>Center for Drug Evaluation and Research</publisher-name>.</mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fedorova</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fecik</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Hedrick</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Hanus</surname><given-names>L. O.</given-names></name><name name-style="western"><surname>Boger</surname><given-names>D. L.</given-names></name><etal/></person-group> (<year>2001</year>). <article-title>Behavioral evidence for the interaction of oleamide with multiple neurotransmitter systems</article-title>. <source>J. Pharmacol. Exp. Ther.</source><volume>299</volume>, <fpage>332</fpage>&#8211;<lpage>342</lpage>.<pub-id pub-id-type="pmid">11561096</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Felsing</surname><given-names>D. E.</given-names></name><name name-style="western"><surname>Anastasio</surname><given-names>N. C.</given-names></name><name name-style="western"><surname>Miszkiel</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Gilbertson</surname><given-names>S. R.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>K. A.</given-names></name></person-group> (<year>2018</year>). <article-title>Biophysical validation of serotonin 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptor interaction</article-title>. <source>PLoS One</source><volume>13</volume>, <fpage>e0203137</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0203137</pub-id><pub-id pub-id-type="pmid">30157263</pub-id><pub-id pub-id-type="pmcid">PMC6114921</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferezou</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>E. L.</given-names></name><name name-style="western"><surname>Cauli</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gibelin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kaneko</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rossier</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Extensive overlap of mu-opioid and nicotinic sensitivity in cortical interneurons</article-title>. <source>Cereb. Cortex</source><volume>17</volume>, <fpage>1948</fpage>&#8211;<lpage>1957</lpage>. <pub-id pub-id-type="doi">10.1093/cercor/bhl104</pub-id><pub-id pub-id-type="pmid">17068095</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fields</surname><given-names>H. L.</given-names></name><name name-style="western"><surname>Margolis</surname><given-names>E. B.</given-names></name></person-group> (<year>2015</year>). <article-title>Understanding opioid reward</article-title>. <source>Trends Neurosci.</source><volume>38</volume>, <fpage>217</fpage>&#8211;<lpage>225</lpage>. <pub-id pub-id-type="doi">10.1016/j.tins.2015.01.002</pub-id><pub-id pub-id-type="pmid">25637939</pub-id><pub-id pub-id-type="pmcid">PMC4385443</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fink</surname><given-names>L. H.</given-names></name><name name-style="western"><surname>Anastasio</surname><given-names>N. C.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>R. G.</given-names></name><name name-style="western"><surname>Rice</surname><given-names>K. C.</given-names></name><name name-style="western"><surname>Moeller</surname><given-names>F. G.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>K. A.</given-names></name></person-group> (<year>2015</year>). <article-title>Individual differences in impulsive action reflect variation in the cortical serotonin 5-HT2A receptor system</article-title>. <source>Neuropsychopharmacology</source><volume>40</volume>, <fpage>1957</fpage>&#8211;<lpage>1968</lpage>. <pub-id pub-id-type="doi">10.1038/npp.2015.46</pub-id><pub-id pub-id-type="pmid">25666313</pub-id><pub-id pub-id-type="pmcid">PMC4839520</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fiorella</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rabin</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Winter</surname><given-names>J. C.</given-names></name></person-group> (<year>1995a</year>). <article-title>Role of 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. II: Reassessment of LSD false positives</article-title>. <source>Psychopharmacol. Berl.</source><volume>121</volume>, <fpage>357</fpage>&#8211;<lpage>363</lpage>. <pub-id pub-id-type="doi">10.1007/BF02246075</pub-id><pub-id pub-id-type="pmid">8584618</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fiorella</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rabin</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Winter</surname><given-names>J. C.</given-names></name></person-group> (<year>1995b</year>). <article-title>The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. I: Antagonist correlation analysis</article-title>. <source>Psychopharmacol. Berl.</source><volume>121</volume>, <fpage>347</fpage>&#8211;<lpage>356</lpage>. <pub-id pub-id-type="doi">10.1007/BF02246074</pub-id><pub-id pub-id-type="pmid">8584617</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fitzgerald</surname><given-names>L. W.</given-names></name><name name-style="western"><surname>Burn</surname><given-names>T. C.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>B. S.</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Corjay</surname><given-names>M. H.</given-names></name><name name-style="western"><surname>Valentine</surname><given-names>P. A.</given-names></name><etal/></person-group> (<year>2000</year>). <article-title>Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine</article-title>. <source>Mol. Pharmacol.</source><volume>57</volume>, <fpage>75</fpage>&#8211;<lpage>81</lpage>.<pub-id pub-id-type="pmid">10617681</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flynn</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>France</surname><given-names>C. P.</given-names></name></person-group> (<year>2021</year>). <article-title>Discriminative stimulus effects of carfentanil in rats discriminating fentanyl: Differential antagonism by naltrexone</article-title>. <source>Drug Alcohol Depend.</source><volume>221</volume>, <fpage>108599</fpage>. <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2021.108599</pub-id><pub-id pub-id-type="pmid">33631547</pub-id></mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Friedman</surname><given-names>S. R.</given-names></name><name name-style="western"><surname>Krawczyk</surname><given-names>N.</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Mateu-Gelabert</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ompad</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Hamilton</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>The opioid/overdose crisis as a dialectics of pain, despair, and one-sided struggle</article-title>. <source>Front. Public Health</source><volume>8</volume>, <fpage>540423</fpage>. <pub-id pub-id-type="doi">10.3389/fpubh.2020.540423</pub-id><pub-id pub-id-type="pmid">33251171</pub-id><pub-id pub-id-type="pmcid">PMC7676222</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaddum</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Hameed</surname><given-names>K. A.</given-names></name></person-group> (<year>1954</year>). <article-title>Drugs which antagonize 5-hydroxytryptamine</article-title>. <source>Br. J. Pharmacol. Chemother.</source><volume>9</volume>, <fpage>240</fpage>&#8211;<lpage>248</lpage>. <pub-id pub-id-type="doi">10.1111/j.1476-5381.1954.tb00848.x</pub-id><pub-id pub-id-type="pmid">13172437</pub-id><pub-id pub-id-type="pmcid">PMC1509436</pub-id></mixed-citation></ref><ref id="B92"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcia-Carceles</surname><given-names>J.</given-names></name><name name-style="western"><surname>Decara</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Vazquez-Villa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>R.</given-names></name><name name-style="western"><surname>Codesido</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cruces</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>A positive allosteric modulator of the serotonin 5-HT(2C) receptor for obesity</article-title>. <source>J. Med. Chem.</source><volume>60</volume>, <fpage>9575</fpage>&#8211;<lpage>9584</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.7b00994</pub-id><pub-id pub-id-type="pmid">29116785</pub-id></mixed-citation></ref><ref id="B93"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcia-Romeu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Erowid</surname><given-names>E.</given-names></name><name name-style="western"><surname>Erowid</surname><given-names>F.</given-names></name><name name-style="western"><surname>Griffiths</surname><given-names>R. R.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>M. W.</given-names></name></person-group> (<year>2019</year>). <article-title>Persisting reductions in cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: An online survey</article-title>. <source>Front. Psychiatry</source><volume>10</volume>, <fpage>955</fpage>. <pub-id pub-id-type="doi">10.3389/fpsyt.2019.00955</pub-id><pub-id pub-id-type="pmid">32038317</pub-id><pub-id pub-id-type="pmcid">PMC6987443</pub-id></mixed-citation></ref><ref id="B94"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ginzel</surname><given-names>K. H.</given-names></name><name name-style="western"><surname>Mayer-Gross</surname><given-names>W.</given-names></name></person-group> (<year>1956</year>). <article-title>Prevention of psychological effects of d-lysergic acid diethylamide (LSD 25) by its 2-brom derivative (BOL 148)</article-title>. <source>Nature</source><volume>178</volume>, <fpage>210</fpage>. <pub-id pub-id-type="doi">10.1038/178210a0</pub-id><pub-id pub-id-type="pmid">13348662</pub-id></mixed-citation></ref><ref id="B95"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glennon</surname><given-names>R. A.</given-names></name></person-group> (<year>1993</year>). <article-title>MDMA-like stimulus effects of alpha-ethyltryptamine and the alpha-ethyl homolog of DOM</article-title>. <source>Pharmacol. Biochem. Behav.</source><volume>46</volume>, <fpage>459</fpage>&#8211;<lpage>462</lpage>. <pub-id pub-id-type="doi">10.1016/0091-3057(93)90379-8</pub-id><pub-id pub-id-type="pmid">7903460</pub-id></mixed-citation></ref><ref id="B96"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glennon</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Young</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jacyno</surname><given-names>J. M.</given-names></name></person-group> (<year>1983</year>). <article-title>Indolealkylamine and phenalkylamine hallucinogens. Effect of alpha-methyl and N-methyl substituents on behavioral activity</article-title>. <source>Biochem. Pharmacol.</source><volume>32</volume>, <fpage>1267</fpage>&#8211;<lpage>1273</lpage>. <pub-id pub-id-type="doi">10.1016/0006-2952(83)90281-2</pub-id><pub-id pub-id-type="pmid">6573879</pub-id></mixed-citation></ref><ref id="B97"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonzalez-Maeso</surname><given-names>J.</given-names></name><name name-style="western"><surname>Weisstaub</surname><given-names>N. V.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ivic</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ang</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior</article-title>. <source>Neuron</source><volume>53</volume>, <fpage>439</fpage>&#8211;<lpage>452</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2007.01.008</pub-id><pub-id pub-id-type="pmid">17270739</pub-id></mixed-citation></ref><ref id="B98"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonzalez-Maeso</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yuen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ebersole</surname><given-names>B. J.</given-names></name><name name-style="western"><surname>Wurmbach</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lira</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex</article-title>. <source>J. Neurosci.</source><volume>23</volume>, <fpage>8836</fpage>&#8211;<lpage>8843</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.23-26-08836.2003</pub-id><pub-id pub-id-type="pmid">14523084</pub-id><pub-id pub-id-type="pmcid">PMC6740401</pub-id></mixed-citation></ref><ref id="B99"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goodwin</surname><given-names>A. K.</given-names></name></person-group> (<year>2016</year>). <article-title>An intravenous self-administration procedure for assessing the reinforcing effects of hallucinogens in nonhuman primates</article-title>. <source>J. Pharmacol. Toxicol. Methods</source><volume>82</volume>, <fpage>31</fpage>&#8211;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1016/j.vascn.2016.07.004</pub-id><pub-id pub-id-type="pmid">27473331</pub-id></mixed-citation></ref><ref id="B100"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Griffiths</surname><given-names>R. R.</given-names></name><name name-style="western"><surname>Grob</surname><given-names>C. S.</given-names></name></person-group> (<year>2010</year>). <article-title>Hallucinogens as medicine</article-title>. <source>Sci. Am.</source><volume>303</volume>, <fpage>76</fpage>&#8211;<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1038/scientificamerican1210-76</pub-id><pub-id pub-id-type="pmid">21141361</pub-id></mixed-citation></ref><ref id="B101"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guillou-Landreat</surname><given-names>M.</given-names></name><name name-style="western"><surname>Quinio</surname><given-names>B.</given-names></name><name name-style="western"><surname>Le Reste</surname><given-names>J. Y.</given-names></name><name name-style="western"><surname>Le Goff</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fonsecca</surname><given-names>J.</given-names></name><name name-style="western"><surname>Grall-Bronnec</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Prospective Study on Factors Associated with Referral of Patients with Opioid Maintenance Therapy from Specialized Addictive Disorders Centers to Primary Care</article-title>. <source>Int. J. Environ. Res. Public Health</source><volume>18</volume>, <fpage>5749</fpage>. <pub-id pub-id-type="doi">10.3390/ijerph18115749</pub-id><pub-id pub-id-type="pmid">34071908</pub-id><pub-id pub-id-type="pmcid">PMC8198158</pub-id></mixed-citation></ref><ref id="B102"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hacksell</surname><given-names>U.</given-names></name><name name-style="western"><surname>Burstein</surname><given-names>E. S.</given-names></name><name name-style="western"><surname>Mcfarland</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>R. G.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>H.</given-names></name></person-group> (<year>2014</year>). <article-title>On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis</article-title>. <source>Neurochem. Res.</source><volume>39</volume>, <fpage>2008</fpage>&#8211;<lpage>2017</lpage>. <pub-id pub-id-type="doi">10.1007/s11064-014-1293-3</pub-id><pub-id pub-id-type="pmid">24682754</pub-id><pub-id pub-id-type="pmcid">PMC4172996</pub-id></mixed-citation></ref><ref id="B103"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halberstadt</surname><given-names>A. L.</given-names></name><name name-style="western"><surname>Chatha</surname><given-names>M.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Wallach</surname><given-names>J.</given-names></name><name name-style="western"><surname>Brandt</surname><given-names>S. D.</given-names></name></person-group> (<year>2020</year>). <article-title>Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species</article-title>. <source>Neuropharmacology</source><volume>167</volume>, <fpage>107933</fpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2019.107933</pub-id><pub-id pub-id-type="pmid">31917152</pub-id><pub-id pub-id-type="pmcid">PMC9191653</pub-id></mixed-citation></ref><ref id="B104"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halberstadt</surname><given-names>A. L.</given-names></name><name name-style="western"><surname>Geyer</surname><given-names>M. A.</given-names></name></person-group> (<year>2010</year>). <article-title>LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT(2A) receptor</article-title>. <source>Psychopharmacol. Berl.</source><volume>208</volume>, <fpage>179</fpage>&#8211;<lpage>189</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-009-1718-x</pub-id><pub-id pub-id-type="pmcid">PMC2797624</pub-id><pub-id pub-id-type="pmid">19937319</pub-id></mixed-citation></ref><ref id="B105"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harris</surname><given-names>G. C.</given-names></name><name name-style="western"><surname>Aston-Jones</surname><given-names>G.</given-names></name></person-group> (<year>2001</year>). <article-title>Augmented accumbal serotonin levels decrease the preference for a morphine associated environment during withdrawal</article-title>. <source>Neuropsychopharmacology</source><volume>24</volume>, <fpage>75</fpage>&#8211;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1016/S0893-133X(00)00184-6</pub-id><pub-id pub-id-type="pmid">11106878</pub-id></mixed-citation></ref><ref id="B106"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hasin</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>O'brien</surname><given-names>C. P.</given-names></name><name name-style="western"><surname>Auriacombe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Borges</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bucholz</surname><given-names>K.</given-names></name><name name-style="western"><surname>Budney</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>DSM-5 criteria for substance use disorders: recommendations and rationale</article-title>. <source>Am. J. Psychiatry</source><volume>170</volume>, <fpage>834</fpage>&#8211;<lpage>851</lpage>. <pub-id pub-id-type="doi">10.1176/appi.ajp.2013.12060782</pub-id><pub-id pub-id-type="pmid">23903334</pub-id><pub-id pub-id-type="pmcid">PMC3767415</pub-id></mixed-citation></ref><ref id="B107"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hasin</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>Shmulewitz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Stohl</surname><given-names>M.</given-names></name><name name-style="western"><surname>Greenstein</surname><given-names>E.</given-names></name><name name-style="western"><surname>Aharonovich</surname><given-names>E.</given-names></name><name name-style="western"><surname>Petronis</surname><given-names>K. R.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Diagnosing prescription opioid use disorder in patients using prescribed opioids for chronic pain</article-title>. <source>Am. J. Psychiatry</source><volume>179</volume>, <fpage>715</fpage>&#8211;<lpage>725</lpage>. <pub-id pub-id-type="doi">10.1176/appi.ajp.21070721</pub-id><pub-id pub-id-type="pmid">35702830</pub-id></mixed-citation></ref><ref id="B108"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heal</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Gosden</surname><given-names>J.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>S. L.</given-names></name></person-group> (<year>2018</year>). <article-title>Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans</article-title>. <source>Neuropharmacology</source><volume>142</volume>, <fpage>89</fpage>&#8211;<lpage>115</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2018.01.049</pub-id><pub-id pub-id-type="pmid">29427652</pub-id></mixed-citation></ref><ref id="B109"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hedlund</surname><given-names>P. B.</given-names></name><name name-style="western"><surname>Carson</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Sutcliffe</surname><given-names>J. G.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>E. A.</given-names></name></person-group> (<year>1999</year>). <article-title>Allosteric regulation by oleamide of the binding properties of 5-hydroxytryptamine7 receptors</article-title>. <source>Biochem. Pharmacol.</source><volume>58</volume>, <fpage>1807</fpage>&#8211;<lpage>1813</lpage>. <pub-id pub-id-type="doi">10.1016/s0006-2952(99)00274-9</pub-id><pub-id pub-id-type="pmid">10571256</pub-id></mixed-citation></ref><ref id="B110"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hedlund</surname><given-names>P. B.</given-names></name><name name-style="western"><surname>Danielson</surname><given-names>P. E.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Slanina</surname><given-names>K.</given-names></name><name name-style="western"><surname>Carson</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Sutcliffe</surname><given-names>J. G.</given-names></name></person-group> (<year>2003</year>). <article-title>No hypothermic response to serotonin in 5-HT7 receptor knockout mice</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>100</volume>, <fpage>1375</fpage>&#8211;<lpage>1380</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0337340100</pub-id><pub-id pub-id-type="pmid">12529502</pub-id><pub-id pub-id-type="pmcid">PMC298780</pub-id></mixed-citation></ref><ref id="B111"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heijmans</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mons</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Joosten</surname><given-names>E. A.</given-names></name></person-group> (<year>2021</year>). <article-title>A systematic review on descending serotonergic projections and modulation of spinal nociception in chronic neuropathic pain and after spinal cord stimulation</article-title>. <source>Mol. Pain</source><volume>17</volume>, <fpage>17448069211043965</fpage>. <pub-id pub-id-type="doi">10.1177/17448069211043965</pub-id><pub-id pub-id-type="pmid">34662215</pub-id><pub-id pub-id-type="pmcid">PMC8527581</pub-id></mixed-citation></ref><ref id="B112"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heinsbroek</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Giannotti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bonilla</surname><given-names>J.</given-names></name><name name-style="western"><surname>Olson</surname><given-names>D. E.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>J.</given-names></name></person-group> (<year>2023</year>). <article-title>Tabernanthalog reduces motivation for heroin and alcohol in a polydrug use model</article-title>. <source>Psychedelic Med.</source><volume>1</volume>, <fpage>111</fpage>&#8211;<lpage>119</lpage>. <pub-id pub-id-type="doi">10.1089/psymed.2023.0009</pub-id><pub-id pub-id-type="pmcid">PMC10286262</pub-id><pub-id pub-id-type="pmid">37360328</pub-id></mixed-citation></ref><ref id="B113"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hendricks</surname><given-names>P. S.</given-names></name><name name-style="western"><surname>Nichols</surname><given-names>C. D.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Geyer</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Griffiths</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nichols</surname><given-names>D.</given-names></name></person-group> (<year>2023</year>). <article-title>Past, Present, and Future of Psychedelics: A Psychedelic Medicine Roundtable Discussion</article-title>. <source>Psychedelic Med.</source><volume>1</volume>, <fpage>2</fpage>&#8211;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1089/psymed.2022.0003</pub-id></mixed-citation></ref><ref id="B114"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Henningfield</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Coe</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Griffiths</surname><given-names>R. R.</given-names></name><name name-style="western"><surname>Belouin</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Berger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Coker</surname><given-names>A. R.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling</article-title>. <source>Neuropharmacology</source><volume>218</volume>, <fpage>109220</fpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2022.109220</pub-id><pub-id pub-id-type="pmid">35987353</pub-id></mixed-citation></ref><ref id="B115"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Higginbotham</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Markovic</surname><given-names>T.</given-names></name><name name-style="western"><surname>Massaly</surname><given-names>N.</given-names></name><name name-style="western"><surname>Moron</surname><given-names>J. A.</given-names></name></person-group> (<year>2022</year>). <article-title>Endogenous opioid systems alterations in pain and opioid use disorder</article-title>. <source>Front. Syst. Neurosci.</source><volume>16</volume>, <fpage>1014768</fpage>. <pub-id pub-id-type="doi">10.3389/fnsys.2022.1014768</pub-id><pub-id pub-id-type="pmid">36341476</pub-id><pub-id pub-id-type="pmcid">PMC9628214</pub-id></mixed-citation></ref><ref id="B116"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Higgins</surname><given-names>G. A.</given-names></name><name name-style="western"><surname>Fletcher</surname><given-names>P. J.</given-names></name><name name-style="western"><surname>Shanahan</surname><given-names>W. R.</given-names></name></person-group> (<year>2020</year>). <article-title>Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential</article-title>. <source>Pharmacol. Ther.</source><volume>205</volume>, <fpage>107417</fpage>. <pub-id pub-id-type="doi">10.1016/j.pharmthera.2019.107417</pub-id><pub-id pub-id-type="pmid">31629010</pub-id></mixed-citation></ref><ref id="B117"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hilger</surname><given-names>D.</given-names></name><name name-style="western"><surname>Masureel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kobilka</surname><given-names>B. K.</given-names></name></person-group> (<year>2018</year>). <article-title>Structure and dynamics of GPCR signaling complexes</article-title>. <source>Nat. Struct. Mol. Biol.</source><volume>25</volume>, <fpage>4</fpage>&#8211;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1038/s41594-017-0011-7</pub-id><pub-id pub-id-type="pmid">29323277</pub-id><pub-id pub-id-type="pmcid">PMC6535338</pub-id></mixed-citation></ref><ref id="B118"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holze</surname><given-names>F.</given-names></name><name name-style="western"><surname>Avedisian</surname><given-names>I.</given-names></name><name name-style="western"><surname>Varghese</surname><given-names>N.</given-names></name><name name-style="western"><surname>Eckert</surname><given-names>A.</given-names></name><name name-style="western"><surname>Liechti</surname><given-names>M. E.</given-names></name></person-group> (<year>2021a</year>). <article-title>Role of the 5-HT(2A) receptor in acute effects of LSD on empathy and circulating oxytocin</article-title>. <source>Front. Pharmacol.</source><volume>12</volume>, <fpage>711255</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2021.711255</pub-id><pub-id pub-id-type="pmid">34326773</pub-id><pub-id pub-id-type="pmcid">PMC8313809</pub-id></mixed-citation></ref><ref id="B119"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holze</surname><given-names>F.</given-names></name><name name-style="western"><surname>Vizeli</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ley</surname><given-names>L.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>F.</given-names></name><name name-style="western"><surname>Dolder</surname><given-names>P.</given-names></name><name name-style="western"><surname>Stocker</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2021b</year>). <article-title>Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects</article-title>. <source>Neuropsychopharmacology</source><volume>46</volume>, <fpage>537</fpage>&#8211;<lpage>544</lpage>. <pub-id pub-id-type="doi">10.1038/s41386-020-00883-6</pub-id><pub-id pub-id-type="pmid">33059356</pub-id><pub-id pub-id-type="pmcid">PMC8027607</pub-id></mixed-citation></ref><ref id="B120"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horvath</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fross</surname><given-names>R. D.</given-names></name><name name-style="western"><surname>Kleiner-Fisman</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lerch</surname><given-names>R.</given-names></name><name name-style="western"><surname>Stalder</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liaudat</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists</article-title>. <source>Mov. Disord.</source><volume>19</volume>, <fpage>656</fpage>&#8211;<lpage>662</lpage>. <pub-id pub-id-type="doi">10.1002/mds.20201</pub-id><pub-id pub-id-type="pmid">15197703</pub-id></mixed-citation></ref><ref id="B121"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Howell</surname><given-names>L. L.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>K. A.</given-names></name></person-group> (<year>2015</year>). <article-title>Serotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorder</article-title>. <source>Pharmacol. Rev.</source><volume>67</volume>, <fpage>176</fpage>&#8211;<lpage>197</lpage>. <pub-id pub-id-type="doi">10.1124/pr.114.009514</pub-id><pub-id pub-id-type="pmid">25505168</pub-id><pub-id pub-id-type="pmcid">PMC4279075</pub-id></mixed-citation></ref><ref id="B122"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Humphreys</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shover</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Bohnert</surname><given-names>A. S. B.</given-names></name><name name-style="western"><surname>Brandeau</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Caulkins</surname><given-names>J. P.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Responding to the opioid crisis in North America and beyond: recommendations of the Stanford-Lancet Commission</article-title>. <source>Lancet</source><volume>399</volume>, <fpage>555</fpage>&#8211;<lpage>604</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(21)02252-2</pub-id><pub-id pub-id-type="pmid">35122753</pub-id><pub-id pub-id-type="pmcid">PMC9261968</pub-id></mixed-citation></ref><ref id="B123"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Humphreys</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shover</surname><given-names>C. L.</given-names></name></person-group> (<year>2023</year>). <article-title>Twenty-Year Trends in Drug Overdose Fatalities Among Older Adults in the US</article-title>. <source>JAMA Psychiatry</source><volume>80</volume>, <fpage>518</fpage>&#8211;<lpage>520</lpage>. <pub-id pub-id-type="doi">10.1001/jamapsychiatry.2022.5159</pub-id><pub-id pub-id-type="pmid">36988923</pub-id><pub-id pub-id-type="pmcid">PMC10061315</pub-id></mixed-citation></ref><ref id="B124"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hutcheson</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Setola</surname><given-names>V.</given-names></name><name name-style="western"><surname>Roth</surname><given-names>B. L.</given-names></name><name name-style="western"><surname>Merryman</surname><given-names>W. D.</given-names></name></person-group> (<year>2011</year>). <article-title>Serotonin receptors and heart valve disease--it was meant 2B</article-title>. <source>Pharmacol. Ther.</source><volume>132</volume>, <fpage>146</fpage>&#8211;<lpage>157</lpage>. <pub-id pub-id-type="doi">10.1016/j.pharmthera.2011.03.008</pub-id><pub-id pub-id-type="pmid">21440001</pub-id><pub-id pub-id-type="pmcid">PMC3179857</pub-id></mixed-citation></ref><ref id="B125"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Im</surname><given-names>W. B.</given-names></name><name name-style="western"><surname>Chio</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>Alberts</surname><given-names>G. L.</given-names></name><name name-style="western"><surname>Dinh</surname><given-names>D. M.</given-names></name></person-group> (<year>2003</year>). <article-title>Positive allosteric modulator of the human 5-HT<sub>2C</sub> receptor</article-title>. <source>Mol. Pharmacol.</source><volume>64</volume>, <fpage>78</fpage>&#8211;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1124/mol.64.1.78</pub-id><pub-id pub-id-type="pmid">12815163</pub-id></mixed-citation></ref><ref id="B126"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeffery</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Chaisson</surname><given-names>C. E.</given-names></name><name name-style="western"><surname>Hane</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rumanes</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tucker</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hang</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Assessment of potentially inappropriate prescribing of opioid analgesics requiring prior opioid tolerance</article-title>. <source>JAMA Netw. Open</source><volume>3</volume>, <fpage>e202875</fpage>. <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.2875</pub-id><pub-id pub-id-type="pmid">32293684</pub-id><pub-id pub-id-type="pmcid">PMC7160686</pub-id></mixed-citation></ref><ref id="B127"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jenks</surname><given-names>C. W.</given-names></name></person-group> (<year>2002</year>). <article-title>Extraction studies of Tabernanthe iboga and Voacanga africana</article-title>. <source>Nat. Prod. Lett.</source><volume>16</volume>, <fpage>71</fpage>&#8211;<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1080/1057563029001/4881</pub-id><pub-id pub-id-type="pmid">11942686</pub-id></mixed-citation></ref><ref id="B128"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>M. W.</given-names></name><name name-style="western"><surname>Griffiths</surname><given-names>R. R.</given-names></name><name name-style="western"><surname>Hendricks</surname><given-names>P. S.</given-names></name><name name-style="western"><surname>Henningfield</surname><given-names>J. E.</given-names></name></person-group> (<year>2018</year>). <article-title>The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act</article-title>. <source>Neuropharmacology</source><volume>142</volume>, <fpage>143</fpage>&#8211;<lpage>166</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2018.05.012</pub-id><pub-id pub-id-type="pmid">29753748</pub-id><pub-id pub-id-type="pmcid">PMC6791528</pub-id></mixed-citation></ref><ref id="B129"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>G. M.</given-names></name><name name-style="western"><surname>Nock</surname><given-names>M. K.</given-names></name></person-group> (<year>2022</year>). <article-title>Exploring protective associations between the use of classic psychedelics and cocaine use disorder: a population-based survey study</article-title>. <source>Sci. Rep.</source><volume>12</volume>, <fpage>2574</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-022-06580-2</pub-id><pub-id pub-id-type="pmid">35173246</pub-id><pub-id pub-id-type="pmcid">PMC8850431</pub-id></mixed-citation></ref><ref id="B130"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ricard</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Lipson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nock</surname><given-names>M. K.</given-names></name></person-group> (<year>2022</year>). <article-title>Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample</article-title>. <source>Sci. Rep.</source><volume>12</volume>, <fpage>4099</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-022-08085-4</pub-id><pub-id pub-id-type="pmid">35393455</pub-id><pub-id pub-id-type="pmcid">PMC8990065</pub-id></mixed-citation></ref><ref id="B131"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Comer</surname><given-names>S. D.</given-names></name></person-group> (<year>2013</year>). <article-title>A review of human drug self-administration procedures</article-title>. <source>Behav. Pharmacol.</source><volume>24</volume>, <fpage>384</fpage>&#8211;<lpage>395</lpage>. <pub-id pub-id-type="doi">10.1097/FBP.0b013e3283641c3d</pub-id><pub-id pub-id-type="pmid">23839027</pub-id><pub-id pub-id-type="pmcid">PMC4080726</pub-id></mixed-citation></ref><ref id="B132"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karst</surname><given-names>M.</given-names></name><name name-style="western"><surname>Halpern</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Bernateck</surname><given-names>M.</given-names></name><name name-style="western"><surname>Passie</surname><given-names>T.</given-names></name></person-group> (<year>2010</year>). <article-title>The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: an open, non-randomized case series</article-title>. <source>Cephalalgia</source><volume>30</volume>, <fpage>1140</fpage>&#8211;<lpage>1144</lpage>. <pub-id pub-id-type="doi">10.1177/0333102410363490</pub-id><pub-id pub-id-type="pmid">20713566</pub-id></mixed-citation></ref><ref id="B133"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kast</surname><given-names>E. C.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>V. J.</given-names></name></person-group> (<year>1964</year>). <article-title>Study of lysergic acid diethylamide as an analgesic agent</article-title>. <source>Anesth. Analgesia</source><volume>43</volume>, <fpage>285</fpage>&#8211;<lpage>291</lpage>. <pub-id pub-id-type="doi">10.1213/00000539-196405000-00013</pub-id><pub-id pub-id-type="pmid">14169837</pub-id></mixed-citation></ref><ref id="B134"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kehne</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Baron</surname><given-names>B. M.</given-names></name><name name-style="western"><surname>Carr</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Chaney</surname><given-names>S. F.</given-names></name><name name-style="western"><surname>Elands</surname><given-names>J.</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>D. J.</given-names></name><etal/></person-group> (<year>1996</year>). <article-title>Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile</article-title>. <source>J.Pharmacol Exp.Ther.</source><volume>277</volume>, <fpage>968</fpage>&#8211;<lpage>981</lpage>.<pub-id pub-id-type="pmid">8627580</pub-id></mixed-citation></ref><ref id="B135"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Bartlett</surname><given-names>S.</given-names></name><name name-style="western"><surname>He</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>C. K.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Kharazia</surname><given-names>V.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Morphine-induced receptor endocytosis in a novel knockin mouse reduces tolerance and dependence</article-title>. <source>Curr. Biol.</source><volume>18</volume>, <fpage>129</fpage>&#8211;<lpage>135</lpage>. <pub-id pub-id-type="doi">10.1016/j.cub.2007.12.057</pub-id><pub-id pub-id-type="pmid">18207746</pub-id><pub-id pub-id-type="pmcid">PMC2997702</pub-id></mixed-citation></ref><ref id="B136"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>K.</given-names></name><name name-style="western"><surname>Che</surname><given-names>T.</given-names></name><name name-style="western"><surname>Panova</surname><given-names>O.</given-names></name><name name-style="western"><surname>Diberto</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Lyu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Krumm</surname><given-names>B. E.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Structure of a hallucinogen-activated Gq-coupled 5-HT2A serotonin receptor</article-title>. <source>Cell</source><volume>182</volume>, <fpage>1574</fpage>&#8211;<lpage>1588</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.08.024</pub-id><pub-id pub-id-type="pmid">32946782</pub-id><pub-id pub-id-type="pmcid">PMC7593816</pub-id></mixed-citation></ref><ref id="B137"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>King</surname><given-names>T.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Okun</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mercado</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>J.</given-names></name><name name-style="western"><surname>Brion</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Contribution of afferent pathways to nerve injury-induced spontaneous pain and evoked hypersensitivity</article-title>. <source>Pain</source><volume>152</volume>, <fpage>1997</fpage>&#8211;<lpage>2005</lpage>. <pub-id pub-id-type="doi">10.1016/j.pain.2011.04.020</pub-id><pub-id pub-id-type="pmid">21620567</pub-id><pub-id pub-id-type="pmcid">PMC3306802</pub-id></mixed-citation></ref><ref id="B138"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koenig</surname><given-names>X.</given-names></name><name name-style="western"><surname>Kovar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Boehm</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sandtner</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hilber</surname><given-names>K.</given-names></name></person-group> (<year>2014</year>). <article-title>Anti-addiction drug ibogaine inhibits hERG channels: a cardiac arrhythmia risk</article-title>. <source>Addict. Biol.</source><volume>19</volume>, <fpage>237</fpage>&#8211;<lpage>239</lpage>. <pub-id pub-id-type="doi">10.1111/j.1369-1600.2012.00447.x</pub-id><pub-id pub-id-type="pmid">22458604</pub-id><pub-id pub-id-type="pmcid">PMC4888945</pub-id></mixed-citation></ref><ref id="B139"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kometer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jancke</surname><given-names>L.</given-names></name><name name-style="western"><surname>Vollenweider</surname><given-names>F. X.</given-names></name></person-group> (<year>2013</year>). <article-title>Activation of serotonin 2A receptors underlies the psilocybin-induced effects on alpha oscillations, N170 visual-evoked potentials, and visual hallucinations</article-title>. <source>J. Neurosci.</source><volume>33</volume>, <fpage>10544</fpage>&#8211;<lpage>10551</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.3007-12.2013</pub-id><pub-id pub-id-type="pmid">23785166</pub-id><pub-id pub-id-type="pmcid">PMC6618596</pub-id></mixed-citation></ref><ref id="B140"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koob</surname><given-names>G. F.</given-names></name><name name-style="western"><surname>Le Moal</surname><given-names>M.</given-names></name></person-group> (<year>2005</year>). <article-title>Plasticity of reward neurocircuitry and the 'dark side' of drug addiction</article-title>. <source>Nat. Neurosci.</source><volume>8</volume>, <fpage>1442</fpage>&#8211;<lpage>1444</lpage>. <pub-id pub-id-type="doi">10.1038/nn1105-1442</pub-id><pub-id pub-id-type="pmid">16251985</pub-id></mixed-citation></ref><ref id="B141"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koob</surname><given-names>G. F.</given-names></name><name name-style="western"><surname>Pettit</surname><given-names>H. O.</given-names></name><name name-style="western"><surname>Ettenberg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bloom</surname><given-names>F. E.</given-names></name></person-group> (<year>1984</year>). <article-title>Effects of opiate antagonists and their quaternary derivatives on heroin self-administration in the rat</article-title>. <source>J. Pharmacol. Exp. Ther.</source><volume>229</volume>, <fpage>481</fpage>&#8211;<lpage>486</lpage>.<pub-id pub-id-type="pmid">6716270</pub-id></mixed-citation></ref><ref id="B142"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koob</surname><given-names>G. F.</given-names></name><name name-style="western"><surname>Volkow</surname><given-names>N. D.</given-names></name></person-group> (<year>2016</year>). <article-title>Neurobiology of addiction: A neurocircuitry analysis</article-title>. <source>Lancet Psychiatry</source><volume>3</volume>, <fpage>760</fpage>&#8211;<lpage>773</lpage>. <pub-id pub-id-type="doi">10.1016/S2215-0366(16)00104-8</pub-id><pub-id pub-id-type="pmid">27475769</pub-id><pub-id pub-id-type="pmcid">PMC6135092</pub-id></mixed-citation></ref><ref id="B143"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koslowski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>M. W.</given-names></name><name name-style="western"><surname>Gr&#252;nder</surname><given-names>G.</given-names></name><name name-style="western"><surname>Betzler</surname><given-names>F.</given-names></name></person-group> (<year>2021</year>). <article-title>Novel treatment approaches for substance use disorders: Therapeutic use of psychedelics and the role of psychotherapy</article-title>. <source>Curr. Addict. Rep.</source><volume>9</volume>, <fpage>48</fpage>&#8211;<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1007/s40429-021-00401-8</pub-id></mixed-citation></ref><ref id="B144"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krebs-Thomson</surname><given-names>K.</given-names></name><name name-style="western"><surname>Paulus</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Geyer</surname><given-names>M. A.</given-names></name></person-group> (<year>1998</year>). <article-title>Effects of hallucinogens on locomotor and investigatory activity and patterns: influence of 5-HT2A and 5-HT2C receptors</article-title>. <source>Neuropsychopharmacology</source><volume>18</volume>, <fpage>339</fpage>&#8211;<lpage>351</lpage>. <pub-id pub-id-type="doi">10.1016/S0893-133X(97)00164-4</pub-id><pub-id pub-id-type="pmid">9536447</pub-id></mixed-citation></ref><ref id="B145"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krebs-Thomson</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ruiz</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Masten</surname><given-names>V.</given-names></name><name name-style="western"><surname>Buell</surname><given-names>M.</given-names></name><name name-style="western"><surname>Geyer</surname><given-names>M. A.</given-names></name></person-group> (<year>2006</year>). <article-title>The roles of 5-HT1A and 5-HT2 receptors in the effects of 5-MeO-DMT on locomotor activity and prepulse inhibition in rats</article-title>. <source>Psychopharmacol. Berl.</source><volume>189</volume>, <fpage>319</fpage>&#8211;<lpage>329</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-006-0566-1</pub-id><pub-id pub-id-type="pmid">17013638</pub-id></mixed-citation></ref><ref id="B146"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lam</surname><given-names>D. D.</given-names></name><name name-style="western"><surname>Przydzial</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Ridley</surname><given-names>S. H.</given-names></name><name name-style="western"><surname>Yeo</surname><given-names>G. S. H.</given-names></name><name name-style="western"><surname>Rochford</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>O'rahilly</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors</article-title>. <source>Endocrinology</source><volume>149</volume>, <fpage>1323</fpage>&#8211;<lpage>1328</lpage>. <pub-id pub-id-type="doi">10.1210/en.2007-1321</pub-id><pub-id pub-id-type="pmid">18039773</pub-id><pub-id pub-id-type="pmcid">PMC2275368</pub-id></mixed-citation></ref><ref id="B147"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le Merrer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Befort</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kieffer</surname><given-names>B. L.</given-names></name></person-group> (<year>2009</year>). <article-title>Reward processing by the opioid system in the brain</article-title>. <source>Physiol. Rev.</source><volume>89</volume>, <fpage>1379</fpage>&#8211;<lpage>1412</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.00005.2009</pub-id><pub-id pub-id-type="pmid">19789384</pub-id><pub-id pub-id-type="pmcid">PMC4482114</pub-id></mixed-citation></ref><ref id="B148"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leiderman</surname><given-names>D. B.</given-names></name></person-group> (<year>2009</year>). <article-title>Risk management of drug products and the U.S. Food and Drug Administration: evolution and context</article-title>. <source>Drug Alcohol Depend.</source><volume>105</volume> (<issue>1</issue>), <fpage>S9</fpage>&#8211;<lpage>S13</lpage>. <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2009.02.007</pub-id><pub-id pub-id-type="pmid">19307069</pub-id></mixed-citation></ref><ref id="B149"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leptourgos</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fortier-Davy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carhart-Harris</surname><given-names>R.</given-names></name><name name-style="western"><surname>Corlett</surname><given-names>P. R.</given-names></name><name name-style="western"><surname>Dupuis</surname><given-names>D.</given-names></name><name name-style="western"><surname>Halberstadt</surname><given-names>A. L.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Hallucinations under psychedelics and in the schizophrenia spectrum: An interdisciplinary and multiscale comparison</article-title>. <source>Schizophr. Bull.</source><volume>46</volume>, <fpage>1396</fpage>&#8211;<lpage>1408</lpage>. <pub-id pub-id-type="doi">10.1093/schbul/sbaa117</pub-id><pub-id pub-id-type="pmid">32944778</pub-id><pub-id pub-id-type="pmcid">PMC7707069</pub-id></mixed-citation></ref><ref id="B150"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leri</surname><given-names>F.</given-names></name><name name-style="western"><surname>Burns</surname><given-names>L. H.</given-names></name></person-group> (<year>2005</year>). <article-title>Ultra-low-dose naltrexone reduces the rewarding potency of oxycodone and relapse vulnerability in rats</article-title>. <source>Pharmacol. Biochem. Behav.</source><volume>82</volume>, <fpage>252</fpage>&#8211;<lpage>262</lpage>. <pub-id pub-id-type="doi">10.1016/j.pbb.2005.08.008</pub-id><pub-id pub-id-type="pmid">16182352</pub-id></mixed-citation></ref><ref id="B151"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lewis</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bonniwell</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Lanham</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Ghaffari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sheshbaradaran</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>A. B.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>A non-hallucinogenic LSD analog with therapeutic potential for mood disorders</article-title>. <source>Cell Rep.</source><volume>42</volume>, <fpage>112203</fpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2023.112203</pub-id><pub-id pub-id-type="pmid">36884348</pub-id><pub-id pub-id-type="pmcid">PMC10112881</pub-id></mixed-citation></ref><ref id="B152"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Blockade of 5-hydroxytryptamine 2A receptor attenuates precipitation of naloxone-induced withdrawal symptoms in opioid-exposed mice</article-title>. <source>Front. Behav. Neurosci.</source><volume>15</volume>, <fpage>797217</fpage>. <pub-id pub-id-type="doi">10.3389/fnbeh.2021.797217</pub-id><pub-id pub-id-type="pmid">35221941</pub-id><pub-id pub-id-type="pmcid">PMC8864093</pub-id></mixed-citation></ref><ref id="B153"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J. X.</given-names></name><name name-style="western"><surname>Koek</surname><given-names>W.</given-names></name><name name-style="western"><surname>Rice</surname><given-names>K. C.</given-names></name><name name-style="western"><surname>France</surname><given-names>C. P.</given-names></name></person-group> (<year>2011</year>). <article-title>Effects of direct- and indirect-acting serotonin receptor agonists on the antinociceptive and discriminative stimulus effects of morphine in rhesus monkeys</article-title>. <source>Neuropsychopharmacology</source><volume>36</volume>, <fpage>940</fpage>&#8211;<lpage>949</lpage>. <pub-id pub-id-type="doi">10.1038/npp.2010.232</pub-id><pub-id pub-id-type="pmid">21209613</pub-id><pub-id pub-id-type="pmcid">PMC3077263</pub-id></mixed-citation></ref><ref id="B154"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lindsley</surname><given-names>C. W.</given-names></name><name name-style="western"><surname>Emmitte</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Hopkins</surname><given-names>C. R.</given-names></name><name name-style="western"><surname>Bridges</surname><given-names>T. M.</given-names></name><name name-style="western"><surname>Gregory</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Niswender</surname><given-names>C. M.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Practical strategies and concepts in GPCR allosteric modulator discovery: Recent advances with metabotropic glutamate receptors</article-title>. <source>Chem. Rev.</source><volume>116</volume>, <fpage>6707</fpage>&#8211;<lpage>6741</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrev.5b00656</pub-id><pub-id pub-id-type="pmid">26882314</pub-id><pub-id pub-id-type="pmcid">PMC4988345</pub-id></mixed-citation></ref><ref id="B155"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Dorsal raphe neurons signal reward through 5-HT and glutamate</article-title>. <source>Neuron</source><volume>81</volume>, <fpage>1360</fpage>&#8211;<lpage>1374</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2014.02.010</pub-id><pub-id pub-id-type="pmid">24656254</pub-id><pub-id pub-id-type="pmcid">PMC4411946</pub-id></mixed-citation></ref><ref id="B156"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopez-Gimenez</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Vilaro</surname><given-names>M. T.</given-names></name><name name-style="western"><surname>Milligan</surname><given-names>G.</given-names></name></person-group> (<year>2008</year>). <article-title>Morphine desensitization, internalization, and down-regulation of the mu opioid receptor is facilitated by serotonin 5-hydroxytryptamine2A receptor coactivation</article-title>. <source>Mol. Pharmacol.</source><volume>74</volume>, <fpage>1278</fpage>&#8211;<lpage>1291</lpage>. <pub-id pub-id-type="doi">10.1124/mol.108.048272</pub-id><pub-id pub-id-type="pmid">18703670</pub-id></mixed-citation></ref><ref id="B157"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopez-Gimenez</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Vilaro</surname><given-names>M. T.</given-names></name><name name-style="western"><surname>Palacios</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Mengod</surname><given-names>G.</given-names></name></person-group> (<year>2001</year>). <article-title>Mapping of 5-HT2A receptors and their mRNA in monkey brain: [3H]MDL100,907 autoradiography and <italic toggle="yes">in situ</italic> hybridization studies</article-title>. <source>J. Comp. Neurol.</source><volume>429</volume>, <fpage>571</fpage>&#8211;<lpage>589</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1096-9861(20010122)429:4&amp;#x0003c;571::aid-cne5&amp;#x0003e;3.0.co;2-x</pub-id><pub-id pub-id-type="pmid">11135236</pub-id></mixed-citation></ref><ref id="B158"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ly</surname><given-names>C.</given-names></name><name name-style="western"><surname>Greb</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Cameron</surname><given-names>L. P.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Barragan</surname><given-names>E. V.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>P. C.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Psychedelics promote structural and functional neural plasticity</article-title>. <source>Cell Rep.</source><volume>23</volume>, <fpage>3170</fpage>&#8211;<lpage>3182</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2018.05.022</pub-id><pub-id pub-id-type="pmid">29898390</pub-id><pub-id pub-id-type="pmcid">PMC6082376</pub-id></mixed-citation></ref><ref id="B159"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meert</surname><given-names>T. F.</given-names></name><name name-style="western"><surname>Vermeirsch</surname><given-names>H. A.</given-names></name></person-group> (<year>2005</year>). <article-title>A preclinical comparison between different opioids: antinociceptive versus adverse effects</article-title>. <source>Pharmacol. Biochem. Behav.</source><volume>80</volume>, <fpage>309</fpage>&#8211;<lpage>326</lpage>. <pub-id pub-id-type="doi">10.1016/j.pbb.2004.12.002</pub-id><pub-id pub-id-type="pmid">15680184</pub-id></mixed-citation></ref><ref id="B160"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>L.</given-names></name><name name-style="western"><surname>Steinberg</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Bjork</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>B. A.</given-names></name><name name-style="western"><surname>Arias</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Terplan</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Cingulo-hippocampal effective connectivity positively correlates with drug-cue attentional bias in opioid use disorder</article-title>. <source>Psychiatry Res. Neuroimaging</source><volume>294</volume>, <fpage>110977</fpage>. <pub-id pub-id-type="doi">10.1016/j.pscychresns.2019.08.005</pub-id><pub-id pub-id-type="pmid">31439409</pub-id><pub-id pub-id-type="pmcid">PMC8598076</pub-id></mixed-citation></ref><ref id="B161"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Madden</surname><given-names>G. J.</given-names></name><name name-style="western"><surname>Petry</surname><given-names>N. M.</given-names></name><name name-style="western"><surname>Badger</surname><given-names>G. J.</given-names></name><name name-style="western"><surname>Bickel</surname><given-names>W. K.</given-names></name></person-group> (<year>1997</year>). <article-title>Impulsive and self-control choices in opioid-dependent patients and non-drug-using control participants: drug and monetary rewards</article-title>. <source>Exp. Clin. Psychopharmacol.</source><volume>5</volume>, <fpage>256</fpage>&#8211;<lpage>262</lpage>. <pub-id pub-id-type="doi">10.1037//1064-1297.5.3.256</pub-id><pub-id pub-id-type="pmid">9260073</pub-id></mixed-citation></ref><ref id="B162"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Madsen</surname><given-names>M. K.</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>P. M.</given-names></name><name name-style="western"><surname>Burmester</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dyssegaard</surname><given-names>A.</given-names></name><name name-style="western"><surname>Stenbaek</surname><given-names>D. S.</given-names></name><name name-style="western"><surname>Kristiansen</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels</article-title>. <source>Neuropsychopharmacology</source><volume>44</volume>, <fpage>1328</fpage>&#8211;<lpage>1334</lpage>. <pub-id pub-id-type="doi">10.1038/s41386-019-0324-9</pub-id><pub-id pub-id-type="pmid">30685771</pub-id><pub-id pub-id-type="pmcid">PMC6785028</pub-id></mixed-citation></ref><ref id="B163"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maguire</surname><given-names>D. R.</given-names></name></person-group> (<year>2023</year>). <article-title>Effects of 2,5-dimethoxy-4-methylamphetamine (DOM) and 2-piperazin-1-yl-quinoline (quipazine) on fentanyl versus food choice in rhesus monkeys</article-title>. <source>J. Pharmacol. Exp. Ther.</source><volume>384</volume>, <fpage>155</fpage>&#8211;<lpage>162</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.122.001318</pub-id><pub-id pub-id-type="pmid">36272734</pub-id><pub-id pub-id-type="pmcid">PMC9827501</pub-id></mixed-citation></ref><ref id="B164"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maguire</surname><given-names>D. R.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J. X.</given-names></name><name name-style="western"><surname>Koek</surname><given-names>W.</given-names></name><name name-style="western"><surname>France</surname><given-names>C. P.</given-names></name></person-group> (<year>2013</year>). <article-title>Effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) and quipazine on heroin self-administration in rhesus monkeys</article-title>. <source>Psychopharmacol. Berl.</source><volume>225</volume>, <fpage>173</fpage>&#8211;<lpage>185</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-012-2803-0</pub-id><pub-id pub-id-type="pmcid">PMC3725280</pub-id><pub-id pub-id-type="pmid">22836370</pub-id></mixed-citation></ref><ref id="B165"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mansour</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Akil</surname><given-names>H.</given-names></name><name name-style="western"><surname>Watson</surname><given-names>S. J.</given-names></name></person-group> (<year>1995</year>). <article-title>Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications</article-title>. <source>Trends Neurosci.</source><volume>18</volume>, <fpage>22</fpage>&#8211;<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1016/0166-2236(95)93946-u</pub-id><pub-id pub-id-type="pmid">7535487</pub-id></mixed-citation></ref><ref id="B166"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mansour</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khachaturian</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Akil</surname><given-names>H.</given-names></name><name name-style="western"><surname>Watson</surname><given-names>S. J.</given-names></name></person-group> (<year>1988</year>). <article-title>Anatomy of CNS opioid receptors</article-title>. <source>Trends Neurosci.</source><volume>11</volume>, <fpage>308</fpage>&#8211;<lpage>314</lpage>. <pub-id pub-id-type="doi">10.1016/0166-2236(88)90093-8</pub-id><pub-id pub-id-type="pmid">2465635</pub-id></mixed-citation></ref><ref id="B167"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marek</surname><given-names>G. J.</given-names></name><name name-style="western"><surname>Aghajanian</surname><given-names>G. K.</given-names></name></person-group> (<year>1998</year>). <article-title>5-Hydroxytryptamine-induced excitatory postsynaptic currents in neocortical layer V pyramidal cells: suppression by mu-opiate receptor activation</article-title>. <source>Neuroscience</source><volume>86</volume>, <fpage>485</fpage>&#8211;<lpage>497</lpage>. <pub-id pub-id-type="doi">10.1016/s0306-4522(98)00043-8</pub-id><pub-id pub-id-type="pmid">9881863</pub-id></mixed-citation></ref><ref id="B168"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marek</surname><given-names>G. J.</given-names></name></person-group> (<year>2003</year>). <article-title>Behavioral evidence for mu-opioid and 5-HT2A receptor interactions</article-title>. <source>Eur. J. Pharmacol.</source><volume>474</volume>, <fpage>77</fpage>&#8211;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1016/s0014-2999(03)01971-x</pub-id><pub-id pub-id-type="pmid">12909198</pub-id></mixed-citation></ref><ref id="B169"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marek</surname><given-names>G. J.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Rasmussen</surname><given-names>K.</given-names></name></person-group> (<year>2019</year>). <article-title>Translating pharmacology into therapeutics to fight the opioid crisis</article-title>. <source>J. Pharmacol. Exp. Ther.</source><volume>371</volume>, <fpage>394</fpage>&#8211;<lpage>395</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.119.262477</pub-id><pub-id pub-id-type="pmid">31628259</pub-id></mixed-citation></ref><ref id="B170"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marona-Lewicka</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kurrasch-Orbaugh</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Selken</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Cumbay</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Lisnicchia</surname><given-names>J. G.</given-names></name><name name-style="western"><surname>Nichols</surname><given-names>D. E.</given-names></name></person-group> (<year>2002</year>). <article-title>Re-evaluation of lisuride pharmacology: 5-hydroxytryptamine1A receptor-mediated behavioral effects overlap its other properties in rats</article-title>. <source>Psychopharmacol. Berl.</source><volume>164</volume>, <fpage>93</fpage>&#8211;<lpage>107</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-002-1141-z</pub-id><pub-id pub-id-type="pmid">12373423</pub-id></mixed-citation></ref><ref id="B171"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Gyawali</surname><given-names>U.</given-names></name><name name-style="western"><surname>Calu</surname><given-names>D. J.</given-names></name></person-group> (<year>2021</year>). <article-title>Effects of 5-HT2A receptor stimulation on economic demand for fentanyl after intermittent and continuous access self-administration in male rats</article-title>. <source>Addict. Biol.</source><volume>26</volume>, <fpage>e12926</fpage>. <pub-id pub-id-type="doi">10.1111/adb.12926</pub-id><pub-id pub-id-type="pmid">32458577</pub-id><pub-id pub-id-type="pmcid">PMC7688480</pub-id></mixed-citation></ref><ref id="B172"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mash</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Ameer</surname><given-names>B.</given-names></name><name name-style="western"><surname>Prou</surname><given-names>D.</given-names></name><name name-style="western"><surname>Howes</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Maillet</surname><given-names>E. L.</given-names></name></person-group> (<year>2016</year>). <article-title>Oral noribogaine shows high brain uptake and anti-withdrawal effects not associated with place preference in rodents</article-title>. <source>J. Psychopharmacol.</source><volume>30</volume>, <fpage>688</fpage>&#8211;<lpage>697</lpage>. <pub-id pub-id-type="doi">10.1177/0269881116641331</pub-id><pub-id pub-id-type="pmid">27044509</pub-id></mixed-citation></ref><ref id="B173"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mash</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Duque</surname><given-names>L.</given-names></name><name name-style="western"><surname>Page</surname><given-names>B.</given-names></name><name name-style="western"><surname>Allen-Ferdinand</surname><given-names>K.</given-names></name></person-group> (<year>2018</year>). <article-title>Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence: Clinical observations and treatment outcomes</article-title>. <source>Front. Pharmacol.</source><volume>9</volume>, <fpage>529</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2018.00529</pub-id><pub-id pub-id-type="pmid">29922156</pub-id><pub-id pub-id-type="pmcid">PMC5996271</pub-id></mixed-citation></ref><ref id="B174"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mash</surname><given-names>D. C.</given-names></name></person-group> (<year>2023</year>). <article-title>IUPHAR - invited review - Ibogaine - A legacy within the current renaissance of psychedelic therapy</article-title>. <source>Pharmacol. Res.</source><volume>190</volume>, <fpage>106620</fpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2022.106620</pub-id><pub-id pub-id-type="pmid">36907284</pub-id></mixed-citation></ref><ref id="B175"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mash</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Staley</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Baumann</surname><given-names>M. H.</given-names></name><name name-style="western"><surname>Rothman</surname><given-names>R. B.</given-names></name><name name-style="western"><surname>Hearn</surname><given-names>W. L.</given-names></name></person-group> (<year>1995a</year>). <article-title>Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin</article-title>. <source>Life Sci.</source><volume>57</volume>, <fpage>PL45</fpage>&#8211;<lpage>PL50</lpage>. <pub-id pub-id-type="doi">10.1016/0024-3205(95)00273-9</pub-id><pub-id pub-id-type="pmid">7596224</pub-id></mixed-citation></ref><ref id="B176"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mash</surname><given-names>D. C.</given-names></name><name name-style="western"><surname>Staley</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Pablo</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Holohean</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Hackman</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Davidoff</surname><given-names>R. A.</given-names></name></person-group> (<year>1995b</year>). <article-title>Properties of ibogaine and its principal metabolite (12- hydroxyibogamine) at the MK-801 binding site of the NMDA receptor complex</article-title>. <source>Neurosci. Lett.</source><volume>192</volume>, <fpage>53</fpage>&#8211;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1016/0304-3940(95)11608-y</pub-id><pub-id pub-id-type="pmid">7675310</pub-id></mixed-citation></ref><ref id="B177"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mcauliffe</surname><given-names>W. E.</given-names></name></person-group> (<year>2013</year>). <article-title>A critique of Minozzi et al.'s pain relief and dependence systematic review</article-title>. <source>Addiction</source><volume>108</volume>, <fpage>1162</fpage>&#8211;<lpage>1169</lpage>. <pub-id pub-id-type="doi">10.1111/add.12181</pub-id><pub-id pub-id-type="pmid">23659847</pub-id></mixed-citation></ref><ref id="B178"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mcclure-Begley</surname><given-names>T. D.</given-names></name><name name-style="western"><surname>Roth</surname><given-names>B. L.</given-names></name></person-group> (<year>2022</year>). <article-title>The promises and perils of psychedelic pharmacology for psychiatry</article-title>. <source>Nat. Rev. Drug Discov.</source><volume>21</volume>, <fpage>463</fpage>&#8211;<lpage>473</lpage>. <pub-id pub-id-type="doi">10.1038/s41573-022-00421-7</pub-id><pub-id pub-id-type="pmid">35301459</pub-id></mixed-citation></ref><ref id="B179"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mcmahon</surname><given-names>L. R.</given-names></name></person-group> (<year>2015</year>). <article-title>The rise (and fall?) of drug discrimination research</article-title>. <source>Drug Alcohol Depend.</source><volume>151</volume>, <fpage>284</fpage>&#8211;<lpage>288</lpage>. <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2015.04.001</pub-id><pub-id pub-id-type="pmid">26207268</pub-id><pub-id pub-id-type="pmcid">PMC4879885</pub-id></mixed-citation></ref><ref id="B180"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meltzer</surname><given-names>H. Y.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>R.</given-names></name><name name-style="western"><surname>Revell</surname><given-names>S.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>H.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bahr</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of Parkinson's disease psychosis</article-title>. <source>Neuropsychopharmacology</source><volume>35</volume>, <fpage>881</fpage>&#8211;<lpage>892</lpage>. <pub-id pub-id-type="doi">10.1038/npp.2009.176</pub-id><pub-id pub-id-type="pmid">19907417</pub-id><pub-id pub-id-type="pmcid">PMC3055369</pub-id></mixed-citation></ref><ref id="B181"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mendez-Diaz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Amancio-Belmont</surname><given-names>O.</given-names></name><name name-style="western"><surname>Estrada-Gonzalez</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ruiz-Contreras</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>Prospero-Garcia</surname><given-names>O.</given-names></name></person-group> (<year>2019</year>). <article-title>CB1R mediates oleamide's reward while 5HT2cR mediates aversion in the nucleus accumbens shell of rats</article-title>. <source>Neurosci. Lett.</source><volume>706</volume>, <fpage>189</fpage>&#8211;<lpage>193</lpage>. <pub-id pub-id-type="doi">10.1016/j.neulet.2019.05.033</pub-id><pub-id pub-id-type="pmid">31116971</pub-id></mixed-citation></ref><ref id="B182"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Merritt</surname><given-names>C. R.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>Khanipov</surname><given-names>K.</given-names></name><name name-style="western"><surname>Golovko</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dineley</surname><given-names>K. T.</given-names></name><name name-style="western"><surname>Anastasio</surname><given-names>N. C.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Heightened cocaine-seeking in male rats associates with a distinct transcriptomic profile in the medial prefrontal cortex</article-title>. <source>Front. Pharmacol.</source><volume>13</volume>, <fpage>1022863</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2022.1022863</pub-id><pub-id pub-id-type="pmid">36588704</pub-id><pub-id pub-id-type="pmcid">PMC9797046</pub-id></mixed-citation></ref><ref id="B183"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miner</surname><given-names>L. A.</given-names></name><name name-style="western"><surname>Backstrom</surname><given-names>J. R.</given-names></name><name name-style="western"><surname>Sanders-Bush</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sesack</surname><given-names>S. R.</given-names></name></person-group> (<year>2003</year>). <article-title>Ultrastructural localization of serotonin2A receptors in the middle layers of the rat prelimbic prefrontal cortex</article-title>. <source>Neuroscience</source><volume>116</volume>, <fpage>107</fpage>&#8211;<lpage>117</lpage>. <pub-id pub-id-type="doi">10.1016/s0306-4522(02)00580-8</pub-id><pub-id pub-id-type="pmid">12535944</pub-id></mixed-citation></ref><ref id="B184"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Minozzi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Amato</surname><given-names>L.</given-names></name><name name-style="western"><surname>Davoli</surname><given-names>M.</given-names></name></person-group> (<year>2013</year>). <article-title>Development of dependence following treatment with opioid analgesics for pain relief: a systematic review</article-title>. <source>Addiction</source><volume>108</volume>, <fpage>688</fpage>&#8211;<lpage>698</lpage>. <pub-id pub-id-type="doi">10.1111/j.1360-0443.2012.04005.x</pub-id><pub-id pub-id-type="pmid">22775332</pub-id></mixed-citation></ref><ref id="B185"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mocci</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jimenez-Sanchez</surname><given-names>L.</given-names></name><name name-style="western"><surname>Adell</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cortes</surname><given-names>R.</given-names></name><name name-style="western"><surname>Artigas</surname><given-names>F.</given-names></name></person-group> (<year>2014</year>). <article-title>Expression of 5-HT2A receptors in prefrontal cortex pyramidal neurons projecting to nucleus accumbens. Potential relevance for atypical antipsychotic action</article-title>. <source>Neuropharmacology</source><volume>79</volume>, <fpage>49</fpage>&#8211;<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2013.10.021</pub-id><pub-id pub-id-type="pmid">24211653</pub-id></mixed-citation></ref><ref id="B186"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohammadi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jahanshahi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jameie</surname><given-names>S. B.</given-names></name></person-group> (<year>2016</year>). <article-title>5-HT2A serotonin receptor density in adult male rats' hippocampus after morphine-based conditioned place preference</article-title>. <source>Basic Clin. Neurosci.</source><volume>7</volume>, <fpage>249</fpage>&#8211;<lpage>258</lpage>. <pub-id pub-id-type="doi">10.15412/J.BCN.03070310</pub-id><pub-id pub-id-type="pmid">27563418</pub-id><pub-id pub-id-type="pmcid">PMC4981837</pub-id></mixed-citation></ref><ref id="B187"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moliner</surname><given-names>R.</given-names></name><name name-style="western"><surname>Girych</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brunello</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Kovaleva</surname><given-names>V.</given-names></name><name name-style="western"><surname>Biojone</surname><given-names>C.</given-names></name><name name-style="western"><surname>Enkavi</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Psychedelics promote plasticity by directly binding to BDNF receptor TrkB</article-title>. <source>Nat. Neurosci.</source><volume>26</volume>, <fpage>1032</fpage>&#8211;<lpage>1041</lpage>. <pub-id pub-id-type="doi">10.1038/s41593-023-01316-5</pub-id><pub-id pub-id-type="pmid">37280397</pub-id><pub-id pub-id-type="pmcid">PMC10244169</pub-id></mixed-citation></ref><ref id="B188"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morse</surname><given-names>W. H.</given-names></name><name name-style="western"><surname>Skinner</surname><given-names>B. F.</given-names></name></person-group> (<year>1958</year>). <article-title>Some factors involved in the stimulus control of operant behavior</article-title>. <source>J. Exp. Anal. Behav.</source><volume>1</volume>, <fpage>103</fpage>&#8211;<lpage>107</lpage>. <pub-id pub-id-type="doi">10.1901/jeab.1958.1-103</pub-id><pub-id pub-id-type="pmid">14476352</pub-id><pub-id pub-id-type="pmcid">PMC1403869</pub-id></mixed-citation></ref><ref id="B189"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moutkine</surname><given-names>I.</given-names></name><name name-style="western"><surname>Quentin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Guiard</surname><given-names>B. P.</given-names></name><name name-style="western"><surname>Maroteaux</surname><given-names>L.</given-names></name><name name-style="western"><surname>Doly</surname><given-names>S.</given-names></name></person-group> (<year>2017</year>). <article-title>Heterodimers of serotonin receptor subtypes 2 are driven by 5-HT2C protomers</article-title>. <source>J. Biol. Chem.</source><volume>292</volume>, <fpage>6352</fpage>&#8211;<lpage>6368</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M117.779041</pub-id><pub-id pub-id-type="pmid">28258217</pub-id><pub-id pub-id-type="pmcid">PMC5391763</pub-id></mixed-citation></ref><ref id="B190"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Takayama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nishitani</surname><given-names>N.</given-names></name><name name-style="western"><surname>Andoh</surname><given-names>C.</given-names></name><name name-style="western"><surname>Koda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shirakawa</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>The Role of Dorsal Raphe Serotonin Neurons in the Balance between Reward and Aversion</article-title>. <source>Int. J. Mol. Sci.</source><volume>21</volume>, <fpage>2160</fpage>. <pub-id pub-id-type="doi">10.3390/ijms21062160</pub-id><pub-id pub-id-type="pmid">32245184</pub-id><pub-id pub-id-type="pmcid">PMC7139834</pub-id></mixed-citation></ref><ref id="B191"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakai</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nakae</surname><given-names>A.</given-names></name><name name-style="western"><surname>Oba</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mashimo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ueda</surname><given-names>K.</given-names></name></person-group> (<year>2010</year>). <article-title>5-HT2C receptor agonists attenuate pain-related behaviour in a rat model of trigeminal neuropathic pain</article-title>. <source>Eur. J. Pain</source><volume>14</volume>, <fpage>999</fpage>&#8211;<lpage>1006</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejpain.2010.04.008</pub-id><pub-id pub-id-type="pmid">20488736</pub-id></mixed-citation></ref><ref id="B192"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nasrallah</surname><given-names>H. A.</given-names></name><name name-style="western"><surname>Fedora</surname><given-names>R.</given-names></name><name name-style="western"><surname>Morton</surname><given-names>R.</given-names></name></person-group> (<year>2019</year>). <article-title>Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist</article-title>. <source>Schizophr. Res.</source><volume>208</volume>, <fpage>217</fpage>&#8211;<lpage>220</lpage>. <pub-id pub-id-type="doi">10.1016/j.schres.2019.02.018</pub-id><pub-id pub-id-type="pmid">30837203</pub-id></mixed-citation></ref><ref id="B193"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Navratilova</surname><given-names>E.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J. Y.</given-names></name><name name-style="western"><surname>Okun</surname><given-names>A.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Eyde</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ci</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Pain relief produces negative reinforcement through activation of mesolimbic reward-valuation circuitry</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>109</volume>, <fpage>20709</fpage>&#8211;<lpage>20713</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1214605109</pub-id><pub-id pub-id-type="pmid">23184995</pub-id><pub-id pub-id-type="pmcid">PMC3528534</pub-id></mixed-citation></ref><ref id="B194"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neelakantan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Holliday</surname><given-names>E. D.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>R. G.</given-names></name><name name-style="western"><surname>Stutz</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Comer</surname><given-names>S. D.</given-names></name><name name-style="western"><surname>Haney</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Lorcaserin suppresses oxycodone self-administration and relapse vulnerability in rats</article-title>. <source>ACS Chem. Neurosci.</source><volume>8</volume>, <fpage>1065</fpage>&#8211;<lpage>1073</lpage>. <pub-id pub-id-type="doi">10.1021/acschemneuro.6b00413</pub-id><pub-id pub-id-type="pmid">28107783</pub-id><pub-id pub-id-type="pmcid">PMC5454249</pub-id></mixed-citation></ref><ref id="B195"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Negus</surname><given-names>S. S.</given-names></name><name name-style="western"><surname>Henriksen</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Mattox</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pasternak</surname><given-names>G. W.</given-names></name><name name-style="western"><surname>Portoghese</surname><given-names>P. S.</given-names></name><name name-style="western"><surname>Takemori</surname><given-names>A. E.</given-names></name><etal/></person-group> (<year>1993</year>). <article-title>Effect of antagonists selective for mu, delta and kappa opioid receptors on the reinforcing effects of heroin in rats</article-title>. <source>J. Pharmacol. Exp. Ther.</source><volume>265</volume>, <fpage>1245</fpage>&#8211;<lpage>1252</lpage>.<pub-id pub-id-type="pmid">8389859</pub-id></mixed-citation></ref><ref id="B196"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nelson</surname><given-names>D. L.</given-names></name><name name-style="western"><surname>Lucaites</surname><given-names>V. L.</given-names></name><name name-style="western"><surname>Wainscott</surname><given-names>D. B.</given-names></name><name name-style="western"><surname>Glennon</surname><given-names>R. A.</given-names></name></person-group> (<year>1999</year>). <article-title>Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, -HT(2B) and 5-HT2C receptors</article-title>. <source>Naunyn Schmiedeb. Arch. Pharmacol.</source><volume>359</volume>, <fpage>1</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1007/pl00005315</pub-id><pub-id pub-id-type="pmid">9933142</pub-id></mixed-citation></ref><ref id="B197"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nichols</surname><given-names>D. E.</given-names></name></person-group> (<year>2016</year>). <article-title>Psychedelics</article-title>. <source>Pharmacol. Rev.</source><volume>68</volume>, <fpage>264</fpage>&#8211;<lpage>355</lpage>. <pub-id pub-id-type="doi">10.1124/pr.115.011478</pub-id><pub-id pub-id-type="pmid">26841800</pub-id><pub-id pub-id-type="pmcid">PMC4813425</pub-id></mixed-citation></ref><ref id="B198"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nichols</surname><given-names>D. E.</given-names></name><name name-style="western"><surname>Walter</surname><given-names>H.</given-names></name></person-group> (<year>2021</year>). <article-title>The history of psychedelics in psychiatry</article-title>. <source>Pharmacopsychiatry</source><volume>54</volume>, <fpage>151</fpage>&#8211;<lpage>166</lpage>. <pub-id pub-id-type="doi">10.1055/a-1310-3990</pub-id><pub-id pub-id-type="pmid">33285579</pub-id></mixed-citation></ref><ref id="B199"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nielsen</surname><given-names>E. B.</given-names></name><name name-style="western"><surname>Ginn</surname><given-names>S. R.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Appel</surname><given-names>J. B.</given-names></name></person-group> (<year>1985</year>). <article-title>Antagonism of the LSD cue by putative serotonin antagonists: relationship to inhibition of <italic toggle="yes">in vivo</italic> [3H]spiroperidol binding</article-title>. <source>Behav. Brain Res.</source><volume>16</volume>, <fpage>171</fpage>&#8211;<lpage>176</lpage>. <pub-id pub-id-type="doi">10.1016/0166-4328(85)90090-7</pub-id><pub-id pub-id-type="pmid">2931089</pub-id></mixed-citation></ref><ref id="B200"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Noller</surname><given-names>G. E.</given-names></name><name name-style="western"><surname>Frampton</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Yazar-Klosinski</surname><given-names>B.</given-names></name></person-group> (<year>2018</year>). <article-title>Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study</article-title>. <source>Am. J. Drug Alcohol Abuse</source><volume>44</volume>, <fpage>37</fpage>&#8211;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1080/00952990.2017.1310218</pub-id><pub-id pub-id-type="pmid">28402682</pub-id></mixed-citation></ref><ref id="B201"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O'brien</surname><given-names>C. P.</given-names></name></person-group> (<year>2009</year>). <article-title>Neuroplasticity in addictive disorders</article-title>. <source>Dialogues Clin. Neurosci.</source><volume>11</volume>, <fpage>350</fpage>&#8211;<lpage>353</lpage>. <pub-id pub-id-type="doi">10.31887/DCNS.2009.11.3/cpobrien</pub-id><pub-id pub-id-type="pmid">19877501</pub-id><pub-id pub-id-type="pmcid">PMC3181920</pub-id></mixed-citation></ref><ref id="B202"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O'connor</surname><given-names>E. C.</given-names></name><name name-style="western"><surname>Chapman</surname><given-names>K.</given-names></name><name name-style="western"><surname>Butler</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mead</surname><given-names>A. N.</given-names></name></person-group> (<year>2011</year>). <article-title>The predictive validity of the rat self-administration model for abuse liability</article-title>. <source>Neurosci. Biobehav Rev.</source><volume>35</volume>, <fpage>912</fpage>&#8211;<lpage>938</lpage>. <pub-id pub-id-type="doi">10.1016/j.neubiorev.2010.10.012</pub-id><pub-id pub-id-type="pmid">21036191</pub-id></mixed-citation></ref><ref id="B203"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Odagaki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kinoshita</surname><given-names>M.</given-names></name><name name-style="western"><surname>Meana</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Callado</surname><given-names>L. F.</given-names></name><name name-style="western"><surname>Garcia-Sevilla</surname><given-names>J. A.</given-names></name></person-group> (<year>2021</year>). <article-title>5-HT<sub>2A</sub> receptor- and M<sub>1</sub> muscarinic acetylcholine receptor-mediated activation of G&#945;<sub>q/11</sub> in postmortem dorsolateral prefrontal cortex of opiate addicts</article-title>. <source>Pharmacol. Rep.</source><volume>73</volume>, <fpage>1155</fpage>&#8211;<lpage>1163</lpage>. <pub-id pub-id-type="doi">10.1007/s43440-021-00248-w</pub-id><pub-id pub-id-type="pmid">33835465</pub-id></mixed-citation></ref><ref id="B204"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okun</surname><given-names>A.</given-names></name><name name-style="western"><surname>Defelice</surname><given-names>M.</given-names></name><name name-style="western"><surname>Eyde</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mercado</surname><given-names>R.</given-names></name><name name-style="western"><surname>King</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Transient inflammation-induced ongoing pain is driven by TRPV1 sensitive afferents</article-title>. <source>Mol. Pain</source><volume>7</volume>, <fpage>4</fpage>. <pub-id pub-id-type="doi">10.1186/1744-8069-7-4</pub-id><pub-id pub-id-type="pmid">21219650</pub-id><pub-id pub-id-type="pmcid">PMC3025866</pub-id></mixed-citation></ref><ref id="B205"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olson</surname><given-names>D. E.</given-names></name></person-group> (<year>2021</year>). <article-title>The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects</article-title>. <source>ACS Pharmacol. Transl. Sci.</source><volume>4</volume>, <fpage>563</fpage>&#8211;<lpage>567</lpage>. <pub-id pub-id-type="doi">10.1021/acsptsci.0c00192</pub-id><pub-id pub-id-type="pmid">33861218</pub-id><pub-id pub-id-type="pmcid">PMC8033607</pub-id></mixed-citation></ref><ref id="B206"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olson</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Keresztes</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tashiro</surname><given-names>J. K.</given-names></name><name name-style="western"><surname>Daconta</surname><given-names>L. V.</given-names></name><name name-style="western"><surname>Hruby</surname><given-names>V. J.</given-names></name><name name-style="western"><surname>Streicher</surname><given-names>J. M.</given-names></name></person-group> (<year>2018</year>). <article-title>Synthesis and evaluation of a novel bivalent selective antagonist for the mu-delta opioid receptor heterodimer that reduces morphine withdrawal in mice</article-title>. <source>J. Med. Chem.</source><volume>61</volume>, <fpage>6075</fpage>&#8211;<lpage>6086</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.8b00403</pub-id><pub-id pub-id-type="pmid">29939746</pub-id></mixed-citation></ref><ref id="B207"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ozdemir</surname><given-names>E.</given-names></name></person-group> (<year>2017</year>). <article-title>The pathophysiological role of serotonin receptor systems in opioid analgesia and tolerance</article-title>. <source>Int. J. Basic &amp; Clin. Pharmacol.</source><volume>6</volume>, <fpage>217</fpage>&#8211;<lpage>228</lpage>. <pub-id pub-id-type="doi">10.18203/2319-2003.ijbcp20170312</pub-id></mixed-citation></ref><ref id="B208"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palfreyman</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>C. J.</given-names></name><name name-style="western"><surname>Sorensen</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Dudley</surname><given-names>M. W.</given-names></name><name name-style="western"><surname>Kehne</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Moser</surname><given-names>P.</given-names></name><etal/></person-group> (<year>1993</year>). <article-title>Electrophysiological, biochemical and behavioral evidence for 5-HT<sub>2</sub> and 5-HT<sub>3</sub> mediated control of dopaminergic function</article-title>. <source>Psychopharmacol. Berl.</source><volume>112</volume>, <fpage>S60</fpage>&#8211;<lpage>S67</lpage>. <pub-id pub-id-type="doi">10.1007/BF02245008</pub-id><pub-id pub-id-type="pmid">7831442</pub-id></mixed-citation></ref><ref id="B209"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y. M.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Blockade of serotonin 5-HT2A receptors suppresses behavioral sensitization and naloxone-precipitated withdrawal symptoms in morphine-treated mice</article-title>. <source>Front. Pharmacol.</source><volume>7</volume>, <fpage>514</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2016.00514</pub-id><pub-id pub-id-type="pmid">28082900</pub-id><pub-id pub-id-type="pmcid">PMC5183621</pub-id></mixed-citation></ref><ref id="B210"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Panlilio</surname><given-names>L. V.</given-names></name><name name-style="western"><surname>Yasar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nemeth-Coslett</surname><given-names>R.</given-names></name><name name-style="western"><surname>Katz</surname><given-names>J. L.</given-names></name><name name-style="western"><surname>Henningfield</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Solinas</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Human cocaine-seeking behavior and its control by drug-associated stimuli in the laboratory</article-title>. <source>Neuropsychopharmacology</source><volume>30</volume>, <fpage>433</fpage>&#8211;<lpage>443</lpage>. <pub-id pub-id-type="doi">10.1038/sj.npp.1300599</pub-id><pub-id pub-id-type="pmid">15536497</pub-id></mixed-citation></ref><ref id="B211"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parke</surname><given-names>L. A.</given-names></name><name name-style="western"><surname>Burton</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mcdonald</surname><given-names>R. V.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>S.</given-names></name></person-group> (<year>2002</year>). <article-title>Ibogaine interferes with motivational and somatic effects of naloxone-precipitated withdrawal from acutely administered morphine</article-title>. <source>Prog. Neuropsychopharmacol. Biol. Psychiatry</source><volume>26</volume>, <fpage>293</fpage>&#8211;<lpage>297</lpage>. <pub-id pub-id-type="doi">10.1016/s0278-5846(01)00268-8</pub-id><pub-id pub-id-type="pmid">11817506</pub-id></mixed-citation></ref><ref id="B212"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peck</surname><given-names>K. R.</given-names></name><name name-style="western"><surname>Nighbor</surname><given-names>T. D.</given-names></name><name name-style="western"><surname>Price</surname><given-names>M.</given-names></name></person-group> (<year>2022</year>). <article-title>Examining associations between impulsivity, opioid use disorder, and posttraumatic stress disorder: The additive relation between disorders</article-title>. <source>Exp. Clin. Psychopharmacol.</source><volume>30</volume>, <fpage>486</fpage>&#8211;<lpage>493</lpage>. <pub-id pub-id-type="doi">10.1037/pha0000507</pub-id><pub-id pub-id-type="pmid">34291989</pub-id><pub-id pub-id-type="pmcid">PMC8782919</pub-id></mixed-citation></ref><ref id="B213"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pehek</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Nocjar</surname><given-names>C.</given-names></name><name name-style="western"><surname>Roth</surname><given-names>B. L.</given-names></name><name name-style="western"><surname>Byrd</surname><given-names>T. A.</given-names></name><name name-style="western"><surname>Mabrouk</surname><given-names>O. S.</given-names></name></person-group> (<year>2006</year>). <article-title>Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress- and drug-induced dopamine release in the rat medial prefrontal cortex</article-title>. <source>Neuropsychopharmacology</source><volume>31</volume>, <fpage>265</fpage>&#8211;<lpage>277</lpage>. <pub-id pub-id-type="doi">10.1038/sj.npp.1300819</pub-id><pub-id pub-id-type="pmid">15999145</pub-id></mixed-citation></ref><ref id="B214"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Picker</surname><given-names>M. J.</given-names></name></person-group> (<year>1997</year>). <article-title>Discriminative stimulus effects of the mixed-opioid agonist/antagonist dezocine: cross-substitution by mu and delta opioid agonists</article-title>. <source>J. Pharmacol. Exp. Ther.</source><volume>283</volume>, <fpage>1009</fpage>&#8211;<lpage>1017</lpage>.<pub-id pub-id-type="pmid">9399970</pub-id></mixed-citation></ref><ref id="B215"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pineyro</surname><given-names>G.</given-names></name><name name-style="western"><surname>Nagi</surname><given-names>K.</given-names></name></person-group> (<year>2021</year>). <article-title>Signaling diversity of mu- and delta-opioid receptor ligands: Re-evaluating the benefits of beta-arrestin/G protein signaling bias</article-title>. <source>Cell Signal</source><volume>80</volume>, <fpage>109906</fpage>. <pub-id pub-id-type="doi">10.1016/j.cellsig.2020.109906</pub-id><pub-id pub-id-type="pmid">33383156</pub-id></mixed-citation></ref><ref id="B216"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pitchers</surname><given-names>K. K.</given-names></name><name name-style="western"><surname>Coppens</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Beloate</surname><given-names>L. N.</given-names></name><name name-style="western"><surname>Fuller</surname><given-names>J.</given-names></name><name name-style="western"><surname>Van</surname><given-names>S.</given-names></name><name name-style="western"><surname>Frohmader</surname><given-names>K. S.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Endogenous opioid-induced neuroplasticity of dopaminergic neurons in the ventral tegmental area influences natural and opiate reward</article-title>. <source>J. Neurosci.</source><volume>34</volume>, <fpage>8825</fpage>&#8211;<lpage>8836</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0133-14.2014</pub-id><pub-id pub-id-type="pmid">24966382</pub-id><pub-id pub-id-type="pmcid">PMC6608201</pub-id></mixed-citation></ref><ref id="B217"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pockros</surname><given-names>L. A.</given-names></name><name name-style="western"><surname>Pentkowski</surname><given-names>N. S.</given-names></name><name name-style="western"><surname>Conway</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Ullman</surname><given-names>T. E.</given-names></name><name name-style="western"><surname>Zwick</surname><given-names>K. R.</given-names></name><name name-style="western"><surname>Neisewander</surname><given-names>J. L.</given-names></name></person-group> (<year>2012</year>). <article-title>5-HT(2A) receptor blockade and 5-HT(2C) receptor activation interact to reduce cocaine hyperlocomotion and Fos protein expression in the caudate-putamen</article-title>. <source>Synapse</source><volume>66</volume>, <fpage>989</fpage>&#8211;<lpage>1001</lpage>. <pub-id pub-id-type="doi">10.1002/syn.21592</pub-id><pub-id pub-id-type="pmid">22886755</pub-id><pub-id pub-id-type="pmcid">PMC3476845</pub-id></mixed-citation></ref><ref id="B218"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pokorny</surname><given-names>T.</given-names></name><name name-style="western"><surname>Duerler</surname><given-names>P.</given-names></name><name name-style="western"><surname>Seifritz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vollenweider</surname><given-names>F. X.</given-names></name><name name-style="western"><surname>Preller</surname><given-names>K. H.</given-names></name></person-group> (<year>2020</year>). <article-title>LSD acutely impairs working memory, executive functions, and cognitive flexibility, but not risk-based decision-making</article-title>. <source>Psychol. Med.</source><volume>50</volume>, <fpage>2255</fpage>&#8211;<lpage>2264</lpage>. <pub-id pub-id-type="doi">10.1017/S0033291719002393</pub-id><pub-id pub-id-type="pmid">31500679</pub-id></mixed-citation></ref><ref id="B219"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pompeiano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Palacios</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Mengod</surname><given-names>G.</given-names></name></person-group> (<year>1994</year>). <article-title>Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors</article-title>. <source>Brain Res. Mol. Brain Res.</source><volume>23</volume>, <fpage>163</fpage>&#8211;<lpage>178</lpage>. <pub-id pub-id-type="doi">10.1016/0169-328x(94)90223-2</pub-id><pub-id pub-id-type="pmid">8028479</pub-id></mixed-citation></ref><ref id="B220"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Porter</surname><given-names>R. H.</given-names></name><name name-style="western"><surname>Benwell</surname><given-names>K. R.</given-names></name><name name-style="western"><surname>Lamb</surname><given-names>H.</given-names></name><name name-style="western"><surname>Malcolm</surname><given-names>C. S.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>N. H.</given-names></name><name name-style="western"><surname>Revell</surname><given-names>D. F.</given-names></name><etal/></person-group> (<year>1999</year>). <article-title>Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells</article-title>. <source>Br. J. Pharmacol.</source><volume>128</volume>, <fpage>13</fpage>&#8211;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bjp.0702751</pub-id><pub-id pub-id-type="pmid">10498829</pub-id><pub-id pub-id-type="pmcid">PMC1571597</pub-id></mixed-citation></ref><ref id="B221"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Preller</surname><given-names>K. H.</given-names></name><name name-style="western"><surname>Herdener</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pokorny</surname><given-names>T.</given-names></name><name name-style="western"><surname>Planzer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kraehenmann</surname><given-names>R.</given-names></name><name name-style="western"><surname>Stampfli</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation</article-title>. <source>Curr. Biol.</source><volume>27</volume>, <fpage>451</fpage>&#8211;<lpage>457</lpage>. <pub-id pub-id-type="doi">10.1016/j.cub.2016.12.030</pub-id><pub-id pub-id-type="pmid">28132813</pub-id></mixed-citation></ref><ref id="B222"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Preller</surname><given-names>K. H.</given-names></name><name name-style="western"><surname>Razi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zeidman</surname><given-names>P.</given-names></name><name name-style="western"><surname>Stampfli</surname><given-names>P.</given-names></name><name name-style="western"><surname>Friston</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Vollenweider</surname><given-names>F. X.</given-names></name></person-group> (<year>2019</year>). <article-title>Effective connectivity changes in LSD-induced altered states of consciousness in humans</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>116</volume>, <fpage>2743</fpage>&#8211;<lpage>2748</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1815129116</pub-id><pub-id pub-id-type="pmid">30692255</pub-id><pub-id pub-id-type="pmcid">PMC6377471</pub-id></mixed-citation></ref><ref id="B223"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Preuss</surname><given-names>C. V.</given-names></name><name name-style="western"><surname>Kalava</surname><given-names>A.</given-names></name><name name-style="western"><surname>King</surname><given-names>K. C.</given-names></name></person-group> (<year>2023</year>). &#8220;<article-title>Prescription of controlled substances: Benefits and risks</article-title>,&#8221; in <source>StatPearls</source> (<publisher-loc>Treasure Island (FL)</publisher-loc>: <publisher-name>StatPearls Publishing LLC.</publisher-name>). <comment>StatPearls Publishing Copyright &#169; 2023</comment>.<pub-id pub-id-type="pmid">30726003</pub-id></mixed-citation></ref><ref id="B224"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Price</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>Sholler</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Stutz</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Anastasio</surname><given-names>N. C.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>K. A.</given-names></name></person-group> (<year>2019</year>). <article-title>Endogenous serotonin 5-HT(2A) and 5-HT(2C) receptors associate in the medial prefrontal cortex</article-title>. <source>ACS Chem. Neurosci.</source><volume>10</volume>, <fpage>3241</fpage>&#8211;<lpage>3248</lpage>. <pub-id pub-id-type="doi">10.1021/acschemneuro.8b00669</pub-id><pub-id pub-id-type="pmid">30645940</pub-id><pub-id pub-id-type="pmcid">PMC6640104</pub-id></mixed-citation></ref><ref id="B225"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prospero-Garcia</surname><given-names>O.</given-names></name><name name-style="western"><surname>Amancio-Belmont</surname><given-names>O.</given-names></name><name name-style="western"><surname>Becerril Melendez</surname><given-names>A. L.</given-names></name><name name-style="western"><surname>Ruiz-Contreras</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>Mendez-Diaz</surname><given-names>M.</given-names></name></person-group> (<year>2016</year>). <article-title>Endocannabinoids and sleep</article-title>. <source>Neurosci. Biobehav Rev.</source><volume>71</volume>, <fpage>671</fpage>&#8211;<lpage>679</lpage>. <pub-id pub-id-type="doi">10.1016/j.neubiorev.2016.10.005</pub-id><pub-id pub-id-type="pmid">27756691</pub-id></mixed-citation></ref><ref id="B226"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Puretic</surname><given-names>M. B.</given-names></name><name name-style="western"><surname>Demarin</surname><given-names>V.</given-names></name></person-group> (<year>2012</year>). <article-title>Neuroplasticity mechanisms in the pathophysiology of chronic pain</article-title>. <source>Acta Clin. Croat.</source><volume>51</volume>, <fpage>425</fpage>&#8211;<lpage>429</lpage>.<pub-id pub-id-type="pmid">23330408</pub-id></mixed-citation></ref><ref id="B227"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quednow</surname><given-names>B. B.</given-names></name><name name-style="western"><surname>Kometer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Geyer</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Vollenweider</surname><given-names>F. X.</given-names></name></person-group> (<year>2012</year>). <article-title>Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers</article-title>. <source>Neuropsychopharmacology</source><volume>37</volume>, <fpage>630</fpage>&#8211;<lpage>640</lpage>. <pub-id pub-id-type="doi">10.1038/npp.2011.228</pub-id><pub-id pub-id-type="pmid">21956447</pub-id><pub-id pub-id-type="pmcid">PMC3260978</pub-id></mixed-citation></ref><ref id="B228"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quirion</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bergeron</surname><given-names>F.</given-names></name><name name-style="western"><surname>Blais</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gendron</surname><given-names>L.</given-names></name></person-group> (<year>2020</year>). <article-title>The delta-opioid receptor; a target for the treatment of pain</article-title>. <source>Front. Mol. Neurosci.</source><volume>13</volume>, <fpage>52</fpage>. <pub-id pub-id-type="doi">10.3389/fnmol.2020.00052</pub-id><pub-id pub-id-type="pmid">32431594</pub-id><pub-id pub-id-type="pmcid">PMC7214757</pub-id></mixed-citation></ref><ref id="B229"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenberg</surname><given-names>D. E.</given-names></name><name name-style="western"><surname>Wolbach</surname><given-names>A. B.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Miner</surname><given-names>E. J.</given-names></name><name name-style="western"><surname>Isbell</surname><given-names>H.</given-names></name></person-group> (<year>1963</year>). <article-title>Observations on direct and cross tolerance with LSD and d-amphetamine in man</article-title>. <source>Psychopharmacologia</source><volume>5</volume>, <fpage>1</fpage>&#8211;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1007/BF00405570</pub-id><pub-id pub-id-type="pmid">14085622</pub-id></mixed-citation></ref><ref id="B230"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramaekers</surname><given-names>J. G.</given-names></name><name name-style="western"><surname>Hutten</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mason</surname><given-names>N. L.</given-names></name><name name-style="western"><surname>Dolder</surname><given-names>P.</given-names></name><name name-style="western"><surname>Theunissen</surname><given-names>E. L.</given-names></name><name name-style="western"><surname>Holze</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers</article-title>. <source>J. Psychopharmacol.</source><volume>35</volume>, <fpage>398</fpage>&#8211;<lpage>405</lpage>. <pub-id pub-id-type="doi">10.1177/0269881120940937</pub-id><pub-id pub-id-type="pmid">32842825</pub-id><pub-id pub-id-type="pmcid">PMC8054163</pub-id></mixed-citation></ref><ref id="B231"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rasmussen</surname><given-names>K.</given-names></name><name name-style="western"><surname>White</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Acri</surname><given-names>J. B.</given-names></name></person-group> (<year>2019</year>). <article-title>NIDA's medication development priorities in response to the Opioid Crisis: ten most wanted</article-title>. <source>Neuropsychopharmacology</source><volume>44</volume>, <fpage>657</fpage>&#8211;<lpage>659</lpage>. <pub-id pub-id-type="doi">10.1038/s41386-018-0292-5</pub-id><pub-id pub-id-type="pmid">30538289</pub-id><pub-id pub-id-type="pmcid">PMC6372702</pub-id></mixed-citation></ref><ref id="B232"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rickli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Luethi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Reinisch</surname><given-names>J.</given-names></name><name name-style="western"><surname>Buchy</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hoener</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Liechti</surname><given-names>M. E.</given-names></name></person-group> (<year>2015</year>). <article-title>Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs)</article-title>. <source>Neuropharmacology</source><volume>99</volume>, <fpage>546</fpage>&#8211;<lpage>553</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.08.034</pub-id><pub-id pub-id-type="pmid">26318099</pub-id></mixed-citation></ref><ref id="B233"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rickli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Moning</surname><given-names>O. D.</given-names></name><name name-style="western"><surname>Hoener</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Liechti</surname><given-names>M. E.</given-names></name></person-group> (<year>2016</year>). <article-title>Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens</article-title>. <source>Eur. Neuropsychopharmacol.</source><volume>26</volume>, <fpage>1327</fpage>&#8211;<lpage>1337</lpage>. <pub-id pub-id-type="doi">10.1016/j.euroneuro.2016.05.001</pub-id><pub-id pub-id-type="pmid">27216487</pub-id></mixed-citation></ref><ref id="B234"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rolland</surname><given-names>B.</given-names></name><name name-style="western"><surname>Jardri</surname><given-names>R.</given-names></name><name name-style="western"><surname>Amad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cottencin</surname><given-names>O.</given-names></name><name name-style="western"><surname>Bordet</surname><given-names>R.</given-names></name></person-group> (<year>2014</year>). <article-title>Pharmacology of hallucinations: several mechanisms for one single symptom?</article-title><source>Biomed. Res. Int.</source><volume>2014</volume>, <fpage>307106</fpage>. <pub-id pub-id-type="doi">10.1155/2014/307106</pub-id><pub-id pub-id-type="pmid">24991548</pub-id><pub-id pub-id-type="pmcid">PMC4065763</pub-id></mixed-citation></ref><ref id="B235"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rothman</surname><given-names>R. B.</given-names></name><name name-style="western"><surname>Baumann</surname><given-names>M. H.</given-names></name></person-group> (<year>2009</year>). <article-title>Serotonergic drugs and valvular heart disease</article-title>. <source>Expert Opin. Drug Saf.</source><volume>8</volume>, <fpage>317</fpage>&#8211;<lpage>329</lpage>. <pub-id pub-id-type="doi">10.1517/14740330902931524</pub-id><pub-id pub-id-type="pmid">19505264</pub-id><pub-id pub-id-type="pmcid">PMC2695569</pub-id></mixed-citation></ref><ref id="B236"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sadzot</surname><given-names>B.</given-names></name><name name-style="western"><surname>Baraban</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Glennon</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Lyon</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Leonhardt</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jan</surname><given-names>C. R.</given-names></name><etal/></person-group> (<year>1989</year>). <article-title>Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis</article-title>. <source>Psychopharmacol. Berl.</source><volume>98</volume>, <fpage>495</fpage>&#8211;<lpage>499</lpage>. <pub-id pub-id-type="doi">10.1007/BF00441948</pub-id><pub-id pub-id-type="pmid">2505289</pub-id></mixed-citation></ref><ref id="B237"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sakloth</surname><given-names>F.</given-names></name><name name-style="western"><surname>Leggett</surname><given-names>E.</given-names></name><name name-style="western"><surname>Moerke</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Townsend</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Banks</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Negus</surname><given-names>S. S.</given-names></name></person-group> (<year>2019</year>). <article-title>Effects of acute and repeated treatment with serotonin 5-HT2A receptor agonist hallucinogens on intracranial self-stimulation in rats</article-title>. <source>Exp. Clin. Psychopharmacol.</source><volume>27</volume>, <fpage>215</fpage>&#8211;<lpage>226</lpage>. <pub-id pub-id-type="doi">10.1037/pha0000253</pub-id><pub-id pub-id-type="pmid">30628811</pub-id><pub-id pub-id-type="pmcid">PMC6690189</pub-id></mixed-citation></ref><ref id="B238"><mixed-citation publication-type="book"><collab>Samhsa</collab> (<year>2021</year>). <article-title>Substance Abuse and Mental Health Services Administration</article-title>. <source>Key substance use and mental health indicators in the United States: results from the 2020 national survey on drug use and health</source>. <publisher-name>HHS Publication No</publisher-name>. <comment><italic toggle="yes">PEP21-07-01-003, NSDUH Series H-56</italic></comment>.</mixed-citation></ref><ref id="B239"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santana</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bortolozzi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Serrats</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mengod</surname><given-names>G.</given-names></name><name name-style="western"><surname>Artigas</surname><given-names>F.</given-names></name></person-group> (<year>2004</year>). <article-title>Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex</article-title>. <source>Cereb. Cortex</source><volume>14</volume>, <fpage>1100</fpage>&#8211;<lpage>1109</lpage>. <pub-id pub-id-type="doi">10.1093/cercor/bhh070</pub-id><pub-id pub-id-type="pmid">15115744</pub-id></mixed-citation></ref><ref id="B240"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sasaki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kamiya</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bamba</surname><given-names>K.</given-names></name><name name-style="western"><surname>Onishi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Matsuda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kohno</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Serotonin plays a key role in the development of opioid-induced hyperalgesia in mice</article-title>. <source>J. Pain</source><volume>22</volume>, <fpage>715</fpage>&#8211;<lpage>729</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpain.2020.12.008</pub-id><pub-id pub-id-type="pmid">33465503</pub-id></mixed-citation></ref><ref id="B241"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Savage</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mccabe</surname><given-names>O. L.</given-names></name></person-group> (<year>1973</year>). <article-title>Residential psychedelic (LSD) therapy for the narcotic addict. A controlled study</article-title>. <source>Arch. Gen. Psychiatry</source><volume>28</volume>, <fpage>808</fpage>&#8211;<lpage>814</lpage>. <pub-id pub-id-type="doi">10.1001/archpsyc.1973.01750360040005</pub-id><pub-id pub-id-type="pmid">4575166</pub-id></mixed-citation></ref><ref id="B242"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schlemmer</surname><given-names>R. F.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Nawara</surname><given-names>C.</given-names></name><name name-style="western"><surname>Heinze</surname><given-names>W. J.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Advokat</surname><given-names>C.</given-names></name></person-group> (<year>1986</year>). <article-title>Influence of environmental context on tolerance to LSD-induced behavior in primates</article-title>. <source>Biol. Psychiatry</source><volume>21</volume>, <fpage>314</fpage>&#8211;<lpage>317</lpage>. <pub-id pub-id-type="doi">10.1016/0006-3223(86)90053-3</pub-id><pub-id pub-id-type="pmid">3947713</pub-id></mixed-citation></ref><ref id="B243"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmidt</surname><given-names>C. J.</given-names></name><name name-style="western"><surname>Sorensen</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Kehne</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Carr</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Palfreyman</surname><given-names>M. G.</given-names></name></person-group> (<year>1995</year>). <article-title>The role of 5-HT2A receptors in antipsychotic activity</article-title>. <source>Life Sci.</source><volume>56</volume>, <fpage>2209</fpage>&#8211;<lpage>2222</lpage>. <pub-id pub-id-type="doi">10.1016/0024-3205(95)00210-w</pub-id><pub-id pub-id-type="pmid">7791509</pub-id></mixed-citation></ref><ref id="B244"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwienteck</surname><given-names>K. L.</given-names></name><name name-style="western"><surname>Faunce</surname><given-names>K. E.</given-names></name><name name-style="western"><surname>Rice</surname><given-names>K. C.</given-names></name><name name-style="western"><surname>Obeng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Blough</surname><given-names>B. E.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats</article-title>. <source>Neuropharmacology</source><volume>150</volume>, <fpage>200</fpage>&#8211;<lpage>209</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2019.01.020</pub-id><pub-id pub-id-type="pmid">30660628</pub-id><pub-id pub-id-type="pmcid">PMC6476319</pub-id></mixed-citation></ref><ref id="B245"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shalit</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rehm</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lev-Ran</surname><given-names>S.</given-names></name></person-group> (<year>2019</year>). <article-title>Epidemiology of hallucinogen use in the U.S. results from the national epidemiologic survey on alcohol and related conditions III</article-title>. <source>Addict. Behav.</source><volume>89</volume>, <fpage>35</fpage>&#8211;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1016/j.addbeh.2018.09.020</pub-id><pub-id pub-id-type="pmid">30245407</pub-id></mixed-citation></ref><ref id="B246"><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Shulgin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shulgin</surname><given-names>A.</given-names></name></person-group> (<year>1991</year>). <source>PiHKAL: a chemical love story</source>. <publisher-loc>Berkeley, CA</publisher-loc>: <publisher-name>Transform Press</publisher-name>.</mixed-citation></ref><ref id="B247"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sierra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Muchhala</surname><given-names>K. H.</given-names></name><name name-style="western"><surname>Jessup</surname><given-names>D. K.</given-names></name><name name-style="western"><surname>Contreras</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>U. H.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>D. L.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Sex-specific role for serotonin 5-HT(2A) receptor in modulation of opioid-induced antinociception and reward in mice</article-title>. <source>Neuropharmacology</source><volume>209</volume>, <fpage>108988</fpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2022.108988</pub-id><pub-id pub-id-type="pmid">35183539</pub-id><pub-id pub-id-type="pmcid">PMC8934299</pub-id></mixed-citation></ref><ref id="B248"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silverstein</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>A.</given-names></name></person-group> (<year>2021</year>). <article-title>The phenomenology and neurobiology of visual distortions and hallucinations in schizophrenia: An update</article-title>. <source>Front. Psychiatry</source><volume>12</volume>, <fpage>684720</fpage>. <pub-id pub-id-type="doi">10.3389/fpsyt.2021.684720</pub-id><pub-id pub-id-type="pmid">34177665</pub-id><pub-id pub-id-type="pmcid">PMC8226016</pub-id></mixed-citation></ref><ref id="B249"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sona</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ojha</surname><given-names>V.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mishra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Identification of dual role of piperazine-linked phenyl cyclopropyl methanone as positive allosteric modulator of 5-HT(2C) and negative allosteric modulator of 5-HT(2B) receptors</article-title>. <source>Eur. J. Med. Chem.</source><volume>164</volume>, <fpage>499</fpage>&#8211;<lpage>516</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejmech.2018.12.070</pub-id><pub-id pub-id-type="pmid">30622024</pub-id></mixed-citation></ref><ref id="B250"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>V. P.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>N. K.</given-names></name><name name-style="western"><surname>Kulkarni</surname><given-names>S. K.</given-names></name></person-group> (<year>2003</year>). <article-title>Fluoxetine suppresses morphine tolerance and dependence: modulation of NO-cGMP/DA/serotoninergic pathways</article-title>. <source>Methods Find. Exp. Clin. Pharmacol.</source><volume>25</volume>, <fpage>273</fpage>&#8211;<lpage>280</lpage>. <pub-id pub-id-type="doi">10.1358/mf.2003.25.4.769675</pub-id><pub-id pub-id-type="pmid">12808472</pub-id></mixed-citation></ref><ref id="B251"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Slocum</surname><given-names>S. T.</given-names></name><name name-style="western"><surname>Diberto</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Roth</surname><given-names>B. L.</given-names></name></person-group> (<year>2022</year>). <article-title>Molecular insights into psychedelic drug action</article-title>. <source>J. Neurochem.</source><volume>162</volume>, <fpage>24</fpage>&#8211;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1111/jnc.15540</pub-id><pub-id pub-id-type="pmid">34797943</pub-id></mixed-citation></ref><ref id="B252"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>R. L.</given-names></name><name name-style="western"><surname>Barrett</surname><given-names>R. J.</given-names></name><name name-style="western"><surname>Sanders-Bush</surname><given-names>E.</given-names></name></person-group> (<year>2003</year>). <article-title>Discriminative stimulus properties of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane [(+/-)DOI] in C57BL/6J mice</article-title>. <source>Psychopharmacol. Berl.</source><volume>166</volume>, <fpage>61</fpage>&#8211;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-002-1252-6</pub-id><pub-id pub-id-type="pmid">12474110</pub-id></mixed-citation></ref><ref id="B253"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Snyder</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Loeza-Alcocer</surname><given-names>E.</given-names></name><name name-style="western"><surname>Omori</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hachisuka</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sheahan</surname><given-names>T. D.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Kappa Opioid Receptor Distribution and Function in Primary Afferents</article-title>. <source>Neuron</source><volume>99</volume>, <fpage>1274</fpage>&#8211;<lpage>1288</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2018.08.044</pub-id><pub-id pub-id-type="pmid">30236284</pub-id><pub-id pub-id-type="pmcid">PMC6300132</pub-id></mixed-citation></ref><ref id="B254"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soria-Gomez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Marquez-Diosdado</surname><given-names>M. I.</given-names></name><name name-style="western"><surname>Montes-Rodriguez</surname><given-names>C. J.</given-names></name><name name-style="western"><surname>Estrada-Gonzalez</surname><given-names>V.</given-names></name><name name-style="western"><surname>Prospero-Garcia</surname><given-names>O.</given-names></name></person-group> (<year>2010</year>). <article-title>Oleamide administered into the nucleus accumbens shell regulates feeding behaviour via CB1 and 5-HT2C receptors</article-title>. <source>Int. J. Neuropsychopharmacol.</source><volume>13</volume>, <fpage>1247</fpage>&#8211;<lpage>1254</lpage>. <pub-id pub-id-type="doi">10.1017/S1461145710000702</pub-id><pub-id pub-id-type="pmid">20663269</pub-id></mixed-citation></ref><ref id="B255"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soto</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Huang-Chi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>R. G.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hooson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Anastasio</surname><given-names>N. C.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>
<italic toggle="yes">In vivo</italic> and <italic toggle="yes">in vitro</italic> analyses of novel peptidomimetic disruptors for the serotonin 5-HT<sub>2C</sub> receptor interaction with phosphatase and tensin homolog (PTEN)</article-title>. <source>Front. Pharmacol.</source><volume>10</volume>, <fpage>907</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2019.00907</pub-id><pub-id pub-id-type="pmid">31507411</pub-id><pub-id pub-id-type="pmcid">PMC6716272</pub-id></mixed-citation></ref><ref id="B256"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spanagel</surname><given-names>R.</given-names></name></person-group> (<year>2017</year>). <article-title>Animal models of addiction</article-title>. <source>Dialogues Clin. Neurosci.</source><volume>19</volume>, <fpage>247</fpage>&#8211;<lpage>258</lpage>. <pub-id pub-id-type="doi">10.31887/DCNS.2017.19.3/rspanagel</pub-id><pub-id pub-id-type="pmid">29302222</pub-id><pub-id pub-id-type="pmcid">PMC5741108</pub-id></mixed-citation></ref><ref id="B257"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stoeber</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jullie</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lobingier</surname><given-names>B. T.</given-names></name><name name-style="western"><surname>Laeremans</surname><given-names>T.</given-names></name><name name-style="western"><surname>Steyaert</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schiller</surname><given-names>P. W.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>A genetically encoded biosensor reveals location bias of opioid drug action</article-title>. <source>Neuron</source><volume>98</volume>, <fpage>963</fpage>&#8211;<lpage>976</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2018.04.021</pub-id><pub-id pub-id-type="pmid">29754753</pub-id><pub-id pub-id-type="pmcid">PMC6481295</pub-id></mixed-citation></ref><ref id="B258"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stoops</surname><given-names>W. W.</given-names></name></person-group> (<year>2022</year>). <article-title>A brief introduction to human behavioral pharmacology: Methods, design considerations and ethics</article-title>. <source>Perspect. Behav. Sci.</source><volume>45</volume>, <fpage>361</fpage>&#8211;<lpage>381</lpage>. <pub-id pub-id-type="doi">10.1007/s40614-022-00330-5</pub-id><pub-id pub-id-type="pmid">35719875</pub-id><pub-id pub-id-type="pmcid">PMC9163231</pub-id></mixed-citation></ref><ref id="B259"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Volkow</surname><given-names>N. D.</given-names></name><name name-style="western"><surname>Degenhardt</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hickman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>K.</given-names></name><name name-style="western"><surname>Koob</surname><given-names>G. F.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Opioid use disorder</article-title>. <source>Nat. Rev. Dis. Prim.</source><volume>6</volume>, <fpage>3</fpage>. <pub-id pub-id-type="doi">10.1038/s41572-019-0137-5</pub-id><pub-id pub-id-type="pmid">31919349</pub-id></mixed-citation></ref><ref id="B260"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sughondhabirom</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gueorguieva</surname><given-names>R.</given-names></name><name name-style="western"><surname>Coric</surname><given-names>V.</given-names></name><name name-style="western"><surname>Berman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lynch</surname><given-names>W. J.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>A paradigm to investigate the self-regulation of cocaine administration in humans</article-title>. <source>Psychopharmacol. Berl.</source><volume>180</volume>, <fpage>436</fpage>&#8211;<lpage>446</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-005-2192-8</pub-id><pub-id pub-id-type="pmid">15726333</pub-id></mixed-citation></ref><ref id="B261"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sullivan</surname><given-names>M. D.</given-names></name><name name-style="western"><surname>Ballantyne</surname><given-names>J. C.</given-names></name></person-group> (<year>2022</year>). <article-title>Understanding the risks of long-term opioid therapy for chronic pain</article-title>. <source>Am. J. Psychiatry</source><volume>179</volume>, <fpage>696</fpage>&#8211;<lpage>698</lpage>. <pub-id pub-id-type="doi">10.1176/appi.ajp.20220592</pub-id><pub-id pub-id-type="pmid">36181333</pub-id></mixed-citation></ref><ref id="B262"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tagen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mantuani</surname><given-names>D.</given-names></name><name name-style="western"><surname>Van Heerden</surname><given-names>L.</given-names></name><name name-style="western"><surname>Holstein</surname><given-names>A.</given-names></name><name name-style="western"><surname>Klumpers</surname><given-names>L. E.</given-names></name><name name-style="western"><surname>Knowles</surname><given-names>R.</given-names></name></person-group> (<year>2023</year>). <article-title>The risk of chronic psychedelic and MDMA microdosing for valvular heart disease</article-title>. <source>J. Psychopharmacol.</source><volume>0</volume>, <fpage>2698811231190865</fpage>. <pub-id pub-id-type="doi">10.1177/02698811231190865</pub-id><pub-id pub-id-type="pmid">37572027</pub-id></mixed-citation></ref><ref id="B263"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kaneko</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mizuno</surname><given-names>N.</given-names></name></person-group> (<year>2000</year>). <article-title>A group of cortical interneurons expressing mu-opioid receptor-like immunoreactivity: a double immunofluorescence study in the rat cerebral cortex</article-title>. <source>Neuroscience</source><volume>98</volume>, <fpage>221</fpage>&#8211;<lpage>231</lpage>. <pub-id pub-id-type="doi">10.1016/s0306-4522(00)00124-x</pub-id><pub-id pub-id-type="pmid">10854753</pub-id></mixed-citation></ref><ref id="B264"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Auerbach</surname><given-names>S. B.</given-names></name></person-group> (<year>2002a</year>). <article-title>GABAergic and glutamatergic afferents in the dorsal raphe nucleus mediate morphine-induced increases in serotonin efflux in the rat central nervous system</article-title>. <source>J. Pharmacol. Exp. Ther.</source><volume>303</volume>, <fpage>704</fpage>&#8211;<lpage>710</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.102.038133</pub-id><pub-id pub-id-type="pmid">12388654</pub-id></mixed-citation></ref><ref id="B265"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Auerbach</surname><given-names>S. B.</given-names></name></person-group> (<year>1995</year>). <article-title>Involvement of the dorsal raphe but not median raphe nucleus in morphine-induced increases in serotonin release in the rat forebrain</article-title>. <source>Neuroscience</source><volume>68</volume>, <fpage>553</fpage>&#8211;<lpage>561</lpage>. <pub-id pub-id-type="doi">10.1016/0306-4522(95)00154-b</pub-id><pub-id pub-id-type="pmid">7477965</pub-id></mixed-citation></ref><ref id="B266"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Auerbach</surname><given-names>S. B.</given-names></name></person-group> (<year>2002b</year>). <article-title>Opioid receptor subtypes differentially modulate serotonin efflux in the rat central nervous system</article-title>. <source>J. Pharmacol. Exp. Ther.</source><volume>303</volume>, <fpage>549</fpage>&#8211;<lpage>556</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.102.037861</pub-id><pub-id pub-id-type="pmid">12388635</pub-id></mixed-citation></ref><ref id="B267"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Karnik</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Auerbach</surname><given-names>S. B.</given-names></name></person-group> (<year>2003</year>). <article-title>Effect of fentanyl on 5-HT efflux involves both opioid and 5-HT1A receptors</article-title>. <source>Br. J. Pharmacol.</source><volume>139</volume>, <fpage>1498</fpage>&#8211;<lpage>1504</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bjp.0705378</pub-id><pub-id pub-id-type="pmid">12922937</pub-id><pub-id pub-id-type="pmcid">PMC1573976</pub-id></mixed-citation></ref><ref id="B268"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Auerbach</surname><given-names>S. B.</given-names></name></person-group> (<year>1998</year>). <article-title>Alteration in regulation of serotonin release in rat dorsal raphe nucleus after prolonged exposure to morphine</article-title>. <source>J. Pharmacol. Exp. Ther.</source><volume>286</volume>, <fpage>481</fpage>&#8211;<lpage>488</lpage>.<pub-id pub-id-type="pmid">9655893</pub-id></mixed-citation></ref><ref id="B269"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tempel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zukin</surname><given-names>R. S.</given-names></name></person-group> (<year>1987</year>). <article-title>Neuroanatomical patterns of the mu, delta, and kappa opioid receptors of rat brain as determined by quantitative <italic toggle="yes">in vitro</italic> autoradiography</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>84</volume>, <fpage>4308</fpage>&#8211;<lpage>4312</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.84.12.4308</pub-id><pub-id pub-id-type="pmid">3035579</pub-id><pub-id pub-id-type="pmcid">PMC305074</pub-id></mixed-citation></ref><ref id="B270"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Carson</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Neal</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Sutcliffe</surname><given-names>J. G.</given-names></name></person-group> (<year>1997</year>). <article-title>Unique allosteric regulation of 5-hydroxytryptamine receptor-mediated signal transduction by oleamide</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>94</volume>, <fpage>14115</fpage>&#8211;<lpage>14119</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.94.25.14115</pub-id><pub-id pub-id-type="pmid">9391162</pub-id><pub-id pub-id-type="pmcid">PMC28442</pub-id></mixed-citation></ref><ref id="B271"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thurner</surname><given-names>P.</given-names></name><name name-style="western"><surname>Stary-Weinzinger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gafar</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gawali</surname><given-names>V. S.</given-names></name><name name-style="western"><surname>Kudlacek</surname><given-names>O.</given-names></name><name name-style="western"><surname>Zezula</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Mechanism of hERG channel block by the psychoactive indole alkaloid ibogaine</article-title>. <source>J. Pharmacol. Exp. Ther.</source><volume>348</volume>, <fpage>346</fpage>&#8211;<lpage>358</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.113.209643</pub-id><pub-id pub-id-type="pmid">24307198</pub-id></mixed-citation></ref><ref id="B272"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tolomeo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Davey</surname><given-names>F.</given-names></name><name name-style="western"><surname>Steele</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Baldacchino</surname><given-names>A.</given-names></name></person-group> (<year>2021</year>). <article-title>Compulsivity and impulsivity in opioid dependence</article-title>. <source>Drug Alcohol Depend.</source><volume>229</volume>, <fpage>109018</fpage>. <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2021.109018</pub-id><pub-id pub-id-type="pmid">34715479</pub-id></mixed-citation></ref><ref id="B273"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trigo</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Martin-Garcia</surname><given-names>E.</given-names></name><name name-style="western"><surname>Berrendero</surname><given-names>F.</given-names></name><name name-style="western"><surname>Robledo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Maldonado</surname><given-names>R.</given-names></name></person-group> (<year>2010</year>). <article-title>The endogenous opioid system: a common substrate in drug addiction</article-title>. <source>Drug Alcohol Depend.</source><volume>108</volume>, <fpage>183</fpage>&#8211;<lpage>194</lpage>. <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2009.10.011</pub-id><pub-id pub-id-type="pmid">19945803</pub-id></mixed-citation></ref><ref id="B274"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Troxler</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hofmann</surname><given-names>A.</given-names></name></person-group> (<year>1957</year>). <article-title>Substitutionen am ringsystem der lysergs&#228;ure. III. Halogenierung. 45. Mitteilung &#252;ber Mutterkornalkaloide</article-title>. <source>Helvetica Chim. Acta</source><volume>40</volume>, <fpage>2160</fpage>&#8211;<lpage>2170</lpage>. <pub-id pub-id-type="doi">10.1002/hlca.19570400716</pub-id></mixed-citation></ref><ref id="B275"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trulson</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>B. L.</given-names></name></person-group> (<year>1977</year>). <article-title>Usefulness of an animal behavioral model in studying the duration of action of LSD and the onset and duration of tolerance to LSD in the cat</article-title>. <source>Brain Res.</source><volume>132</volume>, <fpage>315</fpage>&#8211;<lpage>326</lpage>. <pub-id pub-id-type="doi">10.1016/0006-8993(77)90424-3</pub-id><pub-id pub-id-type="pmid">890483</pub-id></mixed-citation></ref><ref id="B276"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turner</surname><given-names>W. J.</given-names></name><name name-style="western"><surname>Almudevar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Merlis</surname><given-names>S.</given-names></name></person-group> (<year>1959</year>). <article-title>Chemotherapeutic trials in psychosis. III. Addendum-2-brom-d-lysergic acid diethylamide (BOL)</article-title>. <source>Am. J. Psychiatry</source><volume>116</volume>, <fpage>261</fpage>&#8211;<lpage>262</lpage>. <pub-id pub-id-type="doi">10.1176/ajp.116.3.261</pub-id><pub-id pub-id-type="pmid">13839967</pub-id></mixed-citation></ref><ref id="B277"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ubaldi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cannella</surname><given-names>N.</given-names></name><name name-style="western"><surname>Borruto</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Petrella</surname><given-names>M.</given-names></name><name name-style="western"><surname>Micioni Di Bonaventura</surname><given-names>M. V.</given-names></name><name name-style="western"><surname>Soverchia</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Role of nociceptin/orphanin FQ-NOP receptor system in the regulation of stress-related disorders</article-title>. <source>Int. J. Mol. Sci.</source><volume>22</volume>, <fpage>12956</fpage>. <pub-id pub-id-type="doi">10.3390/ijms222312956</pub-id><pub-id pub-id-type="pmid">34884757</pub-id><pub-id pub-id-type="pmcid">PMC8657682</pub-id></mixed-citation></ref><ref id="B278"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ujcikova</surname><given-names>H.</given-names></name><name name-style="western"><surname>Eckhardt</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hejnova</surname><given-names>L.</given-names></name><name name-style="western"><surname>Novotny</surname><given-names>J.</given-names></name><name name-style="western"><surname>Svoboda</surname><given-names>P.</given-names></name></person-group> (<year>2021</year>). <article-title>Alterations in the proteome and phosphoproteome profiles of rat hippocampus after six months of morphine withdrawal: Comparison with the forebrain cortex</article-title>. <source>Biomedicines</source><volume>10</volume>, <fpage>80</fpage>. <pub-id pub-id-type="doi">10.3390/biomedicines10010080</pub-id><pub-id pub-id-type="pmid">35052759</pub-id><pub-id pub-id-type="pmcid">PMC8772819</pub-id></mixed-citation></ref><ref id="B279"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Urban</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Stingl</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Meinhardt</surname><given-names>M. W.</given-names></name></person-group> (<year>2023</year>). <article-title>Mini-review: The neurobiology of treating substance use disorders with classical psychedelics</article-title>. <source>Front. Neurosci.</source><volume>17</volume>, <fpage>1156319</fpage>. <pub-id pub-id-type="doi">10.3389/fnins.2023.1156319</pub-id><pub-id pub-id-type="pmid">37139521</pub-id><pub-id pub-id-type="pmcid">PMC10149865</pub-id></mixed-citation></ref><ref id="B280"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vearrier</surname><given-names>D.</given-names></name><name name-style="western"><surname>Grundmann</surname><given-names>O.</given-names></name></person-group> (<year>2021</year>). <article-title>Clinical pharmacology, toxicity, and abuse potential of opioids</article-title>. <source>J. Clin. Pharmacol.</source><volume>61</volume> (<issue>2</issue>), <fpage>S70</fpage>&#8211;<lpage>S88</lpage>. <pub-id pub-id-type="doi">10.1002/jcph.1923</pub-id><pub-id pub-id-type="pmid">34396552</pub-id></mixed-citation></ref><ref id="B281"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valentino</surname><given-names>R. J.</given-names></name><name name-style="western"><surname>Volkow</surname><given-names>N. D.</given-names></name></person-group> (<year>2018</year>). <article-title>Untangling the complexity of opioid receptor function</article-title>. <source>Neuropsychopharmacology</source><volume>43</volume>, <fpage>2514</fpage>&#8211;<lpage>2520</lpage>. <pub-id pub-id-type="doi">10.1038/s41386-018-0225-3</pub-id><pub-id pub-id-type="pmid">30250308</pub-id><pub-id pub-id-type="pmcid">PMC6224460</pub-id></mixed-citation></ref><ref id="B282"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vanover</surname><given-names>K. E.</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Makhay</surname><given-names>M.</given-names></name><name name-style="western"><surname>Veinbergs</surname><given-names>I.</given-names></name><name name-style="western"><surname>Gardell</surname><given-names>L. R.</given-names></name><name name-style="western"><surname>Lameh</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropylo xy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist</article-title>. <source>J. Pharmacol.Exp.Ther.</source><volume>317</volume>, <fpage>910</fpage>&#8211;<lpage>918</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.105.097006</pub-id><pub-id pub-id-type="pmid">16469866</pub-id></mixed-citation></ref><ref id="B283"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vazquez-Borsetti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Celada</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cortes</surname><given-names>R.</given-names></name><name name-style="western"><surname>Artigas</surname><given-names>F.</given-names></name></person-group> (<year>2011</year>). <article-title>Simultaneous projections from prefrontal cortex to dopaminergic and serotonergic nuclei</article-title>. <source>Int. J. Neuropsychopharmacol.</source><volume>14</volume>, <fpage>289</fpage>&#8211;<lpage>302</lpage>. <pub-id pub-id-type="doi">10.1017/S1461145710000349</pub-id><pub-id pub-id-type="pmid">20374686</pub-id></mixed-citation></ref><ref id="B284"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vazquez-Borsetti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cortes</surname><given-names>R.</given-names></name><name name-style="western"><surname>Artigas</surname><given-names>F.</given-names></name></person-group> (<year>2009</year>). <article-title>Pyramidal neurons in rat prefrontal cortex projecting to ventral tegmental area and dorsal raphe nucleus express 5-HT2A receptors</article-title>. <source>Cereb. Cortex</source><volume>19</volume>, <fpage>1678</fpage>&#8211;<lpage>1686</lpage>. <pub-id pub-id-type="doi">10.1093/cercor/bhn204</pub-id><pub-id pub-id-type="pmid">19029064</pub-id><pub-id pub-id-type="pmcid">PMC2693622</pub-id></mixed-citation></ref><ref id="B285"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vendruscolo</surname><given-names>J. C. M.</given-names></name><name name-style="western"><surname>Tunstall</surname><given-names>B. J.</given-names></name><name name-style="western"><surname>Carmack</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Schmeichel</surname><given-names>B. E.</given-names></name><name name-style="western"><surname>Lowery-Gionta</surname><given-names>E. G.</given-names></name><name name-style="western"><surname>Cole</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Compulsive-like sufentanil vapor self-administration in rats</article-title>. <source>Neuropsychopharmacology</source><volume>43</volume>, <fpage>801</fpage>&#8211;<lpage>809</lpage>. <pub-id pub-id-type="doi">10.1038/npp.2017.172</pub-id><pub-id pub-id-type="pmid">28812595</pub-id><pub-id pub-id-type="pmcid">PMC5809787</pub-id></mixed-citation></ref><ref id="B286"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vetulani</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bednarczyk</surname><given-names>B.</given-names></name><name name-style="western"><surname>Reichenberg</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rokosz</surname><given-names>A.</given-names></name></person-group> (<year>1980</year>). <article-title>Head twitches induced by LSD and quipazine: Similarities and differences</article-title>. <source>Neuropharmacology</source><volume>19</volume>, <fpage>155</fpage>&#8211;<lpage>158</lpage>. <pub-id pub-id-type="doi">10.1016/0028-3908(80)90131-8</pub-id><pub-id pub-id-type="pmid">6244515</pub-id></mixed-citation></ref><ref id="B287"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Volkow</surname><given-names>N. D.</given-names></name><name name-style="western"><surname>Mclellan</surname><given-names>A. T.</given-names></name></person-group> (<year>2016</year>). <article-title>Opioid Abuse in Chronic Pain--Misconceptions and Mitigation Strategies</article-title>. <source>N. Engl. J. Med.</source><volume>374</volume>, <fpage>1253</fpage>&#8211;<lpage>1263</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMra1507771</pub-id><pub-id pub-id-type="pmid">27028915</pub-id></mixed-citation></ref><ref id="B288"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Von Korff</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kolodny</surname><given-names>A.</given-names></name><name name-style="western"><surname>Deyo</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Chou</surname><given-names>R.</given-names></name></person-group> (<year>2011</year>). <article-title>Long-term opioid therapy reconsidered</article-title>. <source>Ann. Intern Med.</source><volume>155</volume>, <fpage>325</fpage>&#8211;<lpage>328</lpage>. <pub-id pub-id-type="doi">10.7326/0003-4819-155-5-201109060-00011</pub-id><pub-id pub-id-type="pmid">21893626</pub-id><pub-id pub-id-type="pmcid">PMC3280085</pub-id></mixed-citation></ref><ref id="B289"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vowles</surname><given-names>K. E.</given-names></name><name name-style="western"><surname>Mcentee</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Julnes</surname><given-names>P. S.</given-names></name><name name-style="western"><surname>Frohe</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ney</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Van Der Goes</surname><given-names>D. N.</given-names></name></person-group> (<year>2015</year>). <article-title>Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis</article-title>. <source>Pain</source><volume>156</volume>, <fpage>569</fpage>&#8211;<lpage>576</lpage>. <pub-id pub-id-type="doi">10.1097/01.j.pain.0000460357.01998.f1</pub-id><pub-id pub-id-type="pmid">25785523</pub-id></mixed-citation></ref><ref id="B290"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wakeman</surname><given-names>S. E.</given-names></name><name name-style="western"><surname>Larochelle</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Ameli</surname><given-names>O.</given-names></name><name name-style="western"><surname>Chaisson</surname><given-names>C. E.</given-names></name><name name-style="western"><surname>Mcpheeters</surname><given-names>J. T.</given-names></name><name name-style="western"><surname>Crown</surname><given-names>W. H.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Comparative effectiveness of different treatment pathways for opioid use disorder</article-title>. <source>JAMA Netw. Open</source><volume>3</volume>, <fpage>e1920622</fpage>. <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2019.20622</pub-id><pub-id pub-id-type="pmid">32022884</pub-id><pub-id pub-id-type="pmcid">PMC11143463</pub-id></mixed-citation></ref><ref id="B291"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walker</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Chambers</surname><given-names>C.</given-names></name><name name-style="western"><surname>Korber</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Tella</surname><given-names>S. R.</given-names></name><name name-style="western"><surname>Prioleau</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>L.</given-names></name></person-group> (<year>2021</year>). <article-title>Antinociceptive and discriminative stimulus effects of six novel psychoactive opioid substances in male rats</article-title>. <source>J. Pharmacol. Exp. Ther.</source><volume>379</volume>, <fpage>1</fpage>&#8211;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.121.000689</pub-id><pub-id pub-id-type="pmid">34244232</pub-id><pub-id pub-id-type="pmcid">PMC8626635</pub-id></mixed-citation></ref><ref id="B292"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>White</surname><given-names>F. J.</given-names></name><name name-style="western"><surname>Appel</surname><given-names>J. B.</given-names></name></person-group> (<year>1982</year>). <article-title>Lysergic acid diethylamide (LSD) and lisuride: differentiation of their neuropharmacological actions</article-title>. <source>Science</source><volume>216</volume>, <fpage>535</fpage>&#8211;<lpage>537</lpage>. <pub-id pub-id-type="doi">10.1126/science.7071600</pub-id><pub-id pub-id-type="pmid">7071600</pub-id></mixed-citation></ref><ref id="B293"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>White</surname><given-names>F. J.</given-names></name></person-group> (<year>1986</year>). <article-title>Comparative effects of LSD and lisuride: clues to specific hallucinogenic drug actions</article-title>. <source>Pharmacol. Biochem. Behav.</source><volume>24</volume>, <fpage>365</fpage>&#8211;<lpage>379</lpage>. <pub-id pub-id-type="doi">10.1016/0091-3057(86)90367-9</pub-id><pub-id pub-id-type="pmid">3952127</pub-id></mixed-citation></ref><ref id="B294"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wild</surname><given-names>C. T.</given-names></name><name name-style="western"><surname>Miszkiel</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Wold</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Soto</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hartley</surname><given-names>R. M.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Design, synthesis, and characterization of 4-undecylpiperidine-2-carboxamides as positive allosteric modulators of the serotonin (5-HT) 5-HT(2C) receptor</article-title>. <source>J. Med. Chem.</source><volume>62</volume>, <fpage>288</fpage>&#8211;<lpage>305</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.8b00401</pub-id><pub-id pub-id-type="pmid">29620897</pub-id><pub-id pub-id-type="pmcid">PMC6533912</pub-id></mixed-citation></ref><ref id="B295"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>J. T.</given-names></name><name name-style="western"><surname>Christie</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Manzoni</surname><given-names>O.</given-names></name></person-group> (<year>2001</year>). <article-title>Cellular and synaptic adaptations mediating opioid dependence</article-title>. <source>Physiol. Rev.</source><volume>81</volume>, <fpage>299</fpage>&#8211;<lpage>343</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.2001.81.1.299</pub-id><pub-id pub-id-type="pmid">11152760</pub-id></mixed-citation></ref><ref id="B296"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Willins</surname><given-names>D. L.</given-names></name><name name-style="western"><surname>Meltzer</surname><given-names>H. Y.</given-names></name></person-group> (<year>1997</year>). <article-title>Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats</article-title>. <source>J. Pharmacol. Exp. Ther.</source><volume>282</volume>, <fpage>699</fpage>&#8211;<lpage>706</lpage>.<pub-id pub-id-type="pmid">9262333</pub-id></mixed-citation></ref><ref id="B297"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Winter</surname><given-names>J. C.</given-names></name></person-group> (<year>1980</year>). <article-title>Effects of the phenethylamine derivatives, BL-3912, fenfluramine, and Sch-12679, in rats trained with LSD as a discriminative stimulus</article-title>. <source>Psychopharmacol. Berl.</source><volume>68</volume>, <fpage>159</fpage>&#8211;<lpage>162</lpage>. <pub-id pub-id-type="doi">10.1007/BF00432134</pub-id><pub-id pub-id-type="pmid">6776559</pub-id></mixed-citation></ref><ref id="B298"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wold</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name></person-group> (<year>2019a</year>). <article-title>Allosteric modulation of class A GPCRs: Targets, agents, and emerging concepts</article-title>. <source>J. Med. Chem.</source><volume>62</volume>, <fpage>88</fpage>&#8211;<lpage>127</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.8b00875</pub-id><pub-id pub-id-type="pmid">30106578</pub-id><pub-id pub-id-type="pmcid">PMC6556150</pub-id></mixed-citation></ref><ref id="B299"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wold</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>E. J.</given-names></name><name name-style="western"><surname>Wild</surname><given-names>C. T.</given-names></name><name name-style="western"><surname>Miszkiel</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Soto</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Discovery of 4-phenylpiperidine-2-carboxamide analogues as serotonin 5-HT(2C) receptor-positive allosteric modulators with enhanced drug-like properties</article-title>. <source>J. Med. Chem.</source><volume>63</volume>, <fpage>7529</fpage>&#8211;<lpage>7544</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.9b01953</pub-id><pub-id pub-id-type="pmid">32567857</pub-id><pub-id pub-id-type="pmcid">PMC8434884</pub-id></mixed-citation></ref><ref id="B300"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wold</surname><given-names>E. A.</given-names></name><name name-style="western"><surname>Wild</surname><given-names>C. T.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name></person-group> (<year>2019b</year>). <article-title>Targeting the 5-HT2C receptor in biological context and the current state of 5-HT2C receptor ligand development</article-title>. <source>Curr. Top. Med. Chem.</source><volume>19</volume>, <fpage>1381</fpage>&#8211;<lpage>1398</lpage>. <pub-id pub-id-type="doi">10.2174/1568026619666190709101449</pub-id><pub-id pub-id-type="pmid">31288724</pub-id><pub-id pub-id-type="pmcid">PMC6761005</pub-id></mixed-citation></ref><ref id="B301"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wulff</surname><given-names>A. B.</given-names></name><name name-style="western"><surname>Nichols</surname><given-names>C. D.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>S. M.</given-names></name></person-group> (<year>2023</year>). <article-title>Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders</article-title>. <source>Neuropharmacology</source><volume>231</volume>, <fpage>109504</fpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2023.109504</pub-id><pub-id pub-id-type="pmid">36921889</pub-id></mixed-citation></ref><ref id="B302"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yadlapalli</surname><given-names>J. S. K.</given-names></name><name name-style="western"><surname>Bommagani</surname><given-names>S. B.</given-names></name><name name-style="western"><surname>Mahelona</surname><given-names>R. D.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gannon</surname><given-names>B. M.</given-names></name><name name-style="western"><surname>Penthala</surname><given-names>N. R.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Evaluation of morphine-like effects of the mixed mu/delta agonist morphine-6-O-sulfate in rats: Drug discrimination and physical dependence</article-title>. <source>Pharmacol. Res. Perspect.</source><volume>6</volume>, <fpage>e00403</fpage>. <pub-id pub-id-type="doi">10.1002/prp2.403</pub-id><pub-id pub-id-type="pmid">29930811</pub-id><pub-id pub-id-type="pmcid">PMC6009770</pub-id></mixed-citation></ref><ref id="B303"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamamoto</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kamegaya</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hagino</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Takamatsu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sawada</surname><given-names>W.</given-names></name><name name-style="western"><surname>Matsuzawa</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Loss of GluN2D subunit results in social recognition deficit, social stress, 5-HT2C receptor dysfunction, and anhedonia in mice</article-title>. <source>Neuropharmacology</source><volume>112</volume>, <fpage>188</fpage>&#8211;<lpage>197</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2016.07.036</pub-id><pub-id pub-id-type="pmid">27480795</pub-id></mixed-citation></ref><ref id="B304"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zamberlan</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sanz</surname><given-names>C.</given-names></name><name name-style="western"><surname>Martinez Vivot</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pallavicini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Erowid</surname><given-names>F.</given-names></name><name name-style="western"><surname>Erowid</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>The varieties of the psychedelic experience: A preliminary study of the association between the reported subjective effects and the binding affinity profiles of substituted phenethylamines and tryptamines</article-title>. <source>Front. Integr. Neurosci.</source><volume>12</volume>, <fpage>54</fpage>. <pub-id pub-id-type="doi">10.3389/fnint.2018.00054</pub-id><pub-id pub-id-type="pmid">30467466</pub-id><pub-id pub-id-type="pmcid">PMC6235949</pub-id></mixed-citation></ref><ref id="B305"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zaveri</surname><given-names>N. T.</given-names></name></person-group> (<year>2016</year>). <article-title>Nociceptin opioid receptor (NOP) as a therapeutic target: Progress in translation from preclinical research to clinical utility</article-title>. <source>J. Med. Chem.</source><volume>59</volume>, <fpage>7011</fpage>&#8211;<lpage>7028</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b01499</pub-id><pub-id pub-id-type="pmid">26878436</pub-id><pub-id pub-id-type="pmcid">PMC5001850</pub-id></mixed-citation></ref><ref id="B306"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X. Y.</given-names></name><name name-style="western"><surname>Dou</surname><given-names>Y. N.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y. J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Different neuronal populations mediate inflammatory pain analgesia by exogenous and endogenous opioids</article-title>. <source>Elife</source><volume>9</volume>, <fpage>e55289</fpage>. <pub-id pub-id-type="doi">10.7554/eLife.55289</pub-id><pub-id pub-id-type="pmid">32519950</pub-id><pub-id pub-id-type="pmcid">PMC7311172</pub-id></mixed-citation></ref><ref id="B307"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Bolinger</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Anastasio</surname><given-names>N. C.</given-names></name></person-group> (<year>2023</year>). <article-title>Novel heterocyclic compounds as serotonin (5-HT) 5-HT2A and 5-HT2C receptor positive allosteric modulators</article-title>. <comment>United States patent application</comment>.</mixed-citation></ref><ref id="B308"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zia</surname><given-names>F. Z.</given-names></name><name name-style="western"><surname>Baumann</surname><given-names>M. H.</given-names></name><name name-style="western"><surname>Belouin</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Dworkin</surname><given-names>R. H.</given-names></name><name name-style="western"><surname>Ghauri</surname><given-names>M. H.</given-names></name><name name-style="western"><surname>Hendricks</surname><given-names>P. S.</given-names></name><etal/></person-group> (<year>2023</year>). <article-title>Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs</article-title>. <source>Neuropharmacology</source><volume>233</volume>, <fpage>109528</fpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2023.109528</pub-id><pub-id pub-id-type="pmid">37015315</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>